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Summary  
In the Dark Agouti (DA) rat, immunisation with the extracellular domain of the myelin 
oligodendrocyte glycoprotein (MOG-Igd) induces both an encephalitogenic T cell response and 
a demyelinating antibody response (Stefferl et al., 2001). These immune effector mechanisms 
synergise to induce a demyelinating and relapsing remitting variant of experimental 
autoimmune encephalomyelitis (RR-EAE), which reproduces the immuno-pathology of 
demyelination observed in a large proportion of multiple sclerosis (MS) patients (Storch et al., 
1998; Lucchinetti et al., 2000). This model was used to investigate two facets of MS that are 
poorly understood; 1) the mechanism(s) responsible for relapse and disease progression, and 2) 
the a possible mechanistic link between milk consumption and disease prevalence. 
This study demonstrates for the first time that pathogenic autoantibodies can become the 
driving force responsible for disease progression in RR-EAE. Although MOG-specific T cells 
can induce repeated episodes of CNS inflammation, this response is self-limiting and the 
intensity of the inflammatory response decreases with time. MOG-specific autoantibodies 
induce demyelination and amplify this inflammatory response, resulting in progressive 
neurological deficits. This has important implications for the treatment of MS, in which MOG-
specific autoantibodies are implicated in the immunopathogenesis of demyelination (Storch et 
al., 1998; Haase et al. 2000; Reindl et al., 1999; Genain et al., 1999; Raine et al., 1999).  
The second part of this thesis evolved from the observation that MOG-specific T cells can 
cross-react with the bovine milk protein butyrophilin (BTN) (Stefferl et al., 2000), which may 
explain the reported correlation between milk consumption and the prevalence of MS (Butcher, 
1986; Malosse et al., 1992; Lauer, 1997). Immunological cross-reactivity or molecular mimicry 
is often discussed as a potential trigger to induce auto-aggression in MS and other autoimmune 
diseases (Fujinami and Oldstone, 1985; Wucherpfennig et al., 1995; Zhao et al., 1998; Gautam, 
1998). This study demonstrates that cross-reactivity with BTN is restricted to a minor subset of 
a very complex, polyclonal MOG-specific T cell repertoire. Nevertheless, stimulation of this T 
cell population with BTN peptide dramatically suppresses the pathogenic potential of MOG 
reactive T cell lines. It is shown that the BTN peptide acts as an altered peptide ligand on 
MOG/BTN-reactive T cells, modifying cytokine synthesis in favour of a counter-inflammatory 
Th2-like response. This demonstrates that dietary derived peptides may have important and 
previously unrecognised effects on the autoimmune repertoire. 
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1 Introduction  
1.1 Multiple sclerosis (MS) - an autoimmune syndrome? 
1.1.1 Disease course  
Multiple Sclerosis (MS) is a chronic disease of the central nervous system (CNS) 
characterised by the presence of multiple inflammatory demyelinating lesions throughout the 
CNS. Depending on their topography, these lesions result in various neurological deficits, such 
as visual impairment, limb weakness, fatigue, cramps, parathesia, ataxia, bladder and bowel 
symptoms and vertigo, and in later stages paralysis and loss of renal and respiratory 
homeostasis, which often contribute to an early death. The clinical course of MS is no less 
variable than its symptoms. A high proportion of patients are diagnosed between 20 and 40 
years of age and develop a relapsing-remitting course of disease, during which clinical 
exacerbations can be followed by intervals of more or less complete recovery. During this 
period the clinical deficits are a direct consequence of the inflammatory demyelinating response 
and recovery is associated with significant remyelination of the affected areas of the CNS. 
However, irreversible axonal loss does occur (Ferguson et al., 1997; Trapp et al., 1998; Kornek 
et al., 2000) and as disease progresses this accumulates and results in chronic disability. In later 
stages of MS most patients develop secondary progressive disease, in which relapses occur 
against a background of a steadily worsening neurological deficit. The pathophysiology of 
secondary progressive MS is poorly understood, and it is now recognised that clinical decline in 
some patients apparently continues in the absence of new episodes of CNS inflammation (Trapp 
et al., 1998). The duration of MS varies dramatically and while many patients will have the 
disease for several decades, approximately 10% develop an acute, fulminant form of MS in 
which clinical deterioration is rapid and the patients die within one to three years. At the other 
end of the clinical spectrum there are patients with very benign disease and a low relapse rate, 
who may never develop a secondary progressive disease.  
 
1.1.2 Aetiology of MS 
MS is the most common inflammatory demyelinating disease of the CNS in Europe and 
North America, where it affects about 80 to 100 per 100,000 people. However, its prevalence is 
not globally uniform, but decreases at lower latitudes reaching levels of only 1 to 2 per 100,000 
in Africa and Asia. The aetiology of MS is unknown, but involves both genetic and 
environmental factors. The involvement of genetic factors is most clearly demonstrated by twin 
Introduction 
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studies, which revealed that concordance in monozygotic twins was 30%, but only 4% in 
dizygotic twins and sibs (Sadovnick 1993; Sadovnick and Ebers, 1995; Ochsenberg and 
Barcellos, 2000). Several susceptibility loci were tentatively identified by whole genome 
screens involving a total of several thousand patients, but the various research groups involved 
identified different loci and it is now generally accepted that MS is a polygenic disorder. The 
only consistent correlation involved the MHC locus and may reflect linkage of MS with the 
MHC class II allele HLA-DR2, which is over-represented in Caucasian MS patients (Martin et 
al., 1992; Liblau et al., 1993). Apart from the importance of genetic factors, the concordance 
rate of only 30% in monozygotic twins also indicates a crucial role for environmental factors in 
disease development. Migration studies showed that moving from a high risk to a low risk area 
will result in acquisition of the risk of the new region, and vice-versa (Gale and Martyn, 1995). 
However, this is only the case if migration occurs before the age of 15, suggesting that the 
impact of the environment is concentrated within a certain time window. This phenomenon has 
been attributed to infectious agents, but could also involve geographical as well as socio-
economic factors, such as better sanitation, diet and stress, features associated with a “western 
life style". Among the individual factors implicated in the aetiology of MS are several dietary 
components, such as milk (Lauer, 1997), as well as a wide range of pathogens including human 
herpes virus 6 (HHV-6, Challoner et al., 1995; Soldan et al., 1997), measles virus (Brody et al., 
1972; Burgoon et al., 1999), Epstein-Barr-Virus (Bray et al., 1983; Ascherio and Munch, 2000) 
and chlamydia (Sriram et al., 1998). However, the association between any of these agents and 
MS is controversial (see Derfuss et al., 2001 with respect to chlamydia) and as yet no infectious 
agent was reproducibly isolated from the central nervous system (CNS) of MS patients.  
 
1.1.3 Immunopathology of MS  
The heterogeneity of the clinical course of MS is paralleled by a similar variation in its 
pathology. Using immunopathological criteria, MS lesions were recently segregated into four 
distinct subtypes (Lucchinetti et al., 2000; Lassmann et al., 2001). The general pathology of 
MS, the formation of demyelinating lesions in the CNS associated with infiltrating CD3+ T cells 
(Traugott et al., 1983), activated macrophages and microglia containing myelin debris (Ulvestad 
et al., 1994; Brück et al., 1995; Storch et al., 1998; Ferguson et al., 1997) and infiltrating B cells 
(Esiri et al., 1977; Lucchinetti et al., 2000) is common to all forms of the disease. However, 
detailed immunopathological analysis of the lesions identified differences in the cellular 
infiltrates, complement and immunoglobulin deposition and apoptosis indicating that at least 
four different pathomechanisms are responsible for lesion formation.  
Introduction 
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Type I and II lesions show a striking resemblance to the lesions seen in certain models of 
experimental autoimmune encephalomyelitis (EAE), an animal model of MS initiated by an 
autoimmune response to CNS myelin autoantigens. In these types of lesions there is a 
pronounced perivascular infiltrate associated with the invasion of T cells and activated 
macrophages into the CNS parenchyma. In addition, type II lesions are associated with 
immunoglobulin deposition on the myelin sheath and the local activation of the complement 
cascade. Type II lesions are by far the most frequent type of MS lesion and were seen in more 
than 50% of MS cases studied by Lucchinetti et al., 2000. The immunopathology and ultra 
structure of type II lesions are reproduced in rat and primate models of EAE, in which 
demyelination is antibody mediated (Linington et al., 1988; Genain et al., 1995; Storch et al., 
1998; Genain et al., 1999; Raine et al., 1999). On the other hand, pattern I lesions are not 
associated with immunoglobulin and complement deposition and have a strong resemblance to 
lesions seen in mouse models of EAE, in which demyelination is thought to be mediated by 
soluble factors such as TNF-α. The resemblance of these animal models to MS has led to the 
concept that the pathogenesis of type I and II lesions involves an autoimmune component. Very 
different pathomechanisms seem to be involved in type III and type IV lesions, which display 
signs of DNA fragmentation in oligodendrocytes indicative of virus or toxin induced 
demyelination rather than autoimmunity. Intriguingly, at a single time point all the lesions in a 
patient are of the same type, but as yet it is unknown whether the type of lesion may change 
during the course of disease. These results clearly demonstrate that several different 
pathomechanisms can lead to the destruction of CNS myelin in MS. This may in part explain 
why it has proved difficult to identify any generalised susceptibility genes, pathogens or 
environmental factors common to all patients as well as the varying clinical responses of 
individual patients to different treatment strategies.  
The inflammatory pathology of MS and its pathological similarity to EAE suggest that 
MS is immune mediated. This concept is supported by the presence of oligoclonal 
immunoglobulin bands in the CSF, genetic linkage to the MHC locus, responsiveness to 
immune-directed therapies, expansion of myelin-specific T and B cell responses as well as 
blood brain barrier leakage detected by MRI.  
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1.1.4 CNS myelin – the target organ   
In the CNS the myelin sheath is formed by an extension of the oligodendrocyte plasma 
membrane, which enwraps axons with multiple layers (10-150) of plasma membranes (Figure 
1.1). The majority of the cytoplasm is extruded, leaving compact multilamellar myelin, which is 
composed of approximately 30% protein and 70% lipid (by dry weight) and is also 
characterised by its low water content of 40%. This structure efficiently isolates the axon to 
enable fast, saltatory conduction. The structure of compact myelin is maintained by its major 
protein components, the cytoplasmic myelin basic protein (MBP) and the transmembrane 
proteolipid protein (PLP), which together comprise approximately 80% of the total myelin 
proteins. In addition, isolated myelin contains a number of minor protein components whose 
functions are obscure. These include 2´3´-cyclic nucleotide, 3´-phosphodiesterase (CNP), 
myelin associated glycoprotein (MAG), oligodendrocyte myelin glycoprotein (OMG), myelin 
oligodendrocyte basic protein (MOBP), myelin oligodendrocyte glycoprotein (MOG), myelin 
/oligodendrocyte specific protein (MOSP) and members of the tetraspan-protein family 
(reviewed in Baumann and Pham-Dinh, 2001). Some of these proteins, such as MAG, may 
interact with axonal proteins and contribute to the macromolecular organisation of the paranodal 
loops of the sheath adjacent to the Node of Ranvier (Bartsch, 1996; Martini and Schachner, 
1997; reviewed in Baumann and Pham-Dinh, 2001). As discussed below, autoimmune 
responses to many myelin proteins can induce an inflammatory response in the CNS, and 
enhanced auto-reactivity to myelin proteins is observed in the majority of MS patients 
suggesting that they may be involved in the pathogenesis of MS. MOG is however unique, 
since it is the only myelin autoantigen for which there is direct clinical evidence for a 
pathogenic autoimmune response in MS (Genain et al., 1998; Raine et al., 1999; Haase et al., 
2000).  
 
1.1.5 Myelin oligodendrocyte glycoprotein (MOG) 
MOG is a type I membrane glycoprotein, which – in contrast to most other myelin 
proteins - is exclusively expressed in the CNS (Linington et al., 1984; Gardinier et al., 1992). 
The mature protein consists of 218 amino acids and is predicted to consist of a N-terminal, 
extracellular IgV-like domain (MOG-Igd; modelled in Hjelmström et al., 1998) containing a 
single N-linked glycosylation site at position Asn31 (Hjelmström et al., 1998), a highly 
hydrophobic membrane spanning domain and a cytoplasmic domain that includes a second 
Introduction 
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Figure 1.1 Schematic view of CNS Myelin 
CNS myelin is formed by oligodendrocyte processes, which enwrap the axon with multiple lamellae of plasma 
membrane. The cytoplasm is extruded as the sheath compacts to form multilamellar myelin, but is retained in the 
paranodal loops to provide a continuous cytoplasmic channel (C) linking the myelin sheath to the oligodendrocyte 
cell body (G). It should be noted that in contrast to the Schwann cells of the PNS, one oligodendrocyte enwraps 
multiple axons. C) paranodal loop, G) oligodendrocyte, N) node of Ranvier (From Baumann and Pham-Dinh, 
2001) 
 
hydrophobic region. This domain is either tightly associated with or integrated into the 
cytoplasmic face of the membrane bilayer (Kroepfl et al., 1996; Della Gaspera et al., 1998; 
Figure 1.2). MOG is a member of the Ig-superfamily and its IgV-like domain is closely related 
to an extended family of B7- and butyrophilin (BTN)-like proteins (Pham Dinh et al., 1993; 
Vernet et al., 1993; Gruen et al., 1996). MOG is encoded in the distal region of the MHC and is 
therefore linked to the MHC class I and II loci associated with MS (Pham-Dinh et al., 1993, 
1995; Lambracht et al., 1995). 
Like other myelin proteins MOG is highly conserved between species (90% a.a. sequence 
identity between human and rat). Amino acid substitutions are concentrated within the putative 
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Figure 1.2 Schematic picture of MOG in the oligodendrocyte plasma membrane 
The N-terminal IgV-like domain is on the extracellular side, the C-terminus intracellular (after Kröpfl et al., 1996) 
The numbers represent the amino acid residues at the proposed membrane boundaries. 
 
transmembrane domain, while the cytoplasmic domain is virtually identical between mouse, rat, 
human and bovine species (Hilton et al., 1995) suggesting that it mediates an important 
interaction with other oligdendrocyte/myelin proteins, possibly components of the cytoskeleton 
(Dyer and Matthieu, 1994). The presence of an extracellular Ig domain certainly suggests that 
MOG may act as a receptor, but the putative ligand and its functional significance are obscure, a 
problem, which the development of MOG-deficient mouse mutants has failed to solve, as these 
animals do not develop any obvious neurological/neurobiological phenotype and myelination is 
completely normal (Pham-Dinh et al., submitted for publication).  
 
1.2 MOG-induced experimental autoimmune encephalomyelitis (EAE) – a model 
for types I and II MS 
Strikingly, there is no spontaneous animal model for MS. “EAE” was first reported in the 
late 19th century by Pasteur, who observed that some of the patients vaccinated against Rabies 
developed an encephalitis. Experiments in monkeys confirmed that this was due to 
contamination of the vaccine with spinal cord tissue and provided the first indication that 
inflammation and demyelination in MS may be autoimmune in origin (Rivers et al., 1933). The 
original studies, however, required multiple injections of spinal cord homogenate to induce 
disease in a small proportion of the experimental animals. Reproducibility was enhanced when 
Kabat, Wolf and Berger introduced Freund´s adjuvant (FA, 1946), an oil in water emulsion 
containing mycobacterium to enhance the immune response. This resulted in a highly 
reproducible disease, experimental autoimmune encephalomyelitis (EAE) that could be induced 
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in rats, mice, rabbits and guinea pigs by a single immunisation with CNS homogenates in FA. 
Histological examination confirmed Rivers´ original observation that disease was associated 
with an inflammatory infiltrate in the CNS and the formation of demyelinating plaques similar 
to those seen in MS.  
Subsequently, single highly purified myelin proteins were identified as encephalitogenic 
components of this CNS homogenate, but in this case EAE was predominantly inflammatory in 
nature and demyelination was either absent or far less extensive (Waksman, 1954; Laatsch et 
al., 1962). This inflammatory pathology was finally attributed to the induction of an 
encephalitogenic T cell response in 1981 (Ben-Nun et al., 1981) and there is now an extensive 
list of myelin and non-myelin CNS autoantigens that can induce an auto-aggressive T cell 
response, including MBP  (Ben Nun et al., 1981), PLP (Sobel et al., 1986), MOG (Linington et 
al., 1993), MAG (Weerth et al., 1998), myelin oligodendrocyte basic protein (MOBP, Kaye et 
al., 2000), as well as the astrocyte protein S100β (Kojima et al. 1994). However, although all of 
these antigens are capable of inducing T cell mediated encephalitis, MOG is the only myelin 
autoantigen that will induce demyelination in rats (Adelmann et al., 1995; Johns et al., 1995; 
Storch et al., 1998) and marmosets (Calltithrix jacchus, a small primate)(Genain et al., 1995, 
1996). In these species, demyelination is strictly dependent on the presence of a MOG-specific 
demyelinating autoantibody response (Adelmann et al., 1995; Johns et al., 1995; Genain et al., 
1995; Bernard et al., 1997; t’Hart et al., 2000), which induces a pathology reproducing that seen 
in type II MS lesions. In contrast, demyelination in murine EAE can also be mediated by TNF-
α dependent mechanisms (Akassoglou et al., 1999) in the absence of a functional B cell 
response (Hjelmström et al., 1998; Eugster et al., 1998; Lyons et al., 1999), and in this species 
the immunopathology of autoimmune demyelination resembles that seen in type I MS lesions.   
MOG was first identified as a target for antibody mediated demyelination in a guinea pig 
model of EAE induced by active immunization with CNS tissue homogenates in complete 
Freunds adjuvant (Lebar et al., 1986; Linington and Lassmann, 1987). The demyelinating 
potential of MOG-specific antibodies is due to the exposure of MOG-Igd at the surface of the 
myelin sheath and olidodendrocytes (Brunner et al., 1989) and was confirmed by the 
intravenous injection of a MOG-specific monoclonal antibody into rats with EAE induced by 
either active immunisation with MBP (Schluesener et al., 1987) or the adoptive transfer of MBP 
specific T cells (Linington et al., 1988; Lassmann et al., 1988). In the absence of the MOG-
specific antibody, the pathology of these disease models is purely inflammatory. Intravenous 
injection of MOG-specific mAb at disease onset, however, induces extensive demyelination, 
enhances the inflammatory response in the CNS and dramatically increases disease severity. 
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The pathogenic potential of MOG-specific mAbs depends on their ability to fix complement or 
to induce antibody dependent cellular cytotoxicity (ADCC) (Linington et al., 1989 B; 
Piddlesden et al., 1991). 
Susceptibility to MOG-Igd-induced EAE is determined mainly by the MHC class II locus, 
but is modified by additional MHC and non-MHC background genes. Studies of MHC 
congenic rats on the Lewis background revealed that the Lewis (LEW) haplotype RT1l confers 
low susceptibility and the Brown Norway (BN) haplotype RT1n is associated with fulminant 
disease, while the haplotype of Dark Agouti (DA) rats (RT1av1) confers high susceptibility 
together with a tendency to develop relapsing remitting EAE (Weissert et al., 1998; Stefferl et 
al., 1999). This was not only seen in DA rats after immunisation with MOG, but also with 
spinal cord homogenates (SCH) (Lorentzen et al., 1995; Weissert et al., 1998). MOG - induced 
EAE in RT1av1 rats is therefore the model system of choice for MS associated with type II 
lesions as it combines both an MS-like pathology and an MS-like disease course.  
 
1.3 The immune system  
The vertebrate immune system has evolved to perform the complex task of defending the 
organism against pathogens, while at the same time ignoring “self”. The mechanisms that 
enable the immune system to distinguish between “self” and “non-self” and prevent 
autoimmune disease are still incompletely understood and their identification remains a major 
goal of immunological research. The major anatomical sites and mechanisms by which self-
tolerance is established during the development of the immune repertoire are now however 
beginning to be elucidated. 
 
1.3.1 Central tolerance 
Immunological protection is generally mediated by a combination of innate and acquired 
mechanisms, which interact to protect the host from most pathogens. Innate immunity has a low 
degree of specificity and pre-dates the adaptive immune response, which evolved with the 
vertebrates. It is the failure to regulate or tolerise the adaptive immune response which is 
responsible for most autoimmune diseases. Flexibility of the adaptive immune response is 
ensured by the presence of a large pool of at least 108 -1010 lymphocytes that differ in their cell 
surface receptors and therefore antigen specificity. Antigen specificity in both naïve T and B 
cells is determined by receptors that mainly differ in sequence in a small region 
(complementarity determining region 3, CDR3) located in a loop of an immunoglobulin 
domain. Their diversity is generated by a complicated process of gene rearrangement, in which 
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different gene fragments are joined together. At this step, additional nucleotides may be inserted 
at the junctions. After this gene rearrangement has occurred, each lymphocyte expresses a 
unique receptor. In T cells the sequence of this receptor (TCR) is then fixed and undergoes no 
further changes. This is not the case in B cells, in which recognition of antigen is associated 
with somatic mutations, concentrated in the CDRs 1-3, that increase the affinity of the receptor 
for their target (affinity maturation) (reviewed in general immunology textbooks, e.g. Abbas, et 
al., 2nd edition 1994; Janeway and Travers, 1994).  
This procedure invariably results in the generation of a large number of auto-reactive pre- 
T and B cells, the majority of which is eliminated in highly specialised immune organs (thymus 
for T cells and bone marrow for B cells) as soon as these gene rearrangements have taken place. 
This process termed negative selection is dependent on the presence of autoantigen in these 
organs and effectively removes maturing auto-reactive cells before they have a chance to enter 
the circulation (Abbas et al., 1994; Janeway and Travers, 1994). However, the efficiency of 
negative selection is concentration dependent. While it may completely eliminate cells 
recognising proteins expressed in the thymus or present in the circulation (such as C5), central 
tolerance may be incomplete for tissue-specific antigens even if they are also present at low 
levels in the thymus. (Wekerle et al., 1996).   
In addition, maturation of T cells in the thymus requires positive selection by low affinity 
recognition of autologous MHC plus “self-peptide”, a mechanism that ensures that auto-
reactivity is an intrinsic component of the T cell repertoire, albeit generally restricted to low 
affinity recognition.  
 
1.3.2 Peripheral tolerance  
Peripheral tolerance provides a second line of defence to remove or inactivate those T and 
B cells that may recognise tissue-specific antigens which are not expressed in thymus or bone 
marrow. The mechanisms responsible for peripheral tolerance are best understood for the T cell 
repertoire. Full activation of T cells not only requires the identification of a specific 
antigen/MHC complex, but also signals provided by a variety of co-stimulatory molecules 
present on antigen presenting cells (APCs). Recognition of antigens in the absence of co-
stimulatory signals leads to the induction of either anergy, a state of functional 
unresponsiveness to antigenic stimulation (Schwartz, 1996) or apoptosis, the physical 
elimination of the T cell from the repertoire (Miller and Basten, 1996). Whether anergy or 
deletion is induced depends to a large amount on the concentration of the antigen and the 
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affinity of the TCR for the MHC/peptide complex. In general, high concentrations favour 
deletion, whereas low concentrations favour the induction of anergy (Liblau et al., 1997). 
All these mechanisms that may maintain self-tolerance are, however, dependent on the 
availability of the antigen. In the case of minor components of the CNS, such as MOG, which is 
<0.05% of the myelin protein, this is unlikely to be the case as they are sequestered behind the 
blood brain barrier (BBB). This barrier restricts the free exchange of antigen and cells between 
the CNS and circulation. In addition, the CNS is devoid of a classical lymphoid drainage system 
further reducing the probability that the immune system will ever normally be exposed to MOG. 
In this case self-tolerance can not be induced and potentially auto-reactive T and B cells will be 
a normal component of the immune repertoire. Their pathogenic potential is, however, held in 
check, as naïve lymphocytes are unable to cross the BBB to find their target antigen. This form 
of passive tolerance is termed clonal ignorance (Miller et al., 1993).  
In addition to these mechanisms based on direct TCR – MHC/peptide complex 
interactions there is increasing evidence for the presence of regulatory or “suppressor T cells” 
that limit autoimmune responses. These include both natural suppressor cells and antigen-
induced populations. Natural suppressor cells, characterised by the phenotype CD4+ CD25+, are 
generated in the thymus - presumably as a consequence of intermediate affinity to autoantigens 
(reviewed in Shevach, 2001). Although these regulatory cells require antigen-specific 
activation, they subsequently suppress the activation of naïve T cells in an antigen-independent 
manner via direct cell-cell interactions.  
In contrast, antigen induced suppressor cells are generated in the periphery, for example 
during oral tolerance (Weiner, 1994). This mechanism is required to eliminate potentially fatal 
immune reactions to the diet or the symbiotic gut flora and involves a specific compartment of 
the immune system, the gut associated lymphatic tissue (GALT). Antigen crossing the gut 
mucosa is processed in the GALT to generate a non-inflammatory T cell response involving 
antigen induced repressor T cells. These act via the secretion of soluble, counter-inflammatory 
cytokines such as IL-10 and TGF-β (Weiner, 1997; Strobel and Mowat, 1998). It should be 
noted that immune regulation by this suppressor cell population is distinct from regulation of 
Th1-responses by Th2 subset T cells, which secrete IL-4 and IL-10, but not TGF-β (Liblau et 
al., 1995). Th1 and Th2 T cell responses are mutually antagonistic by virtue of the reciprocal 
regulatory effects of IFN-γ/IL-12 and IL-4/IL-10. Thus the adoptive transfer of neuroantigen 
specific Th2 T cells can be used to antagonise the development of EAE, a Th1 mediated 
autoimmune disease (Khoruts et al., 1995). Shifting the immune response from Th1 to Th2 
activity or vice versa is known as immune deviation. This can be induced together with deletion 
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and anergy (Gaur et al., 1992; Samson and Smilek, 1995) in the periphery by treatment with 
high dose soluble antigen (Genain et al., 1997).  
Similar mechanisms exist for B cells, but they are not as well characterised. In principle, 
B cell activation requires co-stimulatory signals provided by antigen-specific CD4+ T cells. 
Antigen recognition in the absence of co-stimulatory signals induces deletion of the B cells 
(Russell et al., 1991). Furthermore, abundant soluble proteins can induce a state of anergy in 
mature B cells, characterised by reduced surface IgM and an inability to proliferate and 
differentiate after an immunogenic stimulus (Goodnow et al., 1989). Anergic B cells are then 
excluded from primary follicles in lymph nodes and spleen and are rapidly lost in the absence of 
T cell help (Cyster et al., 1994; Cyster and Goodnow, 1995).  
 
1.3.3 Tolerance to MOG 
The exclusive expression of MOG in the CNS led to the assumption, that the lack of 
reactivity against MOG is maintained by immunological ignorance, a hypothesis recently 
supported by the observation that MOG-deficient mice have identical immune responses to 
MOG as wild type animals (Pham-Dinh et al., submitted). One would therefore assume that 
immunisation with MOG or MOG peptides would automatically induce a highly pathogenic T 
cell response. Intriguingly, this is not necessarily the case. In LEW and BN rats  (Adelmann et 
al., 1995; Stefferl et al., 1999) active immunisation with MOG peptides fails to induce a highly 
encephalitogenic T cell response or clinical EAE. Indeed, in these rat strains even the transfer of 
MOG-specific T cells only results in an asymptomatic inflammatory response in the CNS.  
Is it therefore possible, that tolerance to MOG is maintained by immunological cross- 
reactivity/molecular mimicry with other proteins? MOG is a member of the growing 
butyrophilin gene family, which currently comprises 5 sub-families, each of which consists of 
up to three family members (Stammers et al., 2000; Rhodes et al., 2001). These proteins show a 
high degree of sequence identity in their N-terminal, IgV-like domains (approximately 50% 
between the sub-families), as well as a common predicted IgV-like structure (modelled in 
Hjelmström et al., 1998). Members of the family are expressed in a variety of tissues, including 
immune organs, suggesting that the maintenance of tolerance to these proteins must involve 
active processes. The high homology between MOG and these proteins suggests that at least 
partial tolerance to MOG may result from the deletion of those lymphocytes, which recognise 
cross-reactive peptides derived from MOG-homologue(s). Cross-reactivity between MOG and a 
xenogenic family member, bovine butyrophilin (BTN) was recently demonstrated in the DA rat, 
a rat strain, which develops EAE with an MS-like disease course and pathology (Stefferl et al., 
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2000). This observation for the first time provided the opportunity to study the impact of a 
dietary antigen (environmental factor) on the MOG-specific immune repertoire. 
 
1.4 Objectives 
The aim of this study was to use MOG-induced EAE in the DA rat, a model which 
resembles MS both in disease course and pathology, to investigate the mechanism(s) 
responsible for relapse/disease progression. This first required the establishment of a highly 
reproducible, synchronised model of relapsing EAE. Once this model was set up, MOG-specific 
immune responses should be analysed at different stages of the disease in order to determine the 
relative contributions of T cell- and antibody-mediated pathomechanisms during the course of 
the disease. In detail, the following questions should be addressed: 
• How does the MOG-specific T cell response develop during the course of the 
disease ? 
• Are MOG-specific T cell responses alone capable of inducing EAE in DA rats? 
• If MOG-specific T cell responses are capable of inducing EAE, are they also 
capable of inducing relapse activity ? 
• How does the MOG-specific B cell response develop during the course of EAE ? 
• Can antibodies induce relapse ? 
A second part concerned the identification of the molecular basis and functional consequences 
of the cross-reactive immune response between MOG and bovine BTN. This involved the 
following questions: 
• Why are DA rats not tolerant to BTN although they drink milk during suckling ? 
• Does confrontation with BTN modulate MOG-specific T cell responses ? Does 
BTN act as an APL? 
• Which T cells cross-react? – Is it possible to identify cross-reactive T cell 
receptors (β-chain)? 
• Which BTN residues are involved in the cross-reactive response ? 
• Can BTN replace MOG in the induction of antigen-specific tolerance ? 
• Does the cross-reactivity extend to BTN/MOG-specific antibodies ? 
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2 Material and Methods 
2.1 Materials 
2.1.1 Animals 
Female DA rats were purchased from Harlan Winkelmann, Germany and kept under 
conventional methods in the animal house of the Max Planck Institute for Neurobiology. All 
experimental  procedures performed in this study are covered under the animal licence #AZ211-
2531-69/94 issued by the federal government of Bavaria, Germany 
2.1.2  Cell culture media  
2.1.2.1 Culture medium for bacteria 
LB-Medium (Luria Bertoni) Peptone from Casein   10 g/l 
     Yeast extract    5 g/l 
     NaCl (Sodium chloride)   5 g/l protein expression,  
10 mg/l for plasmid 
preparations 
 
Autoclave, store at 4°C (months). Add selecting antibiotics (100 mg/l Ampicillin +/- 25 mg/l Kanamycin) 
after autoclaving (120°C¸1 atü), immediately before use after cooling to approx. 55°C. 
  
LB agar plates   Agar                                 15g/l in LB medium,  
 
autoclave, store at 4°C (months). Resolubilise in microwave (max 500 ml bottles), add antibiotics 
immediately before use after cooling to approx. 55°C. 
 
2.1.2.2 Medium and buffer for preparation of RbCl-competent bacteria  
MTB medium   tryptone     20    g/l  
yeast extract     5      g/l 
KCl (Porassium chloride)   0.75 g/l 
Autoclave, store at 4°C (months) 
 
TF1 RbCl (Rubidium chloride)   0.1   M (12 g/l) 
 MnCl2 (Manganese chloride)  50 mM (8 g/l) 
 KCH3COO (Potassium acetate)  30 mM (3 g/l) 
 CaCl2 (Calcium chloride)   10 mM (1 g/l) 
 Glycerol    15%     (v/v) 
 Set pH5.8 with acetic acid, sterile filter 
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TF2  RbCl          10 mM (1 g/l)  
 CaCl2          75 mM (8 g/l) 
 Glycerol         15%     (v/v) 
 MOPS (3-[N-Morpholino]butanesulfonic acid) 10 mM (2.3g/l) 
 pH7, sterile filter 
 
2.1.2.3 Culture media for insect cells 
SF9 cells    TNM-FH (Invitrogen)   
10% FCS  
100 U/ml Penicillin/Streptomycin 
 
High 5 cells  High five medium (Invitrogen) 
  100 U/ml Penicillin/Streptomycin 
 
2.1.2.4 Culture media for eucaryotic cells 
Based on Dulbecco´s Modification of Eagle´s Medium (DMEM), 4500 mg/ml glucose with the following 
supplements: 
 
Eagles Hepes   NaHCO3 (Sodiumbicarbonate)  45      mM (3.7 g/l) 
     HEPES (N-[2Hydroxyethyl]piperazine-N´-[2-ethanesulfonic acid])
          25       mM (6 g/l) 
Sterile filter (0.22µm), store at 4°C (months) 
 
DMEM/Asn   NaHCO3    45      mM (3.7 g/l) 
     L-Asparagine    0.024 mM (36 mg/l) 
Sterile filter (0.22µm), store at 4°C (few months) 
 
complete DMEM    DMEM/Asn 
    Penicillin/Streptomycin (10,000U/ml Pen, 10,000µg/ml Strep)
          1%    (v/v) 
     Sodium pyruvate  (100 mM) 1%    (v/v) 
     MEM Non-essentiel Aas (100x)  1%    (v/v) 
     L-Glutamine  (200 mM) 1%    (v/v) 
     0.4% (v/v) ß-Mercaptoethanol  0.1% (v/v) 
Sterile filter (0.22µm), store at 4°C (max. 14 days) 
 
T cell Restimulation medium complete DMEM  
     Rat serum     1%     (v/v) 
Sterile filter (0.22µm), use immediately 
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TCGF (T cell growth factor)  Complete DMEM 
     Heat inactivated horse serum  15% (v/v) 
     MLA-supernatant (source of IL-2)  15% (v/v) 
Sterile filter (0.22µm), store at 4°C for max. 14 days 
 
Freezing medium   EH     45% (v/v) 
     Heat inactivated fetal calf serum   45% (v/v)  
     DMSO (Dimethylsulfoxide)  10% (v/v) 
Filter first serum, then DMSO in EH (0,22µm), use immediately 
 
Medium for Ag8-cells  Complete DMEM 
     Heat inactivated fetal calf serum  10% (v/v) 
Sterile filter (0.22µm), store at 4°C for max. 14 days 
 
Medium for MLA-cells  Complete DMEM 
     Heat inactivated horse serum  15% (v/v) 
Sterile filter (0.22µm), store at 4°C for max. 14 days 
 
2.1.3 Buffer and reagents 
10 x PBS NaCl (Sodium chloride) 1.37 M    (80g/l) 
 KCl (Potassium chloride) 27  mM (2g/l) 
 Na2HPO4 (Disodium phosphate) 100     mM (14.2g/l) 
 NaH2PO4 (Monosodium phosphate) 100 mM (13.8g/l) 
 pH 7.4 with NaOH (Sodium hydroxide pellets) 
 
PFA, 4% Paraformaldehyde (PFA) 4 %    (w/v) 
  in PBS, pH 7.3 
dissolve PFA in water with a drop of NaOH, add 10x PBS after complete dissolution 
 
2.1.3.1 Buffer for FACS-analysis 
FACS-buffer BSA (Bovine serum albumine) 0.2% 
 NaN3 (Sodium azide) 10 mM in PBS 
 
Last wash and analysis in PBS only or PBS/azide 
 
2.1.3.2 ACK lysis buffer for erythrocytes 
ACK buffer  NH4Cl  (Ammonium chloride)  0.15 M (8.6 g/l) 
KHCO3 (Potassium bicarbonate)  1   mM (1 g/l) 
Na2EDTA (TitriplexIII)   0.1 mM (37.2 mg/l) 
set pH 7,2-7,4, sterile filter 
Materials and Methods 
 26
 
2.1.3.3 Buffer for purification of MOG-Igd 
Buffer for Nickel-chelate chromatography 
Urea buffer   Urea     6    M 
 KH2PO4 (Potassiumdihydrogenphosphate) 0.1 M  
 NaCl 0.5 M  
 pH8   
 
Wash buffer Urea buffer 
 Imidazole 40 mM 
 pH8 
  
Elution buffer Urea buffer  
 Imidazole 0.5   M 
 pH8 
 
Buffer for gel exclusion chromatography 
 Urea 6     M 
 ß-Mercaptoethanol 10 mM 
 in PBS 
 
Acetate buffer  
 Sodium acetate (NaCH3COO) 5   mM 
 pH 3 
 
2.1.3.4 Buffer for purification of BTNexo 
          PBS                                           see 2.1.3 
       TBS 
     Tris/Cl pH7.5    100 mM 
     NaCl     150 mM (0.9%) 
 
          Tris/Cl stock solution  
Dissolve 121g Tris base in 800 ml distilled H2O for 1M Tris/Cl 
Adjust pH with concentrated HCl (approximately 70 ml for pH7.4, 42 ml for pH8) - pH is temperature 
sensitive!!! 
Add distilled H20 to 1 l  
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2.1.3.5 Buffer for SDS-PAGE 
Running gel (15%, 50 ml) 1.5 M Tris/HCl pH8.8   12.5 ml 
     30% Acrylamide/Bis   25    ml 
     10% SDS (Sodiumdodecylsulphate) 0.5   ml 
     H2O (Aqua bidest)   12    ml 
10% APS (Ammonium persulfate)  250  µl 
     TEMED (N,N,N´,N´-Tetramethylethylenediamine)  
          25    µl  
 
Stacking gel (12.5 ml)   0.5 M Tris/HCl pH 6.8   3.1   ml 
     30% Acrylamide/Bis   2.5   ml  
10% SDS    250  µl 
     H2O (Aqua bidest)   6.8   ml 
     10% APS    125  µl 
     TEMED     12.5 µl 
 
Running buffer (Laemmli) Tris 25      mM  (3 g/l) 
 Glycine 190    mM  (14.4 g/l) 
 SDS 0.1% (w/v) (1 g/l) 
  
Loading buffer, 10x Tris/HCl, pH7.5 400  mM  
 Glycerol 4.5   g/l 
 Bromphenoleblue 10    mg/l 
 SDS 150   g/l  
 ß-Mercaptoethanol 1.5    M 
 
Stock solutions 
30% Acrylamide/Bis (Roth, ready to use) Acrylamide   30% (w/v) 
     Bisacrylamide    16    g/l 
 Store at 4°C in the dark 
 
1.5 M Tris, pH8.8   Tris/HCl    1.5   M (182 g/l) 
  
10 % SDS   Sodium lauryl phosphate   100  g/l 
              Store at RT, not 4°C! 
 
0.5 M Tris, pH6.8   Tris/HCl    0.5   M (60.3 g/l) 
 
10% APS Ammoniumpersulfate 100  mg/ml                   
              Always prepare freshly! 
TEMED Tetramethylethylenediamine 
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Butanol – water saturated 
 
 
2.1.3.6 Buffer for staining proteins in SDS gels 
Coomassie Blue staining solution Coomassie brilliant blue R250   2       g/l 
     Ethanol     45%  (v/v) (450 ml/l) 
     Acetic acid 37%    90     ml/l 
 
Destaining solution  Ethanol     45%  (v/v) 
     Acetic acid 37%    10%  (v/v) 
 
2.1.3.7 Buffer for Western Blot 
Blotting buffer   Tris     25   mM (3 g/l) 
     Glycine     190 mM (14.3 g/l) 
     SDS     0.1%      (w/v) 
     Methanol    20%       (v/v)  
 
Wash buffer (TBS-T)  Tris/HCl pH7.6    20mM   (2.4 g/l) 
     NaCl     137mM (8 g/l) 
 Tween 20 0.1%     (v/v) 
 
Blocking buffer dried milk powder 5%        (w/v) in TBS-T 
 
Antibody-solution dried milk powder 2%        (w/v) in TBS-T 
 
2.1.3.8 Determination of protein concentration according to Lowry 
All reagents were used according to the SIGMA protein assay kit 
 
2.1.3.9 Determination of protein concentration according to Bradford 
Bradford stock solution was diluted 1/5 and used according to the BIORAD-instructions 
 
2.1.3.10 Buffer for DNA analysis 
TBE    Tris base    89 mM (10.8g/l) 
     Boric acid    89 mM (5.5 g/l) 
     EDTA (ethylenediamine tetraacetic acid)   2mM  
pH8 (with HCl)    (4 ml of 0.5M stock) 
Agarose gels   Agarose     8-20 g/l in TBE 
     Ethidium bromide   0.5   µg/ml 
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(choose agarose content according to the size of the product (0.8-2%), boil in microwave, add ethidium bromide 
after boiling, immediately prior to pouring the gel (cancerogenic)) 
 
Loading buffer   EDTA     100     mM 
     glycerol     30%    (v/v) 
     bromophenole blue   0.25% (w/v) 
 xylene cyanol  0.25% (w/v) 
 
2.1.3.11 Buffer for quick plasmid isolation 
STETL Sucrose 8%     (w/v) 
 Triton X-100 5%     (v/v) 
 Tris/HCl pH8 50      mM 
 EDTA 50      mM 
 Lysozyme 0.5     mg/ml 
Buffer can be stored at 4°C for months, but lysozyme needs to be added freshly 
 
TE Tris/HCl pH8 20     mM 
 EDTA pH8 1      mM 
 
DEPC-H2O 0.01% in H20, leave ON, then autoclave 
 
2.1.3.12 Buffer for ELISA (Enzyme linked immunosorbant assay) 
Coating buffer    NaN3 (Sodium azide)   0.02 % in PBS 
 
Block buffer   BSA (Bovine serum albumine)  1%     (w/v) 
NaN3      0.1% (w/v) in PBS 
 
Wash buffer    Tween 20    0.5%  (v/v) 
NaN3      0.02% (w/v) in PBS 
 
Substrate buffer    Diethanolamine    1 M 
NaN3      0.02% 
MgCl2 x 6 H2O     4 mM 
pH 9,8 Store in dark. 
 
Substrate for alkaline phosphatase  
 p-nitrophenyl phosphate 0.5 - 1 mg/ml 
 
2.1.3.13 Buffer for cytokine ELISAs 
All cytokine ELISAs were performed according to the manufacturer´s instructions (Biosource) using the 
reagents provided. 
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2.1.4 Peptides 
2.1.4.1 Rat MOG peptides (spanning the Ig-domain) 
M1-26  GQF RVI GPG HPI RAL VGD EAE LPC RI 
M14-39   ALV GDE AEL PCR ISP GKN ATG MEV GW 
M27-50     SPG KNA TGM EVG WYR  SPF SRV VHL 
M38-60    GWY RSP FSR VVH LYR NGK DQD AE 
M50-74     LYR NGK DQD AEQ APE YRG RTE LLK E 
M63-87    PEY RGR TEL LKE SIG EGK VAL RIQ N 
M76-100 IGE GKV ALR IQN VRF SDE GGY TCF F 
M89-113 RFS DEG GYT CFF RDH SYQ EEA AVE L 
M101-120 RDH SYQ EEA AVE LKV EDP FY 
M74-90          ESI GEG LVA LRI QNV RF 
M93-109       EGG YTC FFR DHS YQE EA 
M92-109  DEG GYT CFF RDH SYQ EEA 
 
2.1.4.2 Rat MOG peptides for fine mapping of the DA epitopes 
These peptides cover the rat MOG-Igd T cell epitopes of the DA rat. They were 
synthesized on a peptide synthesiser 431A (Applied Biosystems) by Dr. N. Groome,  Oxford, 
UK and were at least 98% pure. 
  
  Peptide         Amino acid residues                                 Sequence 
M 26 62-76 P E Y R G R T E L L K E S I 
M 27 65-79  R G R T E L L K E S I G E G 
M 28 68-82 R T E L L K E S I G E G K V A 
M 29 71-85 L L K E S I G E G K V A L R I 
M 30 74-88 E S I G E G K V A L R I Q N V 
M 31 77-91 G E G K V A L R I Q N V R F S 
M 32 79-93 G K V A L R I Q N V R F S D E 
M 33 84-99 R I Q N V R F S D E G G Y T C 
M 34 87-101 N V R F S D E G G Y T C F F R 
M 35 90-104 F S D E G G Y T C F F R D H S 
M 36 93-107 E G G Y T C F F R D H S Y Q E 
M 37 96-110 Y T C F F R D H S Y Q E E A A 
M 38 99-113 F F R D H S Y Q E E A A V E L 
M 39 102-116 D H S Y Q E E A A V E L K V E 
 
2.1.4.3 Bovine BTN peptides (spanning the first Ig-domain, Genosys) 
B1-26    APF DVI GPQ EPI LAV VGE DAE LPC RL  
B14-39      AVV GED AEL PCR LSP NVS AKG MEL RW  
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B27-50          LSP NVS AKG MEL RWF REK VSP AVF VS 
B38-60        RWF REK VSP AVF VSR  EGQ EQE GE 
B50-74          VSR EGQ EQE GEE MAE YRG RVS LVE D 
B63-87          AEY RGR VSL VED HIA EGS VAV RIQ E 
B76-100        IAE GSV AVR IQE VKA SDD GEY RCF F 
B89-113        KAS DDG EYR CFF RQD ENY EEA IVH L 
B101-120     RQD ENY EEA IVH LKV AAL GS 
B74-90  DHI AEG SVA VRI QEV KA 
2.1.4.4 Alanine-substituted BTN74-90 
BT 1     DHI   AEG  SVA VRI  QEV  KA 
BT 2     AHI   AEG  SVA VRI  QEV  KA 
BT 3     DAI   AEG  SVA VRI  QEV  KA 
BT 4     DHA AEG  SVA  VRI  QEV  KA 
BT 5     DHI   AAG  SVA  VRI  QEV  KA 
BT 6     DHI   AEA  SVA  VRI  QEV  KA 
BT 7     DHI   AEG  AVA  VRI  QEV  KA 
BT 8     DHI   AEG  SAA  VRI  QEV  KA 
BT 9     DHI   AEG  SVG  VRI  QEV  KA 
BT 10   DHI   AEG  SVA  ARI  QEV  KA 
BT 11   DHI   AEG  SVA  VAI  QEV  KA 
BT 12   DHI   AEG  SVA  VRA QEV  KA 
BT 13   DHI   AEG  SVA  VRI  AEV  KA 
BT 14   DHI   AEG  SVA  VRI  QAV  KA 
BT 15   DHI   AEG  SVA  VRI  QEA  KA 
BT 16   DHI   AEG  SVA  VRI  QEV  AA  
 
2.1.4.5 Rat BTN peptides (homologous to the immunogenic MOG-peptides in the DA 
rat) 
Rat B74-90       ARL LDG LAT LRI RGV RV 
Rat BTN92-109 DQG QYR CFL KDN DDS EEA 
 
2.1.5 Primers  
2.1.5.1 Construction of BTN-MOG-fusion protein for DNA vaccination 
1. BTN sense 1    cag aag ccg cca cca tgg cag tct ttc caa act cc 
2. BTN sense 2    cca gca tct tgc tgc cca gaa gcc gcc acc atg gc  
3. BTN sense 3    aac tcg agc cca cca gca tct tgc tgc cca gaa gc 
4. BTN sense 5    aca aac tcg agc cca cca gca tct tgc 
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5. BTN sense 6    aca aac tcg agc cca cca gc 
6. BTN as TM-MOG   acc caa tag aag ggc ctt ggg aag aag gag gct gg 
7. BTN-MOG TM sense  cct tct tcc caa ggc cct tct att ggg tca acc cc 
8. mouse MOG IC as1.1 cga gga tcc gtc gag gct gat cag cgg 
9. mouse MOG IC as1.2 cga gga tcc gtc gag gc 
  
2.1.5.2 Verification of the quality of cDNA: rat ß-Actin 
1. ß- Actin sense  TGC TAG GAG CCA GGG CAG TAA TC 
2. ß-Actin antisense  TAC AAT GAG CTG CGT GTG GCC 
 
2.1.5.3 Sequencing of rat BTN 
1. Mouse BTN sense 1 (placed in the mouse signal sequence) 
CAG TTA GCT CAG AGA TGG CAG TTC CCA CC 
        2.    Mouse BTN sense 2 (placed in the mouse signal sequence) 
CTC CTG CCT CCT GGT CTG TCT GC 
3.    Mouse BTN as 2      (placed in the mouse transmembrane region)   
GCT ACT ATC CAG GGA GTC AGC CTT GG 
4.   Rat BTN as 6 (placed in the second Ig domain, identified in the first round of PCRs) 
   GCA CTC CAG CTC CAT GTC TCC  
        
2.1.5.4 Analysis of tissue specific expression 
1.   rat BTN sense 8 (placed in the N-terminal IgV-like domain) 
CCG AGG AGG CCG CTG TGC  
        2.    rat BTN as 8 (placed in the transmembrane region) 
CGA TTG CGA GAA ACC CTA AGG C 
 
2.1.6 Antibodies for FACS analysis  
antibody   recognised antigen  
R73    C-region of α/β TCR 
W3/25                 CD4 (T helper cells) 
G418                 CD3 (TCR associated) 
OX39                 IL2-R (upregulated on activated T cells) 
OX40                 OX40 R 
OX6   MHC class II 
 
       Cy5-labelled rabbit-anti-mouse F(ab´)2 (DAKO, Denmark), First antibodies were purchased at Serotec  
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2.2 Molecular biology methods 
2.2.1 Preparation of RNAse free water 
All RNA manipulations were performed with twice autoclaved pipet tips and tubes. All solutions were prepared 
with ultrafiltered and autoclaved H2O.  
0.01% Diethylpyrocarbonate (DEPC) was added to doubly distilled water and incubated 
for 24 h at room temperature, after which DEPC was destroyed by autoclaving to avoid 
inactivation of RNA. 
 
2.2.2 Total RNA extraction from tissues or cultured cells 
Total RNA was prepared by the single-step guanidine method according to 
manufacturer’s instructions (Trizol, Gibco BRL). Tissues were flash-frozen in liquid nitrogen 
and stored at –80°C until use. Frozen tissues were dropped into 1 ml Trizol in a 2 ml 
polypropylene tube and homogenized with a Polytron (Kinematica) homogenizer. After 5 min 
incubation at RT, extraction was performed with 200 µl chloroform (vortexed, 2 min RT, 
centrifuged 12000 g, 15 min at 4°C). The upper aqueous phase was taken and RNA precipitated 
with 0,5 ml isopropanol (10 min at RT). After centrifugation (12000 g, 10 min at 4°C) the pellet 
was washed in 1 ml 75 % ethanol, centrifuged, dried and dissolved in 20-200 µl DEPC-H2O. 
RNA concentration was measured by spectrophotometer at A260. 
 
2.2.3 Extraction of mRNA from tissues or cultured cells using Dynabeads 
For small-scale preparations, mRNA was isolated using oligo-dT-coated Dynabeads 
obtained in the “mRNA direct micro kit”, according to manufacturer’s instructions (Dynal, 
Germany). Tissues were flash-frozen in liquid nitrogen and stored at –80°C until use. 
40 µg Dynabeads were aliquoted into the RNAse free Eppendorf tubes and washed twice 
with Lysis/binding buffer. 
5 mg tissue samples were ground on dry ice using a manual tissue grinder, then 200 µl 
Lysis/Binding Buffer was added and tissues were ground for a further 2 minutes. The lysate was 
centrifuged (30-60s, 13,000 rpm, RT) and can be stored like this at –80°C. Clear lysates were 
mixed with the pre-washed dynabeads by pipetting and incubated under gentle rolling for 5 min 
at room temperature. The beads were separated from the supernatant using a Dynabead magnet 
and washed twice with 100 µl washing buffer A and twice with washing buffer B. After this, 
the beads were resuspended in 60 µl ice cold 10 mM Tris-HCl. The mRNA was eluted from the 
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beads by incubation for 5 mins at 50°C and separated at 50°C in the preheated magnet. The 
supernatant containing the mRNA was transferred into fresh tubes and stored at –80°C. RNA 
concentration was measured by spectrophotometer at A260. 
 
2.2.4 Reverse transcription of RNA to cDNA 
Reverse transcription of RNA to cDNA was performed according to manufacturer’s 
instructions (Gibco BRL) in a total volume of 20 µl. For 1 µg total RNA, 1 µl oligo (dT)12-18 
(500 µg/ml) and H2O were added to a volume of 12 µl. Mixture was heated to 65°C for 10 min 
and chilled on ice. The following components were added: 
4 µl 5x 1st strand buffer 
2 µl 0.1 M DTT (Dithiothreitole) 
1 µl 10 mM dNTP mix 
After 2 min incubation at 42°C, 1 µl Superscript II was added and incubation was continued for 
80 min. Reaction was stopped by heating at 70°C for 15 min. 1 µl were taken to perform a PCR 
reaction. 
 
2.2.5 Polymerase chain reaction (PCR) 
The following reagents were added for a PCR reaction: 
x    µl cDNA 
2.5 µl 10x PCR buffer  
0.5 µl 10 mM dNTP mix 
0.5 µl 5’ primer (20 µM) 
0.5 µl 3’ primer (20 µM) 
0.625 units DNA polymerase  
H2O to a total volume of 25 µl 
Samples were amplified in a thermocycler (Perkin-Elmer) with the following standard 
conditions if not otherwise stated: 
4 min at         94°C (denaturation), then 25-35 cycles with 
1 min at         94°C (denaturation) 
1 min at         54-70°C (annealing) 
0.75-1 min at 72°C (elongation) 
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After the last cycle elongation was continued at 72°C for a further 10 min, then samples were 
cooled to 4°C and 8-10 µl were loaded onto an agarose gel for electrophoresis. 
The annealing temperature for each primer was calculated using the formula 
                    (4n + 2m – 4)°C, 
with n= the number of C or G in the primer, and m= the number of A or T in the primer 
Pfu (Pyrococcus furiosus) DNA polymerase (Stratagene) was used for all cloning reactions, 
because of its proofreading activity, Taq (Thermus aquaticus) (QIAGEN) was used in the 
sequencing reactions and expression analysis, because of higher efficiency and lower price. All 
sequences were confirmed at least once on independent PCR products.  
 
2.2.6 Separation of DNA fragments by agarose gel electrophoresis 
  Separation of DNA fragments was performed as described by McDonell et al., 1997 and 
Ausubel et al., (Current Protocols) on 0.8 -1.2 % agarose gels with 0.5 µg/ml ethidium bromide 
in 1 x TBE at 5-10 V/cm. 0,2 volumes of loading mix were added to the DNA before loading on 
the gel. The fragments were separated by electrophoresis according to size and can be 
visualized in UV light due to the presence of ethidium bromide intercalated between the DNA 
strands. Ladder Mix (MBI Fermentas) was used as size standard. 
 
2.2.7 Determination of DNA concentration 
Concentration of DNA, RNA and oligonucleotides was determined by measuring the 
absorption at 260 and 280 nm by spectrophotometer (GeneQuant II, Pharmacia). The maximum 
of absorption of nucleic acids is at 260 nm, the maximum absorption of proteins at 280 nm. At 
260 nm with a 1 cm pathway, an optical density of 1.0 corresponds to 50 µg/ml of double-
stranded DNA, 37 µg/ml of RNA and 20 µg/ml for oligonucleotides. Purity of DNA was 
determined by a 260/280 ratio, which had to be higher than 1.7. Very pure DNA solutions have 
a ratio 260/280 of between1.8 and 1.95, very pure RNA solutions between 1.9 and 2.0. 
 
2.2.8 Isolation of DNA fragments from agarose gels 
To isolate individual DNA fragments from mixtures, e.g. after restriction, DNA was 
separated by agarose gel electrophoresis. The desired fragments were cut from the gel and DNA 
was isolated using a QIAGEN Gel extraction kit (QIAGEN) according to manufacturer’s 
instructions. 
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2.2.9 Purification of DNA 
To remove contaminants and primer from DNA, PCR products were purified using 
QIAGEN PCR purification kit (QIAGEN) according to manufacturer’s instructions. 
 
2.2.10 Restriction of DNA 
1 - 5 U of restriction enzyme(s) were added for 1 µg DNA in the appropriate restriction 
buffer. Volume of buffer used was at least 10 times the volume of enzyme added, as glycerol in 
the enzyme storage buffer may inhibit the reaction/decrease specificity. The restriction mix was 
incubated 2 h at 37°C or according to manufacturer´s instructions (NEB, New England 
Biolabs). 
 
2.2.11 Dephosphorylation of linearised vectors 
To inhibit vector religation, the 5’ end phosphate group were removed from the linearised 
vector. 1 µl of shrimp alkaline phosphatase (USB) was added directly to the restricted DNA in 
20 µl of the restriction buffer. The mix was incubated for 1 h at 37°C and DNA was then 
purified using QIAGEN PCR purification kit 
 
2.2.12 Ligation 
DNA fragments with compatible ends were ligated with T4 DNA ligase (Boehringer, 
Mannheim). The amount of insert used was approximately 3 times that of vector as judged in 
ethidium bromide stained agarose gels. 1 U enzyme in 20 µl ligation buffer (Boehringer 
Mannheim) was added to the appropriate mixture of vector and insert DNA and the reaction 
was incubated overnight at 16°C. Linearised, dephosphorylated vector in the absence of the 
insert was ligated for the negative control 
 
2.2.13 Generation of RbCl-competent cells for transformation 
A fresh E. coli culture (DH5α or JM109) was prepared by inoculating 5 ml MTB medium 
with a single colony and incubating for 37°C/200 rpm up to O.D.550 (approx. 2h). This starter 
culture was used to inoculate 100 ml MTB medium and grown to a density of O.D.550 0.5. The 
cell suspension was chilled on ice and centrifuged at 7,000 g for 5 min at 4°C. Cells were 
resuspended on ice in 30 ml ice cold buffer TF1 and centrifuged again. The pellet was 
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resuspended very carefully on ice in 4 ml ice cold TF2 and stored in 100 µl aliquots at –80°C. 
The final transformation efficiency was approximately 106 cells/µg DNA.  
 
2.2.14 Transformation of bacterial cells by heat shock transformation 
50 µl of competent cells were thawed on ice and incubated with 10 µl ligation mix for 20 
min on ice. The cells were then transferred into 37°C for 2 min, followed by incubation on ice 
for up to 30 min (heat shock, uptake of plasmid). After this 1 ml LB-medium (without 
antibiotics) was added. The cell suspension was incubated at 37°C for 1 h on a shaker in a 
polypropylene tube and then plated on LB-agar plates containing the appropriate selective 
antibiotics and incubated over night at 37 °C. Plates can be stored at 4°C. 
 
2.2.15 Plasmid DNA preparation 
2.2.15.1 Rapid plasmid purification 
3 ml LB medium were inoculated with a single bacterial clone and incubated over night at 
37°C. Cells were centrifuged for 1 min at 13,000 rpm and lysed in 150 µl STETL buffer for 1 
min in a boiling water bath. Bacterial remains were removed using a toothpick and the plasmid 
DNA in the remaining supernatant was precipitated with 180 µl Isopropanol for 10 min at room 
temperature, after which it was centrifuged for 10 min at 13,000 rpm. Pellets were washed in 
70% ethanol and taken up in 50 µl TE after drying. 
   
2.2.15.2 Small scale plasmid preparation using QIAGEN plasmid purification kit 
In order to sequence plasmids, plasmids containing inserts of the correct size were 
purified using the QIAGEN plasmid purification kit according to the manufacturers 
instructions. In short, bacteria are lysed with SDS and NaOH that denature DNA and proteins. 
The mixture is neutralized, causing the covalently closed plasmid DNA to reanneal rapidly. 
While the chromosomal DNA and proteins precipitate, the plasmid DNA in the supernatant is 
washed and concentrated by isopropanol and ethanol precipitation. Maximum yield was 20 µg. 
 
2.2.15.3 Mega- and Gigapreparations 
For preparing large amounts of plasmid for DNA vaccination, Endo-free Mega- and 
Gigapreparations (Qiagen) were performed according to the manufacturers instruction, 
following the same principle of alkaline lysis. Maximum yield is 2,5 mg (Megaprep) and 10 mg 
(Gigaprep), derived from 500 ml or 2.5 l cultures, respectively.  
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Quality of plasmid DNA was verified by spectrophotometer and by agarose gel after 
restriction with appropriate DNA endonucleases. 
 
2.2.16 DNA sequencing 
Sequencing of DNA was performed by Toplab or Willy Metzger in Martinsried, the 
sequencing for the TCR spectratyping was carried out by Frau Ingrid Eiglmeier in the 
neuroimmunology department of the Klinikum Großhadern. 
 
2.2.17 Glycerol stocks 
After verification of the insert, bacterial clones were expanded over night in 5 ml LB 
medium at 37 °C. The solution was diluted 1/1 in sterile cold glycerol and stored at –80°C. 
 
2.2.18 Cloning of the BTN-MOG fusion construct 
The templates for the construction of this plasmid were kindly provided by Dr. Carole 
Bourquin (pcDNA-MOG construct, E.J.I., 2000 encoding mouse MOG under a CMV promoter 
in pcDNA3.1(-), from Invitrogen) and by Dr. I. Mather and Sherry Ogg in Maryland, who 
provided cDNA encoding the signal sequence and the extracellular domains of bovine BTN.  
A 5´non-translated region containing an optimised Kozak sequence as well as a Xho I 
restriction site was added to the 5´end of the BTN signal sequence by sequential PCRs using 
BTN sense primers 1-6 (Figure 2.1, step 1, left) and the anti-sense primer BTN as-TM-MOG. 
This antisense primer not only served for the amplification, but also added the first 14 
nucleotides encoding the MOG-TM region to the construct, fused in-frame to the butyrophilin 
extracellular domains (Figure 2.1, step1, left). In an independent reaction, the sequence 
encoding the transmembrane and intracellular domains of mouse MOG was amplified by PCRs 
using primers BTN-MOG TM sense and MOG cterm as 1 and 2. Once again, the primer used 
for the fusion to MOG (in this case the sense primer) contained an additional sequence of 14 
nucleotides, homologous to the last 14 3´nucleotides encoding the bovine BTN-extracellular 
domain, fused in-frame to the MOG-transmembrane sequence. The antisense primers 
introduced a BamHI endonuclease restriction site to the 3´region of the MOG-intracellular 
domain (Figure 2.1 step1, right).  
The two products were fused together in a new PCR reaction of 10 cycles, in which the 
overlapping 28 nucleotides served as internal primers (Figure 2.1 step 2). After these 10 cycles,  
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Figure 2.1 Cloning scheme for BTN-MOG fusion construct 
In the first step, serial PCRs were carried out to add a 5´nontranslated sequence containing a XhoI endonuclease 
restriction site and an optimised Kozak sequence to the cDNA encoding the extracellular domains of bovine BTN. 
In addition, the 3´end of this cDNA was fused with 15 additional nucleotides, which are homologous with the 5´end 
of MOG-TM/IC. Simultaneously, 14 additional nucleotides were added to the 5´end of the cDNA encoding the 
transmembrane and intracellular domains of MOG, which are homologous to the 3´end of BTN-EC. A BamHI 
endonuclease restriction site was added to the 5´end of MOG-TM/IC. 
In step 2, the two cDNAs were incubated together for 10 PCR cycles in the absence of additional primers. In this 
step, the overlapping nucleotides, which were added in step one, serve as internal primers to obtain fused templates 
In step 3, primers were added to the assay of step 2. 
The following PCR leads to the amplification of the fusion cDNA (step 4). The obtained product was then digested 
with BamH1 and XhoI and ligated into pcDNA 3.1 (-), which had also been digested with BamHI and XhoI. 
 
BTN-EC
Sequential primers adding
5´nontranslated sequence
including Kozak-Sequence
ATG As primer with 14 nt 
overlap MOG
MOG-TM+ICsense primer with 14 nt overlap BTN
 BTN-EC                     MOG BTN      MOG-TM+IC
1
3
4
BTN-MOG
BTN-EC MOG-TM+IC
ATG
XhoI
XhoI
XhoI
XhoI
XhoI
BamHI
BamHI
BamHI
BamHI
BamHI
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 primers BTN sense 6 and MOG cterm 2 were added (Figure 2.1 step 3), and the fusion product  
was amplified in another 30 cycles (Figure 2.1 step 4). The PCR product of 1,100 nt length was 
purified using the QIAGEN gel extraction kit, digested with XhoI and BamHI and ligated into 
pcDNA3.1(-) which had been digested with the same enzymes. Sequence and correct insertion 
were verified by Toplab, Martinsried, using T7 and pcDNA3.1 antisense primer, located behind 
the multiple cloning site. 
 
2.2.19 Sequencing of rat butyrophilin 
The extracellular domain of rat butyrophilin was sequenced using primers derived from 
the published mouse sequence. Primers were placed in the signal sequence and the 
transmembrane regions, because these are regions, which are highly conserved between the 
mouse, rat and bovine gene. Primer rat BTN6 was homologous to a previously identified rat 
sequence. All sequences were confirmed at least twice in independent PCR and sequencing 
reactions. 
 
2.2.20 Sequence comparisons 
Sequence comparisons were performed using the BLAST program provided by the NIH 
(www.ncbi.nlm.nih.gov). 
 
2.2.21 Analysis of the tissue specific expression of rat BTN 
To verify tissue-specific expression of rat BTN, RT-PCR was carried out in a variety of 
DA rat tissues using primers placed in the N-terminal IgV-like domain (rat BTN sense 8) and in 
the transmembrane region (rat BTN as 8) of the rat-BTN-sequence. This results in the 
amplification of a 393 nt fragment of the mRNA and covers (parts of) the exons encoding the 
IgV-like domain, the IgC-like domain and the transmembrane region (amino acids 105-236). 
The genomic sequence would therefore presumably contain two introns (As seem in the mouse, 
gene accession number U67065). This excludes the amplification of genomic DNA, which 
would be several thousand nucleotides long. The PCR was done in the presence of 1 mM 
MgCl2 and run for 35 cycles. Each step (denaturation, primer annealing (58°C) and elongation) 
lasted 1 minute. 
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2.2.22  TCR spectratyping  
This is a RT-PCR technique based on the length polymorphism in the CDR3 
(complementarity determining region) of the TCR and the fact that each T cell expresses a 
single β chain. Primers are placed in the individual Vβ regions and the constant domain of the 
TCR and thus span the CDR3, which is the area in which the TCR rearrangement occurs during 
T cell maturation in the thymus (joining of different D and J regions with a V region, combined 
with junctional diversity). Fluorescence-labelled nucleotides are used for the PCR reactions. 
The PCR products are then separated on polyacrylamide gels (Long ranger single packs; 
Biozym, Hess. Oldendorf) (Figures 3.2.7). To facilitate analysis, size of product and intensity of 
fluorescence are represented as histograms (Figure 3.2.8 and 3.2.9). TCR spectratyping was 
performed by I. Eiglmeier and Dr. N. Goebels, Klinikum Großhadern, Munich, Germany 
 
2.3 Biochemical methods 
2.3.1 SDS PAGE 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was performed according to 
Laemmli (1970) and Ausubel (Current Protocols in mol. biology chap 10.2 A) with the Mini-
Protean II system (Bio-Rad) with 1.5 mm spacers. Electrophoresis was performed in Laemmli 
buffer at 150 V for 1 to 2 h. All samples were mixed with 0.2 Vol. 5 x loading buffer and 
incubated at 95°C for 5 min before loading. Molecular weight markers used were prestained 
and unstained broad range (Bio-Rad). 
 
2.3.2 Staining of proteins in polyacrylamide gel 
The gels were stained with Coomassie Blue staining solution for at least 60 min, then 
incubated for at least 60 min in destaining solution to visualise the separated proteins in 
polyacrylamide gels 
 
2.3.3 Western blotting 
2.3.3.1 Electrotransfer of protein from a polyacrylamide gel onto a nitrocellulose 
membrane 
The electrotransfer of proteins onto a nitrocellulose membrane was performed according 
to Towbin et al., 1979 and Ausubel et al., Current Protocols in mol. biology chap 10.8). After 
separation of proteins by SDS-PAGE, the gel was placed on a nitrocellulose membrane 
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(Hybond ECL, Amersham) soaked in TBE buffer. Gel and membrane were surrounded on both 
sides by buffer saturated Whatman paper No I. Electrotransfer was performed in a blotting 
chamber (Bio-Rad) for 1 h at 100 V and 4°C. To verify successful transfer of protein and note 
the position of the marker, the membrane was stained for 5-15 min in 0,2 % Ponceau solution 
(Sigma) and destained with H2O. 
 
2.3.3.2 Detection of membrane-bound protein by chemoluminescence 
To detect the presence of membrane-bound protein with specific antibodies, unspecific 
binding sites on the membrane were first blocked with blocking buffer for 1 h at room 
temperature (RT). The membrane was then incubated with the specific unlabelled antibody or 
serum at the appropriate concentration for 1 h at RT. After washing 3 x in TBS-T, the 
membrane was incubated in the appropriate concentration of the second peroxidase-conjugated 
antibody for 1 h. The membrane was again washed 3 x and detection by chemiluminescence 
was performed according to manufacturer’s instructions (ECL, Amersham).  
 
2.3.4 Determination of protein concentration according to Lowry 
In this assay, tyrosine residues in the soluble protein react with a Folin-Ciocalteu reagent 
to form a protein-dye complex with a maximal absorption at 600 nm. The assay was performed 
according to manufacturer’s instructions (Sigma) with different dilutions of protein solution and 
absorption was measured at 600 nm. A calibration curve was established using bovine serum 
albumine (BSA, SIGMA) and concentration of the test sample was calculated from the 
absorption value. 
 
2.3.5 Determination of protein concentration according to Bradford 
In this assay, the Coomassie brilliant blue G250 forms a protein/dye complex with 
arginine residues of proteins, with a maximal absorption at 595 nm. 1-10 µl of the protein 
solution were incubated with 1 ml Bradford reagent (1/5 diluted from the stock solution) for 10-
30 min at  room temperature (RT). A calibration curve was established using bovine serum 
albumine (BSA, SIGMA) and concentration of the test sample was calculated from the 
absorption value. The method can be used for end concentrations of 1-10 µg/ml.  
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2.3.6 Purification of recombinant MOG-Igd from bacteria 
The expression of recombinant MOG-Igd was performed in the Escherichia coli - strain 
DH5α Fiq, which had been transformed with pQE12 (Qiagen) containing the cDNA coding for 
the extracellular domain of rat MOG (amino acids 1-125). Gene expression in pQE 12 is under 
regulation of the IPTG inducible lac promoter. The plasmid also codes for 6 C-terminal 
histidines, allowing purification by nickel-chelate chromatography (Amor et al., 1994) and 
contains an ampicillin resistance gene. Transformed bacteria are selected with kanamycin (25 
mg/l) and ampicillin (100 mg/l). Kanamycin resistance is encoded on the Fiq episome.  
2.3.6.1 Expression of recombinant protein in bacteria 
Culture medium (1.2 l) was inoculated with a transformed E. coli glycerol stock and 
incubated over night at 37°C on a shaker. After centrifugation at 5,000 rpm for 20 min, the 
bacterial pellet was resuspended in 12 l of selective culture medium without glucose (glucose is 
a repressor of the lac promoter) and shaken at 37°C. When the absorption at 600 nm reached 
0.7, 10 ml of 0.1 M IPTG (BioTech Trade) were added per liter of culture to induce MOG-Igd 
expression. Incubation was continued for a further 3-4 h, after which the bacteria were 
centrifuged (60 min, 5,000 rpm (max. 10,000rpm), 4°C), resuspended in 200 ml PBS and 
centrifuged again. The pellet was stored over night at –20°C. 
2.3.6.2 Lysis of bacteria 
The bacterial pellet was resuspended in 65 ml PBS and sonicated for 30 min on ice 
(Branson Sonifier 450) to lyse the cells. Like most recombinant proteins, MOG is sequestered 
in inclusion bodies in E coli and is insoluble in PBS. After centrifugation (4°C, 16,000 rpm in 
SS34 rotor, 30 min) the pellet containing the MOG-Igd inclusion bodies and other insoluble 
proteins was resuspended in urea buffer and sonicated for 30 min to dissolve the inclusion 
bodies. The suspension was again centrifuged and the supernatant containing the dissolved 
MOG was used for affinity chromatography, while the pellet was re-sonified in 8 M urea buffer 
before adding it onto the same column. 
2.3.6.3 Nickel-Chelate Affinity Chromotography 
The column (40 ml chelating sepharose, Pharmacia) was washed sequentially with 
distilled water and with 1% EDTA/0.05% Tween 20 to remove the 70 % ethanol used for 
storage and any remaining nickel, followed by another wash with water. The column was 
loaded with a 1% nickel chloride (NiCl2) solution, washed with dH2O and equilibrated with 
urea buffer. The column was then loaded with the sample at a rate of 0.5 ml/min and washed 
with at least 200 ml wash buffer. The elution was performed with an increasing imidazole 
gradient (40 mM – 500 mM over 200 ml). 2 ml fractions were collected and analysed by SDS-
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PAGE. The protein concentration in the eluate was monitored by photometer (280 nm). The 
column was then washed first with 1% EDTA, 0.05% Tween 20 to remove all nickel and then 
with H2O and stored in 70% ethanol. 
2.3.6.4 Dialysis 
After analysis by SDS-PAGE, protein-containing fractions were pooled and transferred 
into dialysis tubes (exclusion 3,500 Da, Biomol). Dialysis was performed for 48 h against 2 x 5 
l 10 mM acetate buffer pH3 at 4°C. Protein concentration was determined and purity was 
verified by SDS-PAGE. Protein was then concentrated to 2 mg/ml using Macrosep centrifugal 
concentrators (PALL FILTRON, cut off: 10 kDa) 
 
2.3.7 Expression of bovine BTNexo using the Baculovirus system 
The extracellular domains of bovine butyrophilin were expressed using the baculovirus 
system in Sf9 (derived from pupal ovarian tissue of the fall army worm, Sporodoptera 
frugiperda) and HiFive (derived from ovarian cells of the cabbage looper, Trichoplusia ni) 
insect cells (Invitrogen). This system allows the production of native, glycosylated proteins, 
fused to a hexa-histidine tag. BTN is secreted into the cell culture medium and thus easily 
purified. Unfortunately the yield of the proteins was low in this system, but attempts to express 
BTNexo in bacteria were unsuccessful both in Munich and Maryland.  
The Baculovirus construct (derived from Autographa California multiple nuclear 
polyhedrosis virus (AcMNPV)) was kindly provided by Sherry Ogg and Dr. Ian Mather at the 
University of Maryland. It contains the cDNA encoding the signal sequence and the two 
extracellular domains of bovine butyrophilin under the control of the polyhedrin promoter (an 
important protein component of the membrane of occluded viruses, therefore highly expressed. 
Since the occluded virus is a replicative form, which is not essential in cell culture, the 
polyhedrin gene could be replaced by the BTN-cDNA), leading to strong expression of the 
transgene.  
 Protein was expressed according to the Invitrogen “MaxBac 2.0 Expression and 
Purification Manual” at 27°C, using TNM-FH or High 5 media purchased from Invitrogen and 
completed with Penicillin/Streptomycin and Serum. High titre virus stock was prepared in 
adhesive cultures of Sf9 cells, protein was obtained from suspension cultures of High five cells 
(2 x 106cells/ml) after 1/10 dilution of the high titre stock in the culture medium. The protein 
was harvested 2-3 days after transfection of the High five cells with the high titre virus stock. 
Cells were centrifuged (3,000 rpm,10 min, 4°C), and the supernatant was dialysed for 48 h 
against at least 10 l of first TBS and then PBS.(exclusion size 12-14 kd). Protein was then 
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purified via Nickel-Chelate chromatography, as described for MOG-Igd, but using PBS as the 
buffer (elution with 500 mM Imidazol in PBS, pH8). Eluate fractions were analysed by SDS-
PAGE, and protein-containing fractions were pooled and concentrated using a Macrosep 
centrifugal concentrators (PALL FILTRON, cut off 10kDa). 
 
2.3.8 Enzyme-linked immunosorbent assay (ELISA) 
This technique (Engvall and Perlmann, 1971) allows the detection of antibodies that bind 
to a plate-bound antigen or antibody by an enzymatic reaction and was used to determine serum 
antibody titers and specificities. 
96-well ELISA plates (polyvinyl coating, Costar) were coated for 1 h at 37°C or over 
night at 4°C with 5 µg/ml antigen in coating buffer (100 µl/well). The plates were washed 3x 
with wash buffer (ELISA-washer, NUNC), and unspecific binding sites on the plate were 
blocked with 200 µl/well blocking buffer for at least 1 h at 37°C or over night at 4°C. After this, 
the plates were washed again and 100 µl rat serum were added to each well at an appropriate 
dilution in coating buffer (often serial dilutions) and incubated at least 1 h at 37°C, followed by 
washing. Bound antibodies were then detected using 100 µl/well anti-rat antibodies (1h, 37°C), 
which were either directly coupled to alkaline phosphatase (anti-rat-IgG(H+L), anti-rat-IgG and 
anti-rat IgM (Southern Biotechnology Associates, Birmingham, Al, USA)) or biotinylated 
(IgG1, 2A, B and C)(Pharmingen), and which were diluted 1/2000 - 1/4000 in coating buffer. 
Plates were washed 3 times. For the biotinylated antibodies, an additional incubation step was 
required with 100 µl/well Streptavidin-alkaline phosphatase conjugate in coating buffer 
(Pharmingen, 1/2000), again 1h at 37°C, followed by washing. 
To develop a colored reaction, p-nitrophenyl phosphate was used as substrate for the 
alkaline phosphatase. 100 µl substrate buffer were added in each well and reaction was 
developed for 5 to 60 min. The plate was read at 405 nm in a spectrophotometer (MR 4000 
ELISA Reader, Dynatech) at different time points. 
 
2.3.9 Cytokine ELISA 
The measurement of cytokines (IL-10, IFN-γ, TNF-α and TGF-β) in T lymphocyte 
culture supernatant was also performed by ELISA. In this assay cytokines were detected by 
sandwich ELISA, in which plates were coated with an anti-cytokine antibody. Binding of 
secreted cytokines was detected by a biotinylated anti-cytokine antibody followed by 
streptavidin coupled to peroxidase. Assays were performed according to manufacturer’s 
instructions (kits from R & D Systems (TGF-β) and Biosource (IL-10, IFN-γ and TNF-α)). In 
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each case, a calibration curve was determined for standard concentrations and titer of the 
sample was calculated from the absorption value at 450 nm. 
 
2.4 Animal experimentation 
2.4.1 Active immunisation of rats with Freund’s adjuvant 
The antigen solution was mixed with an equal volume of complete or incomplete 
Freund’s adjuvant (Gibco, BRL). The mixture was forced through a 24G connector (Hamilton, 
86509, FEM. HUB, GA24, 50 mm) fixed between 2 syringes until a thick emulsion was 
obtained. Rats were injected subcutaneously into the tail after ether anesthesia with 100 µg of 
antigen in 100 µl of emulsion.  
 
2.4.2 Clinical evaluation of EAE 
After immunisation, rats were weighed and clinically assessed on a daily basis. The 
clinical signs of EAE were evaluated according to the following scale: 
0: no signs of disease 
1: loss of muscle tone of tail 
2: paraplesia of hind limbs 
3: paralysis of hind limbs 
4: moribund 
5: dead 
Half-points were also given. 
In accordance with federal guidelines, animals with a score of 3.5 for 2 consecutive days or 
reaching a score of 4 were sacrificed. 
 
2.4.3 EAE-induction via transfer of MOG- or MOG-peptide specific T cells 
MOG- or MOG-peptide specific T cell lines were restimulated for three days in the 
presence of their selecting antigen and irradiated thymocytes, which were used as antigen 
presenting cells (APCs). After this, the cells were centrifuged for 12 min at 4°C and 12,000 rpm 
and washed twice in EH. 1.5 – 50 x106 T cell blasts were injected i.p. in 2 ml EH or 
alternatively in 1 ml EH into the tail vain.  
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2.4.4 DNA vaccination of rats 
For DNA vaccination, the plasmid DNA was injected intramuscularly into the tibialis 
anterior muscle. To avoid a too deep insertion of the needle, a tubing was inserted over the 27G 
canula, covering all but 4-5 mm of the tip. Female rats (age 4-5 weeks) were anesthesized with 
ether and injected in each tibialis anterior muscle with 200 µg DNA in PBS (1 mg/ml). MOG-
specific antibody titers in serum were verified by ELISA 2-8 weeks after immunisation. For 
vaccination with two different constructs, 400 µg of each plasmid were injected into a single 
muscle.  
 
2.4.5 Intranasal application of peptides 
6-8 week old female DA rats were treated for 10 consecutive days with 50 µg peptide (1 
mg/ml), i.e. 25 µl per nostrils, applied using a micropipette. Three days after the last treatment, 
the animals were immunised with 100 µg MOG-Igd in IFA.  
 
2.4.6 Intravenous application of serum or peptides 
For HDSA treatment, 0.5 ml of a 2 mg/ml peptide solution were injected into the tail vein 
2 and 4 d.p.t. of freshly restimulated T cell blasts (1.5 - 50 x 106). For serum transfer, 1 - 2 ml of 
serum were injected at various d.p.i. into the tail vein.  
 
2.4.7 Treatment with Minocycline 
Minocycline (SIGMA) was dissolved to 45 mg/ml in PBS. Animals were treated daily i.p. 
with 45 mg/kg body weight (ca 150-180 µl).   
2.4.8 Preparation of serum 
500-1,000 µl of blood were collected in 1.5 ml polypropylene tubes from the tail vein. 
Blood was left to coagulate a few hours at room temperature (RT) or overnight at 4°C. It was 
then centrifuged 10 min at 1,200 rpm, supernatant was taken and centrifuged again. This step 
was repeated until supernatant was clear. The serum obtained was stored at –20°C. 
Alternatively, blood was collected after dissection of the vena cava superior if the animals were 
to be killed  
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2.4.9 Perfusion of rats 
For histopathological examinations rats were perfused with paraformaldehyde (PFA) 
solution (4% in PBS). Under ether narcosis rats were thoracotomised and the upper vena cava 
was sectioned. 50 ml of PFA solution were injected slowly into the left ventricle. Brain and 
vertebral column were isolated, postfixed overnight in PFA solution, then stored in PBS at 4°C. 
Histopathological examination was carried out on paraffin embedded sections by Drs. R 
Höftberger, M. Storch and A, Stefferl in the group of Prof. H. Lassmann, Vienna.  
 
2.5 Cell biology methods 
2.5.1 Preparation of a single cell suspension from rat tissues 
Thymus was derived from naïve animals, superficial inguinal lymph nodes and/or spleen 
were isolated from immunised rats at different time points after immunisation d.p.i.s in aseptic 
conditions and immediately placed in EH medium on ice. Single cell suspensions were prepared 
by passing the tissues through a glass homogeniser, after which they were washed twice in 35 
ml EH.  
 
2.5.2 Establishment of antigen-specific T cell lines  
2.5.2.1 Primary culture of T lymphocytes 
Lymph node cells or splenocytes in single cell suspension were incubated in restimulation 
medium in the presence of selecting antigens for 3 days at 37°C with 10 % CO2 at a density of 1 
x 107 cells/ml. T cell specificity assays were carried out in parallel (section 2.5.2.4). For 
cytokine ELISA, cells were incubated at a density of 6 x 106 cells in 2 ml restimulation medium 
in 12-well plates in the presence or absence (background) of selecting antigen. Supernatant was 
taken at 72 h and stored at –20°C. 
 
2.5.2.2 Expansion of the T cells in IL-2-containing medium 
After three days of primary culture, the cells were centrifuged and washed with EH and 
transferred into the IL-2 containing TCGF-medium at a concentration of approximately 5 x 105 
cells/ml. 10 ml of this suspension were plated into 10 cm culture plates. The cells were split in 
two whenever they reached a density of about 2 x 106 cells/ml.  
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2.5.2.3 Restimulation of the T cells 
Four to seven days after the transfer into TCGF, the size and proliferation rate of the cells 
was dramatically reduced and the cells had to be restimulated in the presence of freshly 
prepared irradiated thymocytes serving as antigen presenting cells (APCs) and their selecting 
antigens. After washing twice, the thymocytes were resuspended in 5 ml EH and irradiated with 
4,000 rad in order to inhibit their proliferation. The cells were then counted and 108 thymocytes 
were mixed with 2-4 x 106 T cells. This mixture was then centrifuged and resuspended in 5 ml 
restimulation medium/108 thymocytes. 5 ml were plated into 6 cm culture dishes or 
alternatively diluted ¼ for specificity tests in 96-well plates and incubated at 37°C, 100% 
humidity and 10% CO2. For cytokine analysis, 2 to 5 x 105 T cells were cultured with 9-11 x 
107 thymocytes in 2 ml restimulation medium in 12-well plates.  
 
2.5.2.4 T cell specificity assay 
In this assay, which is performed in parallel with each primary culture and restimulation, 
T lymphocytes are incubated in the presence of different antigens and/or various concentrations 
of antigen. Tritium-labelled thymidine is incorporated into the newly synthesized DNA of 
dividing lymphocytes, thus giving a measure of antigen-specific proliferation of T lymphocytes. 
5 x 105 lymph node cells or splenocytes (or 2-4 x 104 T cells with 106 irradiated thymocytes) 
were added in 200 µl of restimulation medium per well into a 96-well plate in the presence of 
specific antigen, the mitogen Con A or in the absence of antigen. Cells were incubated for 2 
days at 37°C with 10 % CO2. 20 µl of 3H-thymidine stock solution were added (final 
concentration 1 µCi/well) and cells were incubated for a further 16-18 h. Cells were then 
transferred to a fiberglass filter, washed and specific activity was measured in a beta-counter 
(Matrix 96 Direct Beta Counter, Packard). The stimulation index (SI) is determined as the ratio 
of the proliferative responses (c.p.m.) in the presence and absence of antigen. An SI larger than 
2 is considered significant. 
 
2.5.2.5 Isolation of T cell blasts by density gradient centrifugation 
After the three days of restimulation, T cell blasts were isolated by density gradient 
centrifugation. The cells were centrifuged and the content of 2-3 6 ml plates was resuspended in 
3 ml Lymphoprep (1.077g/ml density, 280 mOsmol, contains 9.6% sodium-metrizoate and 
5.6% polysaccharide) and carefully overlayed with 3 ml EH. The cells were then centrifuged for 
30 min at 4°C and 3,000 rpm (2,500 g)(breaks off!), after which T cell blasts could be found in 
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the interphase, while small cells or debris were in the pellet. Blasts were washed in serum 
containing medium to avoid clumping, then propagated for 4-7 days in TCGF.  
  
2.5.3 Determination of cell numbers 
Trypan Blue staining differentiates between live and dead cells, as the membrane of dead 
but not of live cells is permeable to the stain. The cell suspension was mixed with Trypan Blue 
at the appropriate dilution (1/2 – 1/10) and 10 µl were transferred to a Neubauer hemocytometer 
chamber. 100-200 live cells (unstained, round and bright) were counted under the microscope. 
Cell number was calculated as follows: 
[Cells in one big square] x [dilution factor] x 104 = cells/ml 
 
2.5.4 Freezing and thawing of cells 
Cells were taken up in ice-cold freezing medium and stored at –18°C for 1 h and then 
transferred to –80°C. All cell types were thawed rapidly and immediately transferred into serum 
containing medium. T cells, Ag8 and MLA cells were then centrifuged to get rid of all DMSO, 
resuspended in their culture medium and incubated at 37°C, 10% CO2 and 100% humidity. 
   
2.5.5 Culture of the monkey cell line MLA 
The monkey cell line MLA (Chen et al., 1985) was grown in MLA culture medium at 
37°C, 100% humidity and 10 % CO2. Cells were diluted 1/2 in fresh medium whenever the 
medium had turned yellow. Cell supernatant was aliquoted and stored at –18°C. 
 
2.5.6 Culture of insect cell lines High five and SF9 
Insect cells were kept according to the Invitrogen manual “ Growth and Maintenance of 
Insect Cell Lines”. In short, insect cells were thawed and first kept as adherent cultures in their 
appropriate medium at 27°C. Cells were monitored daily and split upon reaching confluency in 
order to keep them in log-phase. SF9-cells were infected with low titre of Bacculovirus for the 
creation of high titre stocks. High FiveR cells were transferred into suspension culture (to start 
with in the presence of 10 I.E. heparin) and kept at a concentration of 1-2 x 106 cells/ml. Once 
they reached log phase proliferation, the 2 106 cells/ml were infected with 1/10 volume of the 
high titre virus stock (ca. 10 MOI). Virus-infected cells were autoclaved twice before disposal. 
Supernatant was collected for the isolation of BTNexo. 
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2.5.7 Culture of a myeloma cell line (Ag8) 
The myeloma cell line Ag8 was grown in Ag8 culture medium at 37°C and 10 % CO2. 
Cells were diluted 1/3 in fresh medium every 3-5 days. MOG-transfected Ag8-cells were kept 
in the presence of 1.5 mg/ml geneticin (G418) 
 
2.5.8 Flow cytometry 
Cell surface antigens can be recognized by specific antibodies coupled to fluorescent 
markers and detected by flow cytometry. A fluorescence-activated cell sorter (FACS) measures 
the light emission generated by single cells flowing through a laser beam (excitation wavelength 
488 nm). Several parameters can be measured: size (forward scatter, FSC) and granularity (side 
scatter, SSC) of cells, as well as fluorescence emitted from surface-bound antibodies coupled to 
fluorochromes. The following fluorochromes were used: fluorescein isocyanate (FITC, 
emission at 530 nm, FL1), phycoerythrein (PE, emission at 578 nm, FL2) and RPE-Cy5 
(emission at 667 nm, FL3). Dead cells were stained with propidium iodide as the membrane of 
live cells is impermeable to this compound. 
 
2.5.8.1 FACS analysis of Ag8-cells 
105-106 cells from a single cell suspension were added in 50 µl FACS buffer per well of a 
96-well plate. Cells were washed twice by centrifugation (1200 rpm, 6 min) in 100 µl FACS 
buffer and resuspended in 50 µl FACS buffer containing an optimal concentration of the first 
antibody (unlabelled or coupled to biotin or to FITC) or rat serum to be tested. Cells were 
incubated on ice for 20-45 min and washed twice with FACS buffer. To detect an unlabeled 
first antibody, a second FITC or PE-labelled antibody directed against the Ig of the first 
antibody species was added. To detect biotin in the first staining, PE-coupled streptavidin 
(Amersham) was added. Cells were again incubated on ice for 20-45 min, washed twice and 
transferred to FACS tubes in 100-200 µl FACS buffer. Propidium iodide was added at a 
concentration of 10 µg/ml. Fluorescence was measured with a FACS Scan (Becton-Dickinson) 
and results were analysed with Becton-Dickinson software (Lysis). 
 
2.5.8.2 FACS-analysis of T cells 
Cell types as well as their activation status are characterised by a specific pattern of cell 
surface molecules. These were measured by FACS analysis, using non-conjugated first 
antibodies (mouse) and RPE-Cy-5-labelled second antibodies (rabbit anti-mouse). The 
antibodies were used in 1/100 dilutions of a 1 mg/ml stock. After three days of antigen-specific 
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restimulation, 104-105 T cell blasts were isolated by density gradient centrifugation and washed 
three times with FACS buffer. T cells were then incubated for 1 h on ice with 100 µl non-
conjugated cell surface marker-specific antibodies. After this, unbound antibody was washed 
off (3x with FACS buffer) and the cells were incubated with Cy5-labelled second antibody. 
Again, unbound antibody was washed off (3x with FACS buffer) and binding was detected 
using FACS. 
 
2.5.9 Statistical analysis 
Data are generally represented as average and standard deviation, and in some cases with 
standard error (always marked in the figure legend). Significance was calculated using 
Student´s t-test and Duncan´s post-hoc test. 
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3 Results 
3.1 The impact of antibody dependent effector mechanisms on disease 
progression in a model of relapsing remitting EAE 
There is no spontaneous animal model for MS. However, in many species the 
immunisation with spinal cord homogenates (SCH) or several different myelin proteins induces 
EAE, an autoimmune disease which resembles MS and has provided the basis for most of the 
current knowledge about this disease. It should be noted that EAE, like MS, is not a 
homogeneous disease, but varies in disease course, intensity and pathological features. These 
are influenced by a variety of factors, such as nature and dose of antigen, adjuvant, species, 
(inbred) strain/genotype, age and gender, as well as external stress factors. This leads to a wide 
range of different disease models, all of which are initiated by the peripheral activation of 
myelin-specific T cells, an event, which is also thought to initiate MS (Hohlfeld, 1997).  
However, little is known about the mechanisms responsible for the classical clinical 
course of MS, an initial period of relapsing-remitting disease followed by a progressive 
worsening of the clinical deficit. In mice (SJL/J and Biozzi) (Brown and McFarlin, 1981; Baker 
et al., 1990), EAE often follows a similar relapsing remitting disease course (RR-EAE). In these 
animals disease is T cell mediated, since the adoptive transfer of encephalitogenic CD4+ T cells 
alone can induce relapsing remitting disease and demyelination (Mokhtarian et al., 1984). 
Relapse activity is associated with epitope spreading, the sequential switch/diversification of the 
autoimmune T cell response to additional CNS target autoantigens as disease progresses 
(reviewed in Tuohy et al., 1998). Pathologically, these mouse model develop lesions mimicking 
type I lesions, which are seen in a minor subgroup of MS patients (Lucchinetti et al., 2000; 
Lassmann et al., 2001; section 1.1.3).  
Most patients, however, develop lesions which are characterised by the deposition of 
antibody and complement on the myelin sheath in addition to inflammatory infiltrates (type II 
lesions, Lucchinetti et al., 2000; Lassmann et al., 2001), indicating that antibodies play a major 
role in disease pathogenesis. This concept is supported by the observation that plasmapheresis 
often induces remission in patients with acute, steroid-non-responsive relapses (Weinshenker et 
al., 1999).  
Clearly more insight is required into the mechanisms responsible for driving disease 
progression in MS, in particular the potential role of autoantibodies. RR-EAE induced by active 
immunisation with MOG-Igd in the rat is an obvious candidate for such studies. As in the 
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mouse, the clinical course is genetically determined by multiple loci (Weissert, 1998). DA rats 
are particularly susceptible to develop RR-EAE after active immunisation with either SCH 
(Lorentzen et al., 1995) or MOG-Igd (Weissert et al., 1998). Crucially, the immunopathology 
reproduces type II-antibody mediated demyelination (Storch et al., 1998) suggesting that this 
strain will provide a deeper insight into the pathomechanisms involved in this large subset of 
MS patients. However, any studies of RR-EAE are complicated by inter-animal variation in 
disease progression. Analysis of the mechanisms responsible for relapse and disease 
progressions requires a highly predictable time frame. Preliminary studies indicated that this 
may be possible in DA rats following immunisation with MOG-Igd in IFA, a protocol that also 
avoids adjuvant-induced arthritis (AA). The first experiments revealed that while low doses of 
MOG-Igd in IFA (10-50µg) would induce relapsing-remitting disease, a higher dose (100 µg) 
was required to synchronise the onset of relapse. 
 
3.1.1 Sensitisation with MOG-Igd in IFA results in a predictable pattern of disease 
remission and relapse.  
Immunisation with 100 µg MOG-Igd in IFA resulted in a synchronised biphasic disease 
course in female DA rats (Figure 3.1.1). The first clinical symptoms appeared 7-10 d.p.i. (days 
post immunisation), the severity of the clinical deficit then increased rapidly to reach a peak 10 
to 11 d.p.i., after which the animals began to recover. Clinical recovery was complete in 
approximately 50% of the animals by 15 d.p.i., whereas the remainder showed some degree of 
residual disease activity (grade 0.5 to 1.5). This remission lasted for 2 to 3 days, but irrespective 
of the extent of recovery this was followed by a relapse characterised by a progressive increase 
in disease severity. The majority of the rats developed severe hind limb paralysis with fore limb 
paraplegia by 20 to 25 d.p.i. and were sacrificed in accordance with the animal regulations of 
the federal government of Bavaria. 
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Figure 3.1.1 Disease course in DA rats after immunisation with 100 µg MOG-Igd/IFA.  
Depicted is the average and standard deviation of the clinical course of 23 rats, of which 5 were euthanised 10 d.p.i; 
9 rats 15 d.p.i. and the last 9 rats 19 d.p.i. 
 
3.1.2 The pathology of MOG-Igd/IFA induced EAE.  
Animals were immunised with 100 µg MOG-Igd/IFA and perfused for immuno/histo-
pathological analysis of the CNS 4, 10, 15 and 21 d.p.i. (Figure 3.1.2: collaboration with 
Professsor H. Lassmann and Dr. R. Höftberger, University of Vienna, Vienna, Austria). This 
revealed that CNS pathology changed dramatically during the course of the disease (Figure 
3.1.2). Four d.p.i., i.e. three to four days before the onset of any clinical signs of EAE, no 
obvious pathological changes were seen in the CNS (Figure 3.1.2 1a-e). However, six days later 
(10 d.p.i.), coincident with the first peak of disease, an intense inflammatory response had 
developed in the CNS, characterised by large numbers of ED1+ monocytes (Figure 3.1.2 2C) 
and W3/13+ T cells and polymorphonuclear cells (PMNs) (Figure 3.1.2 2E) infiltrating into the 
perivascular space and CNS parenchyma. At this time point demyelination was minimal (Figure 
3.1.2 2B) and restricted to small areas around perivascular/sub-pial infiltrates. Five days later, 
when the animals were in clinical remission, the inflammatory infiltrate was greatly reduced 
with respect to W3/13+ T cells (Figure 3.1.2 3E) as well as ED1+ macrophages/microglia 
(Figure 3.1.2 3C). There was still no obvious evidence of demyelination (Figure 3.1.2 3B). This 
was in striking contrast to the situation 21 d.p.i., when the rats were in relapse and had 
developed severe clinical disease. At this late time point disease was associated with extensive 
demyelination throughout the CNS (spinal cord, fore brain and cerebellum) (Figure 3.1.2 4B) 
accompanied by a diffuse inflammatory infiltrate of ED1+ and W3/13+ cells (Figure 3.1.2 4C  
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Figure 3.1.2. Histopathology in the different stages of MOG-Igd/IFA induced EAE.  
DA rats were immunised with 100 µg MOG-Igd/IFA and perfused 4 d.p.i. (1); 10 d.p.i. (2); 15 d.p.i. (3) and 21 
d.p.i. (4). Serial sections were stained for a) inflammatory infiltrates (hematoxylin eosin); b) myelin (Luxol fast 
blue); c) activated microglia and macrophages (ED1, mouse mAb); d) complement deposition (rabbit anti-C9) and 
e) T cells and polymorphonuclear cells (W3/13, mouse mAb). Amplification is 40x in a) - c) and 400x in d) and e). 
Photos by Dr. R. Höftberger, Vienna. 
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and 4E). These active demyelinating lesions were associated with the deposition of antibodies 
and C9 (Figure 3.1.2 4D) in the affected white and grey matter, characteristic features of 
antibody- mediated demyelination in the rat (Linington et al., 1988; Linington et al., 1989 A; 
Storch et al., 1998).  
As summarised in Table 3.1.1, relapse is clearly associated with the onset of extensive 
demyelination, while the initial phase of EAE is purely inflammatory. 
 
Phase of disease Inflammation Demyelination 
Preclinical (4 d.p.i.) - - 
First peak of disease (10 d.p.i.) +++ +/- 
Remission (15 d.p.i.) + +/- 
Relapse     (19 d.p.i.) ++ ++++ 
 
Table 3.1.1 Summary of the pathological analysis. 
The symbols represent:  - absent; +/- questionable; + to ++++ relative increase in severity 
 
3.1.3 Is there a progressive change in the immune effector mechanisms responsible for 
disease activity in this model of MS ? 
The observation that the initial phase of disease induced following immunisation with 
MOG-Igd/IFA was associated with CNS inflammation whereas clinical relapse was 
characterised by inflammation plus extensive demyelination suggests that there is a progressive 
change in the immune effector mechanisms responsible for disease pathogenesis in this model. 
Previous studies have shown that in the rat the inflammatory response in EAE is triggered by a 
CD4+ Th1 T cell response, which induces the recruitment and activation of ED1+ macrophages 
into the CNS and blood brain barrier (BBB) dysfunction (Ben-Nun et al., 1981). However, this 
T cell mediated response alone is unable to induce demyelination (Linington et al., 1988). 
Demyelination in EAE in both rats and marmosets (Callithrix jacchus, a non-human primate) 
requires the participation of a myelin-specific antibody response (Lassmann et al., 1988; 
Linington et al., 1988; Genain et al., 1995). This is associated with the deposition of 
immunoglobulin and complement on the myelin sheath, myelin vesiculation and the 
phagocytosis of opsonised myelin debris by macrophages (Linington et al., 1988; Storch et al., 
1998 b; Genain et al., 1999; Raine et al., 1999). In view of the obvious changes that occur in the 
immunopathology of MOG-Igd-induced EAE during the course of the disease, we anticipated 
that the first, inflammatory phase of disease was driven by a MOG-specific CD4+ T cell 
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response, while MOG-specific antibodies evolved to become the dominant pathomechanism 
responsible for driving disease activity in relapse. In order to test this hypothesis, we 
investigated the characteristics of the MOG-specific T cell- and antibody-response at the 
following time points: 
 
I. Preclinical (4 d.p.i.) 
II.  First peak of disease (10/11 d.p.i.) 
III. Remission (15 d.p.i.) 
IV. Relapse (19/21 d.p.i.) 
 
3.1.3.1 Characterisation of the MOG-Igd-specific T cell response 
3.1.3.1.1 MOG-specific T cell proliferation is maximal during the first peak of disease 
A MOG-Igd-specific proliferative response was detected in the draining lymph nodes as 
early as 4 d.p.i. The stimulation index increased over the next six days, reaching a maximum 10 
d.p.i., concurrent with the first peak of disease, after which it decreased, but remained 
significantly increased over baseline levels (Figure 3.1.3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.3 Time course of MOG-Igd-specific T cell proliferation in the draining lymph nodes 
Shown is the mean stimulation index and standard deviation obtained after immunisation with 100 µg MOG-
Igd/IFA, using three animals per time point, which were analysed individually in quadruplicate 
 
A similar, but less pronounced response was observed in the spleen (data not shown). It should 
be noted that no significant increase in antigen-specific proliferation in the peripheral immune 
organs was associated with clinical relapse. 
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3.1.3.1.2 The MOG-specific T cell response recognises two distinct epitopes after 
sensitisation with MOG-Igd/IFA 
Previous studies of MOG-Igd/CFA induced EAE in the DA rat identified two 
encephalitogenic T cell epitopes (Stefferl et al., 2000; Schubart et al., 2001; Iglesias et al., 
2001). The relative contribution of these epitopes to the IFA model was analysed 10 d.p.i. by 
epitope mapping using a panel of nine overlapping peptides spanning the complete Ig-domain. 
Cells derived from both the draining lymph nodes and spleen proliferated in response to MOG-
Igd, and a dominant epitope was identified within the amino acid sequence M89-113 (Figure 3.1.4 
A). A minor response was observed to the overlapping peptides M63-87 and M76-100. The fine 
specificity of this response was determined using MOG-Igd-specific T cell lines (TCLs) and a 
panel of shorter overlapping 15-mer peptides (Figure 3.1.4 B). This analysis identified M93-109 
as the immunodominant MOG-Igd-epitope and confirmed the presence of a second epitope 
within  M74-90. 
 
3.1.3.1.3 Characterisation of MOG-Igd and MOG-peptide specific T cell lines  
In order to test the hypothesis that the first phase of MOG-Igd-induced EAE may be 
driven by a pathogenic CD4+ T cell response, we analysed the surface phenotype and cytokine 
spectrum of MOG-, M93-109 and M74-90-specific T cell lines (TCLs) derived from the draining 
lymph nodes 10 d.p.i. and then tested their pathogenicity by adoptive transfer into naive 
syngeneic recipients. After three to four rounds of in vitro selection, all three TCLs were highly 
specific for their selecting antigen. In addition, the peptide-specific TCLs retained their 
responsiveness to MOG-Igd, and the MOG-Igd selected TCLs continued to respond to both 
peptide epitopes (Table 3.1.2).   
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Figure 3.1.4 Epitope mapping of MOG-Igd-specific T cells.  
A) Peptide specificity of lymph node cells pooled from 2 rats 10 d.p.i. with 100 µg MOG-Igd/IFA; B) Data for a MOG-specific 
T cell line, which was analysed using smaller peptides that spanned the sequences identified in A). Depicted are the average 
c.p.m. (counts per minute) and standard deviation of quadruplicate measurements.  
 
 
 
                               Proliferation (c.p.m.) Antigen 
T cell line No antigen MOG M93-109 M74-90 
MOG-Igd 72.5 +/- 2 2403 +/- 192 1383 +/- 90 1078 +/- 68 
M93-109 38 +/- 11 3017 +/- 486 3710 +/-564 20 +/-5 
M74-90 155 +/- 76 1126 +/- 100 164+/- 36 2284 +/- 132 
 
Table 3.1.2 Proliferative response of the MOG-Igd or MOG-peptide specific T cell lines (TCLs) to MOG and 
the two MOG epitopes.  
Shown are mean counts per minute (c.p.m.) and standard deviation of quadruplicate or triplicate analysis of 
representative restimulation assays.  
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FACS analysis revealed that these TCLs consisted of pure CD4+ T cell populations 
(>99% CD3+, >99% αβTCR+, >98% CD4+, see Figure 3.1.5 for a representative analysis). 
When stimulated with their selecting, cognate antigen, all TCLs secreted large amounts of IFN-
γ (30-60 ng/ml), IL-10 (0.5-1.8 ng/ml) and TNF-α (1.5 - 6 ng/ml), as described previously for in 
vitro selected Th1 subset rat T cell lines (Stefferl et al., 1999; Lenz et al., 1999). 
 
 
 
Figure 3.1.5 Representative FACS analysis of a M74-90-specific T cell line.  
Histograms show A) isotype control; B) CD3; C) IL-2R; D) MHC class II; E) CD4; F) OX 40 antigen; G) TCR in 
blue and the isotype control overlay in green; H) dot plot illustrating the cell population gated for analysis. 
 
A) B) C)
D) E) F)
G) H)
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 To investigate their pathogenicity, MOG-Igd- or MOG-peptide (M93-109 or M74-90) - 
specific T cell blasts were harvested after 72 hours of antigen-driven restimulation in vitro and 
adoptively transferred into naïve syngeneic recipients. All three cell lines were pathogenic and 
induced a monophasic disease, which started 4-5 d.p.t. (days post transfer, see Figure 3.1.6 for a 
representative disease course). The severity of disease increased rapidly for the next 24 to 48 
hours, after which the animals recovered. Clinical recovery was complete by 10 - 11 d.p.t.. 
Histopathological investigations revealed that disease was associated with an intense 
inflammatory response in the CNS that was dominated by macrophages. There was no evidence 
of demyelination. (Figure 3.1.7) 
The pathogenicity of the MOG-specific T cell response in DA rats was striking as this 
was not the case in either LEW and BN rats (Stefferl et al., 1999; Linington et al., 1993; 
Adelmann et al., 1995). In these other rat strains the adoptive transfer of MOG-specific CD4+ 
Th1 T cells fails to induce clinical disease although they trigger the recruitment of T cells into 
the CNS. The observation that the DA T cell response to MOG is highly pathogenic, but fails to 
initiate demyelination supports the hypothesis that this response alone may be responsible for 
the first, inflammatory phase of disease in MOG-Igd/IFA induced EAE in DA rats.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.6 Clinical course of EAE induced by adoptive transfer of M93-109-specific T cells.  
Depicted is the mean and standard deviation of the clinical course of 15 DA rats injected with 1.7 x 106 M93-109 -
specific T cells.  
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Figure 3.1.7 CNS pathology 6 d.p.t. of 5 x 106 MOG-Igd-specific T cells 
Serial sections were stained with 1) Luxol fast blue (LFB), revealing a complete absence of demyelination (32x); 2) 
Hemytoxylin eosin (cellular infiltrates); 3) ED1 (activated microglia and macrophages) and 4) W3/13 (T cells and 
granulocytes). 2) – 4) 300x. Stainings reveal strong perivascular infiltrates of macrophages, T cells and 
granulocytes. The rat had grade 4 disease at the day of perfusion. Photo provided by Dr. M. Storch, University Med 
School Graz, Austria  
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3.1.3.2 Analysis of the antibody response 
If the hypothesis is correct that the first phase of MOG-Igd induced EAE in the DA rat is 
purely T cell mediated, the MOG-specific antibody response should be minimal during the 
initial phase of disease and only start to increase in remission. 
Analysis by ELISA using sera taken at four time points (Figure 3.1.8 A) demonstrated 
that this was indeed the case. MOG-Igd-specific antibodies were absent 4 d.p.i., and only low 
levels were detected during the first peak of disease (10 d.p.i.). The antibody titre then increased 
rapidly, 3.5-fold in the next 5 days, and then another nine fold in the following 4 days, so that 
during relapse the total MOG-specific antibody titre was approximately 30-fold higher than 
during the first phase of disease.  
Analysis of the isotype-composition of the MOG-Igd-specific antibody response revealed 
that MOG-specific IgM dominated the early response (10 d.p.i.) and increased slightly over the 
next nine days (Figure 3.1.8 B). In contrast, the levels of MOG-specific IgG, IgG1, Ig2A, 
IgG2B and IgG2C were very low during the first acute phase of disease, but increased 
dramatically between 15 and 19 d.p.i.. This reflects the normal course of maturation of an 
antibody response. While early adaptive immune responses are generally characterised by the 
secretion of IgM (IgM pentamers have a high avidity to their antigen, even if the affinity of the 
antibodies is still low), a cytokine-mediated recombination of DNA takes place in parallel with 
affinity maturation, leading to isotype switching.  
The epitope specificity of MOG-Igd-specific antibodies was characterised using a panel 
of nine overlapping synthetic 18 - 25-mer peptides. During the first phase of disease (10 d.p.i.), 
when the antibody titre was still low, we observed an immunodominant response to the N-
terminal peptide M1-26 (Figure 3.1.8 C). Nine days later, during relapse, the response to M1-26 
was still dominant, but was now accompanied by a response to a second peptide, M50-74 (Figure 
3.1.8 D). This demonstrates that not only titre and isotype distribution of the antibody response, 
but also its specificity and complexity develops with time. The rapid increase in the MOG-
specific antibody titre and complexity occurs as the animals relapse and is associated with the 
onset of widespread demyelination. 
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Figure 3.1.8 Analysis of the antibody response after immunisation with 100 µg MOG-Igd in IFA.  
A) Time course of the total MOG-Igd-specific antibody response (IgG + IgM). Diamonds: 4 d.p.i., squares 10 d.p.i., triangles 15 
d.p.i., circles 19 d.p.i. Shown are the mean O.D.405 values and standard deviations obtained using sera pooled from 2-3 rats per 
time point and analysed in quadruplicate. B) Time course of the isotype composition of the MOG-Igd-specific antibodies. 
Depicted are the mean O.D.405 values and standard deviations obtained using sera pooled from 2-3 rats per time point and 
analysed in quadruplicate. Sera were diluted 1/300 for IgM (diamond); 1/900 for IgG (square); 1/300 for IgG1(triangle) and 
1/100 for IgG2A (cross). IgG2B- and IgG2C-responses were similar to the IgG2A response. C), D) Analysis of the epitope 
specificity 10 d.p.i. (C) and 19 d.p.i. (D) revealed that two linear epitopes were recognised during relapse, but only one at the 
earlier time point. Shown are the mean O.D.405 values and standard deviations of 3 individually analysed rats 10 d.p.i. and 6 
individually analysed rats 19 d.p.i.. The serum of each rat was analysed in quadruplicate. Note that the two ELISAs were 
developed for different times in order to give a comparable response to peptide 1-26 and MOG-Igd. E, F) representative FACS 
analysis of sera derived 19 d.p.i. with MOG-Igd/IFA. Shown is the binding to MOG-transfected (blue) or to untransfected  
(green) Ag8-cells. E) Serum derived 19 d.p.i with MOG-Igd/IFA; F) positive control using 8-18C5, a monoclonal MOG-specific 
antibody. No specific binding was detectable 19 d.p.i.. Serum was pooled from 3 rats derived 19 d.p.i. and analysed in a 1/40 
dilution. 8-18C5 was analysed at 25 µg/ml. Figures E and F) provided by Dr. C. Bourquin, Martinsried. 
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3.1.3.2.1 The titre of demyelinating  antibodies is low in the periphery 
A prerequisite for antibody-mediated demyelination is that antibodies bind to native 
antigen expressed on the surface of the myelin sheath (Brehm et al., 1999). Recognition of 
native MOG can be assayed in vitro by FACS analysis using MOG-transfected target cells 
(Brehm et al., 1999; Bourquin et al., 2000; Haase et al., 2000). Previous studies using this 
approach suggest that the pathogenic component of the MOG-specific antibody response is 
conformation dependent (Bourquin et al., 2000; Haase et al., 2000). This response can not be 
distinguished from the response to linear epitopes by ELISA, as the recombinant antigen used in 
these studies is partially denatured and will therefore bind antibodies directed against both types 
of determinants. We therefore tested the capability of MOG-Igd-specific antibodies to bind to 
native antigen expressed on the surface of a myeloma cell line (Ag8) that had been transfected 
with full length MOG via FACS analysis (Bourquin et al., 2000).  
Intriguingly, even 19 d.p.i. we were unable to detect any significant binding of MOG-
specific antibodies to the transfectants (3.1.8 E), suggesting that the level of pathogenic 
antibodies in the periphery is very low. In view of the intense demyelinating pathology 
associated with antibody and C9 deposition in the CNS during relapse, it is probable that the 
pathogenic component of the antibody response is rapidly absorbed within the CNS. Absorption 
of MOG-specific antibodies within the CNS was already suggested to occur in a guinea pig 
model of CR-EAE (Linington and Lassmann, 1987) and this was subsequently confirmed 
experimentally in the course of this study (see section 3.1.3.4) 
 
3.1.3.3 Combined T cell- and antibody-mediated immune effector mechanisms 
reproduce the biphasic course of MOG-Igd/IFA-induced EAE 
The different kinetics of the MOG-Igd-specific T- cell and antibody responses support the 
concept that different effector mechanisms are responsible for the clinical deficits associated 
with the initial phase of disease and relapse. Disease was initially associated with a highly 
encephalitogenic T cell response, while the antibody titre was low. This correlated with the 
observation that early lesions were purely inflammatory and demyelination minimal, similar to 
the pathology observed after the transfer of activated MOG-Igd- or MOG-peptide-specific T 
cell blasts. In relapse, this situation was reversed. The T cell response was reduced, while the 
antibody response had greatly increased in titre and had matured with respect to antigen 
specificity and isotype usage. Correspondingly, the pathology was dominated by extensive 
demyelination in the context of a diffuse inflammatory infiltrate.  
If the hypothesis that relapse is mediated by pathogenic autoantibodies is correct, it 
should be possible to reproduce the biphasic disease course seen after immunisation with MOG-
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Igd by actively inducing an encephalitogenic T cell response and then adoptively transferring 
demyelinating autoantibodies after clinical recovery.  
 
3.1.3.3.1 Immunisation with the immunodominant peptide induces attenuated disease 
As a first step to ”reconstruct” the clinical course and pathology of MOG-Igd/IFA 
induced EAE, we studied the pathogenicity of the response induced by active immunisation 
with the immunodominant T cell epitope M93-109. Previous studies indicated that the antibody 
response to this linear peptide would not bind to the native protein and fail to induce 
demyelination (Brehm, 1999b). DA rats were therefore immunised with 100 µg M93-109 in IFA. 
This induced a monophasic disease resembling the first phase of MOG-induced EAE in 89% of 
the animals (Figure 3.1.9 A). The first clinical symptoms were seen 7-11 d.p.i., disease peaked 
2-3 days later, after which the animals recovered slowly. The disease was usually monophasic, 
but in one rat (n=27), which had failed to recover completely, clinical relapses were observed 
20 and 27 d.p.i.. Pathology at the peak of disease was dominated by infiltrating ED1+ 
macrophages, comparable to the pathology observed in the early phases of MOG-Igd-induced 
EAE. There was no evidence of demyelination. 
Increasing the immunogenicity of the emulsion by adding 25µg Mycobacterium 
smegmatis per rat (CFA-) did not greatly influence disease onset, but increased the incidence to 
100% and resulted in a relapsing remitting disease course in the majority of the rats 
(10/11)(Figure 3.1.9 B). In this model, the clinical severity of relapses tended to decrease with 
time and their onset became progressively less synchronised, a first relapse occurring between 
18 and 25 d.p.i. and a third bout of disease activity starting between 26 and 39 d.p.i.. Disease 
was associated with scattered lesions containing activated ED1+ macrophages/microglia and 
W3/13+ T cells (Figure 3.1.10). Strikingly, although antibodies derived 20 and 40 d.p.i. 
recognised both M93-109 and MOG-Igd in ELISA (Figure 3.1.9 C), no demyelination was 
detected in the CNS, and sera from healthy M93-109 immunised rats failed to bind to native MOG 
expressed on MOG-transfected Ag8 cells (Figure 3.1.9 D, E). These results not only 
demonstrate that M93-109-specific antibodies are incapable of binding to the native protein and 
mediate demyelination, but also that multiple episodes of CNS inflammation fail to induce 
demyelination in this disease model. 
In the absence of a demyelinating antibody response, M93-109 –peptide induced EAE is 
self-limiting and the animals eventually recover, a situation very different to the lethal disease 
induced by approximately 1/10th of the molar dose of MOG-Igd in IFA.  
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Figure 3.1.9 Disease course of M93-109-induced EAE.  
A) Female DA rats were immunised with 100 µg M93-109  in IFA. Represented is the mean clinical score and 
standard deviation of 26 rats; B) Female DA rats were immunised with 100 µg M93-109 in CFA. Shown is the mean 
clinical course and standard deviation of 11 rats. C) ELISA analysis of sera taken 20 d.p.i. after immunisation with 
M93-109 in IFA. Shown is the average O.D.405 and standard deviation derived from 3 rats, analysed individually in 
quadruplicate. D) FACS analysis of serum derived 40 d.p.i. with M93-109; E) positive control using 8-18C5, a 
monoclonal MOG-specific antibody. Shown is the binding to MOG-transfected (blue) or to untransfected (green) 
Ag8-cells. No specific binding was detectable. Serum was pooled from 3 rats and analysed in a 1/40 dilution. 8-
18C5 was used at 25 µg/ml. Figures D) and E) provided by Dr. C. Bourquin. 
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Figure 3.2.10 Pathology 29 d.p.i. with M93-109 in IFA 
DA rats were immunised with 100 µg M93-109 in IFA and perfused 29 d.p.i. Serial sections were stained for A) 
inflammatory infiltrates (hematoxylin eosin); B) myelin (Luxol fast blue); C) activated microglia and macrophages 
(ED1). There is no evidence of demyelination. Photos provided by Dr. R. Höftberger, Vienna, Austria 
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3.1.3.3.2 DNA vaccination induces high titres of demyelinating MOG-specific 
antibodies 
Since the titre of pathogenic antibodies in the sera of animals immunised with MOG-Igd 
was effectively undetectable, it was apparent that very large numbers of donors would be 
required to obtain sufficient antibody for adoptive transfer experiments. We therefore 
investigated whether DNA vaccination with a plasmid encoding MOG could induce high titres 
of pathogenic antibodies to MOG-Igd in DA rats, as reported for mice (Bourquin et al., 2000). 
DA rats aged 4-5 weeks were injected intramuscularly with 200 µg of a plasmid encoding 
full length MOG (Bourquin et al., 2000) into each tibialis anterior muscle. A MOG-Igd-specific 
antibody-response could be detected 11 days post vaccination (d.p.v.) and this increased 
steadily over the following 4 weeks, while no response was detected in control animals 
vaccinated with the original “empty” plasmid pcDNA3.1 (Figure 3.1.11 A). As observed in 
mice, none of the rats developed EAE, presumably due to the blood brain barrier, which inhibits 
the entry of antibodies into the CNS (Litzenburger et al., 1998). 
Analysis of antibody isotypes 6 weeks after vaccination revealed the presence of IgM, 
IgG2A and IgG2B-isotypes. IgG1 was absent, indicating a purely Th1-associated antibody 
response (Figure 3.1.11 B). The titre of MOG-Igd specific antibodies detected by ELISA was 
approximately hundred-fold lower than 19 d.p.i. with MOG-Igd/IFA. However, in contrast to 
the response after active immunisation, the antibody-response after DNA vaccination was 
purely conformation dependant, as ELISA revealed a complete lack of binding to linear MOG 
peptides (Figure 3.1.11 C), while FACS analysis demonstrated specific binding to the surface of 
MOG-transfected Ag8 cells (Figure 3.1.11 D, E).  
The pathogenicity of this established immune response was confirmed by the transfer of 2 
x 106 M93-109-specific T cells into MOG- or control-vector-vaccinated rats 4 weeks after 
vaccination. MOG vaccinated animals developed a rapidly lethal disease with early onset, 
compared to the relatively mild disease in control animals (Figure 3.1.12 A). Pathological 
analysis revealed extensive demyelination, deposition of immunoglobulins and C9 as well as a 
PMN infiltrate, findings characteristic for antibody mediated demyelination (Linington et al., 
1988; Linington et al., 1989; Storch et al., 1998) and similar to those seen in relapse of MOG-
induced EAE (Figure 3.1.12 B). 
Serum of DNA-vaccinated animals therefore seemed to be an ideal source for passive 
transfer studies. In addition, DNA vaccinated animals provide an appropriate model system to 
investigate the specific absorption of MOG-specific antibodies into the CNS (see 3.1.3.4).  
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Figure 3.1.11 Analysis of the antibody response induced by vaccination with a plasmid encoding MOG.   
A) Development of the antibody response after vaccination with pcDNA-MOG. Shown is the mean O.D.405 and 
standard deviation of serum derived from 4 rats bled at different times post vaccination and analysed individually in 
quadruplicate. Serum was analysed at a dilution of 1/100. Control animals vaccinated with pcDNA3.1 developed no 
MOG-specific antibody response; B) analysis of the isotype distribution 28 d.p.v.. Note that the values are not 
directly comparable, since different secondary antibodies were used for the detection. However, this response was 
significantly different to the response after immunisation with MOG-Igd in IFA, where all isotypes were clearly 
detectable and the response was “dominated” by IgG1. C), D) Epitope specificity of the antibody response after 
vaccination with pcDNA-MOG. C) DNA vaccination induced no response to linear peptides. Shown is the data 
derived from 5 rats analysed individually in quadruplicates at a dilution of 1/100. D) FACS analysis clearly 
demonstrates specific binding of sera from MOG-vaccinated DA rats to the MOG-transfected Ag8 cells (blue). In 
contrast, no binding was detected using naïve control serum (black) or untransfected Ag8-cells (green). Sera were 
used at a dilution of 1/40. E) Positive control using 8-18C5 a monoclonal MOG-specific antibody. 8-18C5 was 
used at a dilution of 25 µg/ml. Figures D) and E) provided by Dr. C. Bourquin. 
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Figure 3.1.12  DNA vaccination with pcDNA-MOG enhances severity of tEAE and induces a demyelinating 
pathology   
2 x 106  M93-109-specific T cells were transferred into MOG- or control-vector-vaccinated DA rats 4 weeks after 
vaccination. A) Shown is the average and standard deviation of the clinical scores of 4 (pcDNA-MOG) or 5 rats 
(control vector). B) Enhanced disease activity is associated with enhanced demyelination/inflammation in the CNS. 
Represented is a spinal cord cross section from a pcDNA-MOG-vaccinated rat 3 d.p.t., stained for myelin (LFB). 
Note that demyelination is extensive considering the early time point after diesase onset. Photo by Dr. A. Stefferl, 
Vienna 
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3.1.3.3.3 The transfer of demyelinating autoantibodies can induce relapse 
In order to test the hypothesis that antibodies are the driving force for the relapse in 
MOG-Igd in IFA-induced EAE, we investigated whether a combination of immunisation with 
the immunodominant MOG peptide M93-109 in IFA and antibody co-transfer would replicate the 
biphasic disease course seen after immunisation with MOG-Igd in IFA. DA rats were 
immunised with 100 µg M93-109 in IFA and then after complete recovery, 20 and 21 d.p.i. 
injected i.v. with 1 and 2 ml, respectively, of serum derived from MOG-DNA vaccinated rats.   
Strikingly, the injection of anti-MOG-serum induced severe disease within 48 hours of 
transfer in all animals tested (Figure 3.1.13 B). In contrast, no relapse activity was observed in 
animals injected with serum derived from naïve animals (Figure 3.1.13 A). This clearly 
demonstrates that MOG-specific autoantibodies are capable of initiating relapse in peptide 
primed animals if they are available during the period in which relapse activity is seen in 
animals immunised with either MOG-Igd/IFA, or M93-109/CFA (and occasionally even in IFA).  
Histopathological analysis demonstrated that relapse induced by the transfer of anti-MOG 
sera was associated with extensive demyelination and a diffuse inflammatory infiltrate. In 
contrast, inflammation in the control animals had resolved by the time they were perfused (24 
d.p.i.) (Figure 3.1.14 A). 
However, would the passive transfer of MOG-specific antibodies also induce relapse 
during remission? To test this, 2 ml of serum derived from MOG-DNA vaccinated rats were 
injected 15 and 16 d.p.i. i.v.. At this time one animal had fully recovered, while the remaining 
two animals showed residual disease activity (grades 0.5 and 1.5). Within 72 hours of the first 
injection, those rats with residual disease relapsed and developed severe EAE (grade 3 and 3.5), 
while the other animal, which had fully recovered only developed mild clinical symptoms 
(grade 1) (Figure 3.1.13 C). Therefore, pathogenic antibodies were capable of inducing relapse 
during early remission, even when the recipient had fully recovered. However, the clinical 
effect of serum transfer at this time point was not as dramatic and more variable compared to 
the transfer 20/21 d.p.i., suggesting that the blood brain barrier may be less compromised at this 
time point and/or that the tissue itself may be less vulnerable to antibody-mediated damage.  
This interpretation is supported by the observation that demyelination was less 
pronounced after serum transfer at the earlier time point (Figure 3.1.14 B). Strikingly, even in 
the absence of antibody-transfer large inflammatory infiltrate were detected in the CNS four 
days later, when the rats were perfused (20 d.p.i.).  
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Figure 3.1.13 Co-transfer of sera derived from MOG-vaccinated DA rats into rats immunised with M93-109 
induces severe relapse.  
A) Rats injected with control serum at either 20/21 or 15/16 d.p.i.; B) rats injected with two doses of serum of 
pcDNA-MOG vaccinated rats 20 and 21d.p.i.; C) rats injected with two doses of serum of pcDNA-MOG 
vaccinated rats 15 and 16 d.p.i.. Shown are the average and standard deviation for 3 rats in B), and C) and for 6 rats 
in A).  The arrows indicate the time of antibody transfer. In A) this was either 15/16 d.p.i. or 20/21 dp.i.. 
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Figure 3.1.14 A) Pathological analysis after co-transfer of MOG-specific antibodies 20 and 21 d.p.i. into DA 
rats immunised with M93-109 in IFA.  
Serial sections derived 24 d.p.i. from representative DA rats, which were immunised with M93-109 in IFA and co-
injected with control- or MOG-serum 20 and 21 d.p.i.. Note that inflammation at the time of perfusion (24 d.p.i.) is 
minimal in control animals. Sections were stained for inflammatory infiltrates (HE); myelin (LFB); activated 
microglia or macrophages (ED1); complement deposition (C9) or T cells (W3/13). Photos by Dr. R. Höftberger, 
Vienna, Austria              
Control serum Anti – MOG serum
HE, 40x
LFB, 40x
ED1, 40x
C9, 400x
W3/13, 400x
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Figure 3.1.14 B) Pathological analysis after co-transfer of MOG-specific antibodies 15 and 16 d.p.i. into DA 
rats immunised with M93-109 in IFA.  
Serial sections derived 20 d.p.i. from representative DA rats, which were immunised with M93-109 in IFA and co-
injected with control- or MOG-serum 15 and 16 d.p.i.. Note that in comparison to the control animals at 24 d.p.i.. 
inflammation at this time of perfusion (20 d.p.i., figure 3.1.14 A) is very pronounced in the controls. Sections were 
stained for inflammatory infiltrates (HE); myelin (LFB) and activated microglia or macrophages (ED1). Photos by 
Dr. R. Höftberger, Vienna, Austria  
Control serum Anti – MOG serum
HE, 40x
LFB, 40x
ED1, 40x
C9, 400x
W3/13, 400x
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3.1.3.4 Pathogenic antibodies are selectively absorbed into the inflamed CNS  
As mentioned above (Section 3.1.3.2.4), previous studies in the guinea pig suggested that 
the opening of the BBB in response to CNS inflammation is correlated with a decrease in the 
MOG-specific antibody titre due to selective absorption of MOG-specific antibodies in the CNS 
(Linington and Lassmann, 1987). We proposed that this could be the reason why we were 
unable to detect pathogenic MOG-specific antibody in the serum of DA rats with MOG-Igd-
induced EAE. Having established a method to produce a demyelinating MOG-specific antibody 
response, which is normally excluded from the CNS by the BBB, it was now possible to 
determine, whether a damage of the BBB would lead to selective absorption of this antibody 
response. DA rats were vaccinated with a combination of two plasmids, pcDNA-MOG and a 
control vector (pcDNA-BTN/MOG). This vector encodes a fusion protein, whose N-terminal 
IgV like domain is homologous to MOG and which induces a non-demyelinating antibody 
response after vaccination (see section 3.2.7). 28 d.p.v. all animals had developed antibody 
responses to both MOG and BTN, and were then injected with 2.8 x 106 freshly activated 
MOG-specific T cells to induce EAE. The rats were then bled on a daily basis and the levels of 
MOG and BTN-specific antibody determined by ELISA. As the animals started to develop 
disease, the MOG-specific antibodies in the periphery decreased dramatically in all animals (to 
67% +/- 11; range 20-44% at 4 d.p.t., compared to 1 d.p.t.; p<0.01). In contrast, the titre of 
peripheral BTN-specific antibodies was virtually unchanged (mean 102% +/- 17; range 89-
128%, not significant) (Figure 3.1.15). This differential decrease in the two responses in the 
periphery demonstrates that MOG-specific antibodies are selectively absorbed within the CNS 
once the BBB is disrupted. As suggested previously (Linington and Lassmann, 1987; Haase et 
al., 2000), in the case of a very low titre demyelinating response to MOG this effect may reduce 
the level of circulating antibodies below detection limits of the FACS assay.  
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Figure 3.1.15 The transfer of MOG-specific T cells induces a selective reduction of MOG-specific antibodies 
in the periphery 
Female DA rats were vaccinated with both pcDNA-MOG and pcDNA-BTN/MOG and injected with 2.8 x 106 
MOG-specific T cells 28 d.p.v.. A) Analysis of the titre of MOG-Igd- and BTNexo-specific antibodies. Sera were 
taken daily after the transfer and analysed by ELISA at a dilution of 1/100. Shown is the percent reduction 
compared to 1 d.p.i. and standard deviation of the four rats (three rats at 5 d.p.i.) analysed individually in 
quadruplicate. Standard deviation in the individual rats was around 5-10%. Black: MOG-specific antibodies, 
white: BTN-specific antibodies. The titre of MOG-specific antibodies was significantly reduced 4 and 5 d.p.i. 
(p<0.01, using one-tailed Student´s t-test, comparison to the titre 2 d.p.i.). In contrast, the titre of BTN-specific 
antibodies was unsignificantly reduced; B) Clinical course of the same rats after the T cell transfer. Shown is the 
mean and standard deviation of 4 rats (n=3 at 5 d.p.i.). The titre of MOG-specific antibodies dropped significantly 
concurrent with the onset of clinical symptoms. 
 
 
  
A)
0
20
40
60
80
100
120
140
1 2 3 4 5
d.p.t.
%
 o
f d
1
B)
0
1
2
3
4
5
0 1 2 3 4 5
d.p.t.
m
ea
n 
cli
ni
ca
l s
co
re
Results: The impact of antibodies 
 79 
3.1.4 Discussion 
Traditionally, EAE studies in the rat have mainly dealt with monophasic models of T cell 
mediated EAE and investigated questions pertaining to the cellular and molecular basis of 
induction and recovery rather than relapse. Recovery from acute inflammatory CNS disease in 
the rat is attributed to multiple cellular (Sun et al., 1988; Lenz and Swanborg, 1999; Karpus and 
Swanborg, 1991; Schwartz and Cohen, 2000), humoral (McPhee et al., 1990; Asakura et al., 
1998) and hormonal (Mason et al., 1990; Hohlfeld et al., 2000) immunoregulatory mechanisms, 
all of which contribute to the resolution of clinical disease and the development of tolerance to a 
second encephalitogenic challenge with the same antigen. However, unlike these acute, T cell 
mediated models of EAE, MS normally presents as a relapsing remitting disease, which 
eventually becomes chronic progressive with no obvious remissions. Virtually nothing is known 
about the mechanisms responsible for either triggering relapses early in disease, or the switch to 
a chronic progressive disease course.  
Relapse is commonly attributed to either the failure of one or more of the mechanisms 
mentioned above, or alternatively to epitope spreading, the development of encephalitogenic 
responses to additional CNS specific T cell epitopes as disease progresses (Tuohy et al., 1998; 
Vanderlukt et al., 1998). However, irrespective of the mechanisms involved, relapse activity in 
EAE is determined by multiple genetic loci. (Lorentzen et al., 1997 ; Olsson et al., 2000). This 
is very clearly seen in MOG-Igd-induced EAE in the rat. DA rats are highly susceptible to 
relapse, while LEW rats show a very low relapse activity (Weissert et al., 1998;  Olsson et al., 
2000; Lorentzen et al., 1997). This is strongly influenced by the DA MHC locus (RT1av1 
haplotype), but also by other, yet ill-defined non-MHC “background” genes. (Weissert et al., 
1998; Lorentzen et al., 1997). The current study demonstrates for the first time that in the 
context of this susceptible genotype, clinical relapse and the initiation of chronic progressive 
disease can be driven by the development of a pathogenic, demyelinating antibody response. 
As demonstrated in a transgenic mouse model, the presence of circulating MOG-specific 
autoantibodies alone is insufficient to induce EAE (Litzenburger et al., 1998). Disease induction 
not only requires a dysfunctional BBB, which is essential for the entry of antibodies into the 
CNS, but in all probability also a susceptible milieu within the CNS, since inflammatory factors 
such as IFN-γ are vital for significant amplification of disease activity by the antibody response 
(Vass et al., 1992). Only when these two criteria are fulfilled will antibodies, which can bind to 
the myelin surface, be able to efficiently induce demyelination, amplify the inflammatory 
response in the CNS and induce a severe episode of EAE.  
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Previous studies have shown that the adoptive transfer of MOG-specific antibodies can 
induce relapse after incomplete recovery in chronic relapsing EAE in SJL/J mice (Schluesener 
et al., 1987) and amplify the clinical deficit when co-transferred with MBP-specific T cells in 
LEW rats. In addition, the MOG-specific antibody response potentiates disease activity in BN 
and LEW rats. In these two rat strains, the MOG-specific T cell response alone is insufficient to 
induce clinical symptoms of EAE, as shown by adoptive transfer studies of MOG-specific T 
cells (Adelmann et al., 1995; Stefferl et al., 1999) or immunisation with MOG-peptides 
(Adelmann et al., 1995). Immunisation with MOG-Igd, on the other hand, induces fulminant 
(BN) or chronic progressive (LEW) EAE. In contrast, the MOG-specific T cell response alone 
is highly pathogenic in the DA rat and the adoptive transfer of 1.7 to 5 x 106 MOG-specific T 
cells induces severe clinical EAE associated with a strong inflammatory response in the CNS 
(Figures 3.1.6/3.1.7). The pathogenicity of this response is determined by the RT1av1 MHC 
haplotype (Stefferl, pers. comm.) and may reflect the high affinity of this peptide to the MHC 
(Weissert et al., 2001; De Graaf, pers. comm.).  
This inflammatory pathology is reproduced when DA rats are actively immunised with 
the immunodominant peptide M93-109 in IFA, a protocol which generally induces a single 
episode of clinical EAE. Earlier studies using CNS homogenates to induce disease 
demonstrated that DA rats are susceptible to develop relapsing remitting EAE (Lorentzen et al., 
1995). Relapse activity was also seen in 91% of the animals immunised with M93-109 in CFA 
(Figure 3.1.9 B), although here the disease was self-limiting and histopathological analysis 
revealed an absence of demyelination. These observations indicate that although the T cell 
response to MOG can induce multiple relapses, regulatory mechanisms eventually develop to 
suppress their clinical impact. Relapse activity was not normally seen in M93-109-Igd/IFA 
immunised animals, but inflammatory activity was observed in CNS tissues of apparently 
healthy animals 20 d.p.i. (Figure 3.1.14 B, control) suggesting that waves of inflammation also 
occur in M93-109/IFA-immunised animals. However, after the initial episode of disease, the 
intensity of the inflammatory insult fails to cross the threshold required to induce an obvious 
clinical deficit. The adoptive transfer of demyelinating MOG-specific antibodies 20 and 21 
d.p.i. with M93-109/IFA confirms that the BBB is compromised during this episode of subclinical 
inflammation and that the CNS milieu is exquisitely sensitive to the pathogenic effects of 
antibody mediated demyelination. 
It is no coincidence that the onset of relapse and irreversible disease progression in MOG-
Igd/IFA-induced EAE occurs after a rapid increase of the antibody titre, at a time, when a 
second sub-clinical wave of inflammation is developing within the CNS. As demonstrated in 
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animals immunised with MOG93-109 in either IFA or CFA, the T cell mediated component of the 
disease would be self-limiting. The presence of a demyelinating MOG-specific antibody 
response, however, amplifies this subclinical response, leading to a secondary progressive 
disease from which the animals fail to recover. 
Interestingly, antibody transfer during the remission phase of MOG-peptide induced EAE 
was less efficient at inducing relapse, but still potentiates disease activity, even in a clinically 
fully recovered animal (Figure 3.1.14 B). In contrast, in a mouse model of RR-EAE antibody 
transfer has no effect once the animals had clinically recovered (Schluesener et al., 1987), 
suggesting a species specific difference in the recovery of the BBB after CNS inflammation. In 
DA rats the inflammatory response in the CNS is dramatically reduced, but still present during 
remission (Dr. R. Höftberger, pers. communications; Stefferl et al., 2001). It is yet unknown 
whether the lower efficiency of the antibody to induce relapse at this time is due to recovery of 
BBB function and exclusion of antibodies from the CNS (Dore-Duffy et al., 1996), or the 
development of a transient “counter-inflammatory” CNS environment. The latter possibility is 
supported by the local down regulation of IL-1β expression in the CNS during remission 
(Stefferl et al., 2001) which suggests that the inflammatory milieu in the CNS is less 
“permissive” for antibody-mediated augmentation of EAE (Vass et al., 1992). Nevertheless, 
pathogenic autoantibodies antibodies are able to override the regulatory mechanisms 
responsible for the transient resolution of clinical disease activity and enhance both 
inflammation and demyelination. However, if antibody can only promote relapse by amplifying 
an existing inflammatory response in the CNS, it remains to be determined why the DA rat fails 
to control the T cell mediated inflammatory reaction in the CNS after the initial immune attack.  
Relapsing remitting EAE induced in the DA rat using MOG93-109 in CFA provides a 
purely inflammatory model of CNS disease characterised by a high incidence (>90%) of well 
synchronised relapse activity (in the first relapse), which can be used to answer this question. In 
particular, it will be possible to determine the relative importance of peripheral antigen depot, 
epitope spreading and defects in the neuroendocrine axis/immunoregulation. The suppression of 
disease activity in a guinea pig model of RR-EAE after excision of the injection site indicates 
that the peripheral antigen depot may be essential to continue driving relapses in EAE (Tabira et 
al., 1984). A role for the peripheral depot, as opposed to secondary response to autoantigen 
derived from the inflamed CNS i.e. epitope spreading is also supported by the observation that 
even 30 d.p.i. no detectable response to other encephalitogens e.g. MBP has been detected (A. 
Stefferl, pers. communication) 
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In contrast, the importance of neuroendocrine control in determining relapse activity was 
recently demonstrated in the MOG/IFA paradigm (Stefferl et al., 2001). This study revealed that 
relapse was associated with a desensitisation of the HPA axis to immunological stress, resulting 
in a corresponding inability of the affected animals to mount a regulatory, counter-inflammatory 
corticosteroid response as they entered the second phase of disease. However, considering the 
complexity of the effector mechanisms involved in disease pathology and the fact that multiple 
genetic loci determine whether the disease follows a relapsing remitting course, it is to be 
expected that more than one mechanism is involved in the regulation of this model of MS.  
The induction of relapse due to the development of a pathogenic antibody response in 
clinically healthy animals is a novel mechanism that may help to understand disease progression 
in those cases of MS associated with a demyelinating autoantibody response (Genain et al., 
1999; Haase et al., 2000; Lucchinetti et al., 2000), and supports the use of plasmapheresis to 
treat selected patients (Weinshenker, 1999 and 2001). However, this study does not eliminate 
the role of T cells, but stresses that clinical progression - while T cell dependent - may be driven 
by antibody mediated mechanisms. It should not be forgotten that in the case of MS, this 
antibody response might not be specific for MOG, but may also be directed against other yet 
unidentified targets on the surface of the myelin sheath.  
Despite the high proportion of MS-cases with type II lesions (indicative of antibody 
mediated immune mechanisms, Lucchinett et al., 2000), only a small proportion of MS patients 
have serum antibodies capable of binding native MOG expressed on the cell surface of 
transfected cell lines (Haase et al., 2000). In contrast, MOG-Igd-specific antibodies recognising 
linear peptide epitopes are present in 30 - 60% of patients (Reindl et al., 1999; Lindert et al., 
1999; Haase et al., 2000). This discrepancy between the high number of patients with 
“antibody-mediated” type II lesions and the low frequency of patients with “pathogenic” 
antibody responses to MOG was attributed to either the existence of other target antigens or to a 
selective absorption of demyelinating antibodies into the brain (Haase et al., 2000). Using DNA 
vaccination in rats (reviewed in Gurunathan et al., 2000), this study has clearly demonstrated 
that such an absorption can have a pronounced effect on the level of circulating antibodies. This 
will have to be taken into account for the development of serological assays, which will identify 
patients with antibody-mediated effector mechanisms at an early time point. 
The pathology of this model of highly synchronised relapsing remitting EAE closely 
resembles that of the major subset of MS patients (type II lesions) with respect to microglial 
activation, the recruitment of immune effector cells into the CNS, deposition of antibody and 
C9 on the myelin sheath, myelin degradation and vesiculation, the presence of macrophages 
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carrying immunoglobulin, C9 and myelin debris, and finally axonal loss. This model, which 
lasts only 3-4 weeks provides the opportunity not only to test immune directed therapies, but 
also remyelination strategies or neuroprotection (with respect to the axonal loss). One such 
investigation is presented in Appendix I.  
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3.2 Molecular mimicry with the milk protein butyrophilin modulates MOG-Igd - 
induced EAE  
Little is known about the aetiology of multiple sclerosis (MS), but it is generally agreed 
that it involves the interplay of both genetic and environmental factors. This concept is 
supported by twin and familial studies, which demonstrate that the concordance rate for disease 
is about 30% in monozygotic twins but only about 4% in dizygotic twins (Sadovnick et al., 
1993; Sadovnick and Ebers, 1995; Oksenberg and Barcellos, 2000). These observations indicate 
that while genetic factors play an important role in determining disease susceptibility, other as 
yet unidentified “environmental” factors must act as disease triggers, possibly by disrupting 
self-tolerance to CNS myelin antigens (Gale et al., 1995).  
One mechanism by which environmental factors may disrupt self-tolerance to tissue 
specific autoantigens is molecular mimicry, an amino acid sequence homology between two 
unrelated antigens which leads to a cross-reactive immune response (Fujinami and Oldstone, 
1985). In this situation, a protective immune response induced by a pathogen may also 
recognise epitopes derived from a tissue specific autoantigen and mediate tissue specific auto-
aggression. Molecular mimicry in the context of EAE was first described in rabbits with respect 
to an encephalitogenic T cell epitope of MBP and a homologous peptide present in hepatitis B 
virus polymerase (Fujinami and Oldstone, 1985). This concept was later investigated in man 
using human MBP-specific T cell clones, which were found to cross-react with different 
synthetic viral peptides in vitro (Wucherpfennig et al., 1995). Moreover, in experimental 
animals immunisation with synthetic microbial peptides can induce an auto-aggressive T cell 
response in vivo (Fujinami and Oldstone, 1985; Gautam et al., 1998; Ufret-Vincenty et al., 
1998).  
Molecular mimicry can lead to a cross-reactive T cell response because recognition of 
MHC/peptide complexes by the T cell receptor is degenerate. This results in the recognition of 
multiple, possibly thousands of agonistic and antagonistic peptide ligands by a single T cell 
receptor (Mason, 1991; Gran et al., 1999). It was recently demonstrated that molecular mimicry 
involving an epitope of HSV-1 was directly involved in the aetiology of a murine model of 
herpes stromal keratitis (HSK) by inducing an autoimmune response to a yet unidentified retinal 
antigen (Zhao et al., 1998). However, whether or not mimicry involving microbial pathogens 
and myelin autoantigens leads to CNS auto-aggression during the natural course of any 
infection remains unknown.  
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Microbial antigens are not the only candidates to trigger auto-aggression by molecular 
mimicry, but theoretically any antigen may induce a cross-reactive immune response, including 
components of the diet. Indeed, dietary exposure to a bovine albumin peptide has been proposed 
as a trigger for autoimmune diabetes by inducing a cross-reactive antibody-response to the β-
cell surface protein p69 (Karjalainen et al., 1992; reviewed in Berdanier et al., 1995).   
However, dietary antigens normally stimulate a very different immune response to that 
induced following challenge with an infectious agent. Infections generally induce a Th1 
dominated inflammatory response in order to effectively eliminate the pathogen, a situation 
mimicked in EAE and other models of autoimmune diseases by immunisation with 
protein/adjuvant emulsions. These inflammatory responses are, however, dangerous as they 
may damage surrounding tissue and disrupt normal physiological function. Specific 
mechanisms have therefore evolved in the gastro-intestinal tract to suppress potentially lethal 
inflammatory responses to components of the diet and symbiotic gut flora. This is termed oral 
tolerance (Weiner et al., 1994; Chen et al., 1994; Chen et al., 1996; Strobel 1996; Weiner, 1997, 
Gutgemann, 1998; Strobel and Mowat, 1998) and is maintained by multiple mechanisms, 
including the induction of apoptosis (programmed cell death) and anergy (unresponsiveness) of 
the potential effector cells and/or the generation of suppressor responses (reviewed in Weiner 
1997 and Strobel and Mowat, 1998). Intriguingly, although the induction and activation of 
suppressor cells by oral tolerance is antigen specific, these cells act via the secretion of soluble 
mediators (IL-10 and TGF-β) and are hence capable of inducing bystander suppression 
(Weiner, 1997). The relative importance of the individual mechanisms in oral tolerance is 
determined by nature and dose of antigen, the frequency of exposure as well as genetic factors. 
The redundancy of mechanisms involved in oral tolerance provides a robust system leading to 
long lasting, systemic tolerance.  
However, soluble factors secreted by pathogens within the gastro-intestinal tract can 
disrupt oral tolerance. This is well documented for cholera toxin, which when fed with an 
unrelated antigen abrogates oral tolerance and induces immune responses (Hornquist and Lycke 
1993; reviewed in Weiner, 1997; Hänninen et al., 2000). In addition, oral application of soluble 
proteins in neonates (under 4 - 6 days of age in mice) may prime the immune system rather than 
inducing tolerance (Miller et al., 1994; reviewed in Strobel and Mowat, 1997). This 
demonstrates that in specific circumstances molecular mimicry between a dietary antigen and 
self can result in a potentially auto-aggressive Th1 response and trigger autoimmune disease.   
It was therefore interesting to find extensive sequence homology between MOG-Igd and 
the N-terminal Ig-domain of the milk protein butyrophilin (BTN) (Gardinier et al., 1992)(Figure 
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3.2.1). As BTN is a major component of the milk fat globule membrane (Jack and Mather, 
1990), this observation immediately raised the question, whether exposure to BTN in the diet 
could influence the composition or function of the MOG-reactive repertoire in MS patients. 
This is an intriguing possibility in the light of epidemiological studies that identified an 
association between the consumption of milk and dairy produce and the prevalence of MS 
(Butcher 1986; Malosse et al., 1992; reviewed in Lauer, 1997). 
Indeed, in an initial study we demonstrated that immunisation with bovine BTN or 
purified bovine milk fat globule membrane could induce a sub-clinical inflammatory response 
in the CNS in the context of a permissive MHC-haplotype (e.g. RT1av1, DA rat) (Stefferl et al., 
2000). This was due to the induction of a T cell response that cross-reacted with the peptide 
M74-90, a subdominant MOG-T cell epitope in the DA rat. The pathogenicity of this response 
was confirmed by adoptive transfer of BTN/MOG cross-reactive T cell lines, which induced an 
inflammatory response in the CNS and mild clinical symptoms of EAE in naïve syngeneic 
recipients (Stefferl et al., 2000). Interestingly, the CNS lesions induced by the transfer of B74-90-
specific T cells remained restricted to the perivascular space and failed to recruit macrophages 
into the CNS. This correlated with a low pathogenicity of this T cell response, resembling EAE 
induced by the adoptive transfer of T cells specific for the astrocyte protein S100β in the Lewis 
rat (Kojima et al., 1994) rather than disease induced by TCLs specific for MOG in DA (section 
3.1.3.1.3). These experiments demonstrated that molecular mimicry can occur between MOG 
and BTN, but left a number of important questions unanswered.  
Particularly intriguing was the question, why BTN74-90-selected T cells were significantly 
less pathogenic than those cells selected using the homologous MOG peptide, although both 
recognise the same pair of antigens. Several explanations could possibly account for this 
observation. First, it could be due to oral tolerance induced by autologous BTN during suckling. 
Alternatively, the two antigens may either select different but partially overlapping T cell 
populations that differ in their pathogenicity or the two peptides may elicit different cytokine 
responses in the cross-reactive T cell population and thereby modify T cell function.  
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-------------------------------------------------------------------------------------------------------------------- 
Rat MOG   GQFRVIGPGHPIRALVGDEAELPCRISPGKNATGMEVGWYRSPFSRVVHLYRNGKDQDAEQA 
Bov BTN   AP-D----QE--L-V--ED------L--NVS-K---LR-F-EKV--A-FVS-E-QE-EGEEM  
          1                                                             62 
 
Rat MOG   PEYRGRTELLKESIGEGKVALRIQNVRFSDEGGYTCFFRDHSYQEEAAVELKVED 
Bov BTN   A-----VS-VEDH-A--S--V---E-KA--D-E-R----QDENY---I-H---AA  
         63                                                     117 
-------------------------------------------------------------------------------------------------------------------- 
Fig. 3.2.1 Structural and amino acid sequence homologies between BTN and MOG 
Upper panel: Structural comparison of BTN and MOG. BTN contains two extracellular Ig domains (Ω-shaped in 
this figure) as well as a transmembrane domain and intracellular domains (Jack and Mather, 1990). MOG consists 
of a single extracellular Ig domain, one hydrophobic transmembrane domain and the cytoplasmic tail containing a 
second hydrophobic region (Kroepfl et al., 1996; Della Gaspera et al., 1998). Note that only the N-terminal IgV-like 
domain of BTN has a significant sequence identity to MOG. Lower panel: Amino acid sequence comparison 
between rat MOG-Ig (Gardinier et al., 1992, accession number: M99485) and the N-terminal Ig-domain of bovine 
butyrophilin (BTN) (Jack and Mather, 1990, accession number: M35551). Amino acids are represented in the one-
letter-code, amino acids that are identical in the two proteins are represented as dashes in the BTN sequence. The 
immunodominant T cell epitope of rat MOG (a.a. 93-109) is printed in red, the subdominant epitope (a.a. 74-90) in 
blue. The numbers represent the amino acid residues in the mature protein 
BTN MOG
N-Terminus
Transmembrane
domains
IgC-like
IgV-like
IgV-like
~ 50% sequence identity
Extracellular
Intracellular
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3.2.1 Rat BTN fails to influence the bovine BTN/rat MOG cross-reactive T cell 
response  
The observation that T cell responses to the bovine BTN peptide B74-90 are potentially 
encephalitogenic in DA rats (Stefferl et al., 2000), albeit less than the cross-reactive MOG 
TCLs indicates that the ingestion of BTN via the mothers milk fails to induce complete oral 
tolerance to the xenogenic BTN in the pups. This is in direct contradiction to experiments using 
ovalbumin as a control antigen, in which repeated feeding of rat pups resulted in a firm state of 
long-term tolerance (Brown et al., 1994; Wald et al., 1987; Hall et al., 1988). However, one 
simple explanation for this observation could be that the amino acid sequence of the N-terminal 
IgV-like domain of BTN is not highly conserved between species. In this case tolerance would 
be established to the autologous protein, but would not extend to BTN derived from other 
species – in this case the bovine protein. Comparison of the published BTN sequences, which 
were available for Homo sapiens (Vernet et al., 1994; Accession number NM_001732), Bos 
taurus (Jack and Mather, 1990; accession number M35551) and Mus musculus (Ogg et al., 
1996; accession number NM_013483), suggested that this may indeed be the case, the amino 
acid sequence conservation between the N-terminal IgV-like domains of mouse and bovine 
BTN being only 56%.  
To confirm that lack of sequence identity was responsible for the failure of the rat to 
develop tolerance to bovine BTN, the deduced amino acid sequence of the extracellular 
domains of rat BTN was obtained by RT-PCR sequencing. This allowed a direct comparison 
with the published bovine and mouse sequences and enables the analysis of immune responses 
to the autologous protein. Several primer pairs were selected from regions of mouse BTN which 
had the highest levels of conservation between species and used to generate RT-PCR products 
from lactating rat mammary gland mRNA (Materials and Methods, 2.2.19). This approach 
identified products of the appropriate sizes, which were then sequenced. 
In order to confirm that the amplified cDNA encoded for butyrophilin rather than a BTN 
homologue (Henry et al., 1999; Stammers et al., 2000; Rhodes et al., 2001), we analysed its 
expression pattern in various organs by RT-PCR using primers placed in the exons encoding the 
N-terminal IgV-region and the transmembrane region (Materials and Methods 2.2.20). As 
predicted for butyrophilin, expression was restricted to the lactating mammary gland. (Figure 
3.2.2) 
 
Results: Molecular Mimicry 
 89 
 
 
 
 
 
 
 
Figure 3.2.2 RT-PCR analysis of rat BTN expression in different tissues 
Left) β-actin control; right) rat BTN. 1. Liver; 2. Thymus; 3.Spleen; 4. Brain; 5. Mammary gland; 6. Heart; 7. 
Lung and 8. negative control in the absence of cDNA. The BTN primers used amplified a fragment of 393 nts, 
corresponding to the sequence encoding amino acids 105-236. The expected size of the β-Actin product was 700 
nts. 
 
-------------------------------------------------------------------------------------------------------------------- 
Rat BTN   1   APFNVTAPQESVLAVVGSDAELTCRFSPNASSEQMELLWFRQTRSPAVLLYRAGQEQEGE 
Mouse BTN     ---D------P---L---------G--------Y-----------T------D------Q 
Bovine BTN    ---D-IG---PI-----E----P--L---V-AKG---R---EKV----FVS-E------- 
 
Rat BTN     QMTEYHGRATLVTARLLDGLATLRIRGVRVSDQGQYRCFLKDNDDSEEAAVHLKVAA 117  
Mouse BTN   -----R-----A--G----R---L--D-------E---LF-----F-----Y----- 84% 
Bovine BTN  E-A--R--VS--EDHIAE-SVAV--QE-KA--D-E----FRQDENY---I------- 58% 
---------------------------------------------------------------------------- 
Figure 3.2.3 Amino acid sequence comparison between rat, mouse and bovine BTN. 
Amino acids are represented in the one-letter-code, amino acids identical to rat BTN are represented as bars. The 
sequence homologous to the immunodominant MOG peptide (a.a. residues 93-109) is printed in red, the part 
corresponding to the subdominant MOG-peptide (a.a. residues 74-90) in blue. The sequence was confirmed at least 
once for each residue using different PCR reactions for the each sequencing reaction.  
 
Comparison of the predicted sequence of the N-terminal IgV-like domain of rat BTN with 
the homologous mouse and bovine BTN domains identified a relatively strong conservation of 
the rat and mouse sequences (84% sequence identity in the first Ig-domain), which is 
significantly higher than sequence identity with either of the known mouse BTN homologues 
(Henry et al., 1999; Stammers et al., 1999; Rhodes et al., 2001) or with bovine BTN (58% 
sequence identity in the first Ig-domain, Figure 3.2.3). Intriguingly, the homology between rat 
and bovine BTN was not evenly distributed throughout this Ig domain. An area of low 
homology was found within the a.a. residues 73-90, exactly the sequence containing the epitope 
responsible for the cross-reactive T cell response between rat MOG and bovine BTN. In this 
peptide the sequence identity was only 23.5% (Figure 3.2.3, in blue). 
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-------------------------------------------------------------------------------------------------------------------- 
Rat MOG   GQFRVIGPGHPIRALVGDEAELPCRISPGKNATGMEVGWYRSPFSRVVHLYRNGKDQDAEQA 
Bov BTN   AP-D----QE--L-V--ED------L--NVS-K---LR-F-EKV-PA-FVS-E-QE-EGEEM  
Rat BTN   AP-N-TA-QESVL-V--SD---T--F--NASSEQ--LL-F-QTR-PA-L---A-QE-EGE-M 
 
Rat MOG   PEYRGRTELLKESIGEGKVALRIQNVRFSDEGGYTCFFRDHSYQEEAAVELKV 
Bov BTN   A-----VS-VEDH-A--S--V---E-KA--D-E-R----QDENY---I-H--- 51% 
Rat BTN   T--H--AT-VTARLLD-LAT---RG--V--Q-Q-R--LK-NDDS-----H--- 44% 
-------------------------------------------------------------------------------------------------------------------------------------------- 
Figure 3.2.4 Amino acid comparison between rat MOG and bovine and rat butyrophilin.  
Amino acids are represented in the one-letter-code, amino acids identical to rat MOG are represented as bars. The 
immunodominant MOG peptide (93-109) is printed in red, the subdominant MOG peptide (74-90) in blue. 
Homology of rat MOG to rat BTN (44%) was slightly lower than that to bovine BTN (52%) 
 
Comparison of rat MOG and the autologous milk protein revealed an overall sequence 
identity of 44% between the N-terminal Ig domains, which is only slightly lower than the 
homology between rat MOG and bovine BTN (51%). The homology in the “epitope of interest” 
(a.a. residues 74-90) was reduced from a 53% identity between bovine BTN and rat MOG to 
only 35% identity between autologous BTN and MOG (Figure 3.2.4). 
Having obtained the rat BTN sequence, it was now possible to investigate directly 
whether the cross-reactivity between rat M74-90 and bovine B74-90 extended to the corresponding 
rat BTN peptide. Strikingly, synthetic rat-BTN74-90 was unable to induce either a proliferative 
response or cytokine secretion (IL-10, IFN-γ, TNF-α or TGF-β) in M74-90/B74-90-reactive TCLs 
(data not presented). This lack of a response could have several explanations. The peptide could 
be incapable of binding to the DA-MHC class II molecules or even if bound fail to stimulate the 
TCR of the M74-90/B74-90-reactive cells. On the other hand, although rat-BTN74-90 may not 
directly cross-react with the M74-90/B74-90-reactive T cells, the peptide may still be immunogenic, 
in which case ingestion of rat BTN during suckling would have resulted in a “suppressor“ cell 
population characterised by antigen-specific secretion of IL-10 and TGF-β (Weiner, 1997). 
Splenocytes derived from naïve rats were therefore restimulated with rat-BTN74-90, and rat-
BTN93-109. Neither peptide induced proliferation or the secretion of IL-10, IFN-γ, TNF-α or 
TGF-β, demonstrating that DA rats fail to induce a T cell response to these two rat-BTN 
peptides.  
This clearly demonstrates that the neonatal exposure to rat BTN does not modulate the 
cross-reactive T cell response between bovine BTN and MOG. The reduced pathogenicity of 
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BTN-selected TCLs is therefore not due to a modulation by autologous BTN, but must involve 
other mechanisms. 
 
3.2.2 Is B74-90 an altered peptide ligand (APL) for M74-90-specific T cells?  
A reasonable explanation for the failure of the BTN-specific T cells to induce 
macrophage recruitment could be that TCR signalling induced by the MHC/BTN peptide 
complex may differ from that induced by the autologous MOG peptide/MHC complex, possibly 
due to differences in affinity. Such effects are well documented for the response of MBP- or 
PLP-specific T cell clones to peptide “mimics” or “altered peptide ligands” (APL) (Nicholson et 
al., 1995; Smilek et al., 1991; Gaur et al., 1997) and can dramatically influence cytokine 
production. This may lead to reduced secretion of Th1-associated proinflammatory cytokines 
such as IFN-γ, while enhancing the secretion of Th2-associated counter-inflammatory cytokines 
such as IL-4 and IL-10 in encephalitogenic T cells (Nicholson et al., 1995). In vivo, this APL 
mediated effect on cytokine synthesis (immune deviation) can be exploited to suppress CNS 
inflammation and thereby disease activity in EAE (Nicholson et al., 1995).  
The possibility that bovine BTN could provide a naturally occurring APL, which modifies 
the MOG-specific T cell response, is intriguing. In order to determine whether this was the case, 
proliferation, cytokine secretion, cell surface phenotype and finally the pathogenicity of M74-90-
specific TCLs were compared following restimulation with either M74-90 or B74-90 in vitro. 
 
3.2.2.1 Restimulation with B74-90 reduces proliferation of M74-90-specific T cells 
The two M74-90-selected TCLs used in this study proliferated in response to both MOG 
and their cognate ligand M74-90, but not to the second encephalitogenic MOG-epitope M93-109 
(Figure 3.2.5 A and Table 3.2.1 for one of the lines). Proliferation was also observed in 
response to the homologous BTN peptide, B74-90. However, over a wide range of peptide 
concentrations B74-90 induced less proliferation than M74-90. Interestingly, the two TCLs varied 
in their relative responsiveness to B74-90. In one line, B74-90 only induced 50% of the response 
seen with M74-90, whereas in the other line this was approximately 80%.  
 
3.2.2.2 Restimulation with B74-90 fails to alter the cell surface phenotype of M74-90 -
specific T cells 
Optimal restimulation of T cells with their cognate antigen induces an increase in cell size 
as well as a number of activation-associated changes in the surface phenotype. This includes the 
down-modulation of the CD3/TCR complex and the up-regulation of IL-2R and OX40 antigen-
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receptor (CD 134)(Flügel et al., 2001; Nohara et al., 2001). We therefore compared the surface 
expression of these molecules on M74-90-specific T cell blasts following restimulation with 
either M74-90 or B74-90 to determine whether both peptides induced similar levels of activation.  
M74-90-specific T cells were restimulated with M74-90 or B74-90. After 72 hours of 
restimulation, T cell blasts were analysed for the expression of IL-2R, TCR, CD3, CD4, OX40 
antigen or MHC class I by FACS analysis. We were unable to detect any significant, 
reproducible differences in the expression of these molecules following restimulation with 
cognate or xenogenic ligand (Figure 3.2.6). This demonstrates that all M74-90-specific T cells 
which cross-react with B74-90 are fully activated and express the same pattern of cell surface 
markers seen on other encephalitogenic T cell lines (Flügel et al., 2001; Kojima et al., 1994)  
 
3.2.2.3 Restimulation with B74-90 modulates the cytokine spectrum of M74-90-specific T 
cell lines 
Many T cell functions are mediated by secreted cytokines, and the ratio of individual 
cytokines has a major influence on the outcome of the immune response (Liblau, et al., 1995). 
Some cytokines, like IFN-γ and TNF-α, are characteristic for inflammatory responses mediated 
by Th1 T cells, while others, such as IL-10 and TGF-β, are generally considered as mediating 
counter-inflammatory functions and are associated with the Th2 T cell subset. Nevertheless, 
these divisions are not absolute and encephalitogenic rat T cell lines secrete both IFN-γ and IL-
10 (Stefferl et al., 1999; Lenz et al., 1999). In order to determine whether B74-90 acts as an APL 
and affects the cytokine balance of the M74-90-specific T cells, M74-90-specific T cell lines were 
restimulated with a range of concentrations of B74-90 and M74-90 and cytokine secretion assayed 
by ELISA (Figure 3.2.5 B, C, D). Intriguingly, despite the difference of the two lines in terms of 
their proliferative response to B74-90, restimulation with this peptide induced a consistent shift in 
cytokine secretion in favour of IL-10 relative to TNF-α and IFN-γ. For the TCL shown in 
Figure 3.2.5 A-D, despite its reduction of the proliferative response, restimulation with B74-90 
did not modify the secretion of IL-10, while secretion of IFN-γ was decreased by 40% and 
secretion of TNF-α reduced by 80%. No significant secretion of TGF-β was detected (data not 
shown). However, the presence of TGF-β in the serum added to the restimulation medium 
generated a high background, which may significantly reduce the detection limit of the method. 
These results demonstrate that restimulation with the cross-reactive BTN peptide is 
associated with immune deviation, in this case away from a “pro-inflammatory” Th1-like 
towards a counter-inflammatory Th2-like response.   
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3.2.2.4 Restimulation with B74-90 reduced the pathogenicity of M74-90 specific T cells 
The counter-inflammatory properties of IL-10 have been exploited previously to suppress 
disease activity in EAE (Rott et al., 1994), and increased IL-10 production is generally 
associated with a reduction in the pathogenicity of auto-aggressive Th1 T cell lines. It was 
therefore anticipated that the relative increase in the synthesis of IL-10 by the M74-90 selected T 
cell lines following restimulation with B74-90 would be associated with a decrease of the 
pathogenic potential of the TCLs.  
M74-90-selected T cell lines were therefore restimulated with either M74-90 or B74-90 for 72 
hours and 5 x 106 T cell blasts transferred into naïve DA rats. Strikingly, although the same 
number of T cell blasts was transferred, disease onset was delayed and disease severity 
strikingly reduced in those rats injected with T cell blasts that had been restimulated with the 
BTN-derived peptide (Figure 3.2.5 E).  
Bovine BTN therefore acts as an APL for M74-90-specific TCLs and provides a model 
system in which APL-mediated effects can modulate the autoimmune repertoire. The generation 
of TCR transgenic rats over-expressing the appropriate cross-reactive TCR(s) would open the 
door to analyse the in vivo effect of a dietary APL on the cross-reactive T cells as well as 
facilitating the generation of T cell clones for the analysis of the in vitro effects on a clearly 
defined T cell population.  
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Figure 3.2.5 Analysis of the phenotype of M74-90-selected T cells in response to M74-90  or B74-90   
A) Proliferation of M74-90 selected T cells to a range of concentrations of M74-90 (black columns) or B74-90 (white 
columns). Shown are the mean c.p.m. and standard deviations of a quadruplicate analysis. B - D) ELISA analysis of 
the secreted cytokines of the cells restimulated in A). B) IL-10, C) IFN-γ and D) TNF-α. Shown are the averages of 
duplicate analyses. Cells were restimulated in the presence of M74-90 (black columns) or B74-90 (white columns). E) 
Pathogenicity of 5 x 106 T cell blasts. M74-90  selected T cells were restimulated for 72 hours with M74-90 (diamonds) 
or B74-90 (squares). Shown is the average of two animals per group of a representative experiment. 
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Figure 3.2.6 FACS analysis of M74-90 selected T cells after restimulation with the two peptides.  
M74-90 selected TCLs were restimulated in the presence of irradiated thymocytes and either M74-90 or B74-90. 3 days 
later, T cell blast were analysed for the expression of cell surface markers. Blue: Restimulation with M74-90; green: 
restimulation with B74-90; red overlay represents the negative control. Shown is a representative analysis. Shifts are 
minimal and did not always follow the same trend. Cells are stained for A) isotype control; B) CD3; C) IL-2R; D) 
MHC class II; E) CD4; F) OX40; G) α/β TCR. H) and I) represent the gated populations.  
 
 
3.2.3 Repeated selection with B74-90 or M74-90 results in the expansion of T cell clones 
with identical  TCR usage 
A pre-requisite for any future studies involving TCR transgenic rats is a full molecular 
characterisation of the TCR(s) used by the cross-reactive T cell response. Previous studies 
indicate that encephalitogenic T cell responses are associated with a limited number of clonal 
expansions (Chluba et al., 1989; Burns et al., 1989; Wucherpfennig et al., 1990). These can be 
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identified by spectratyping of the β chain of the T cell receptor (TCR spectratyping) (in 
collaboration with Dr. N. Goebels and I. Eiglmeier, Klinikum Großhadern, Munich). 
This is a RT-PCR technique based on the length polymorphism in the CDR3 
(complementarity determining region) of the TCR and the fact that each T cell expresses a 
single β chain. Primers are placed in the individual Vβ regions and the constant domain of the 
TCR and thus span the CDR3, which is the area in which the TCR rearrangement occurs during 
T cell maturation in the thymus (joining of different D and J regions with a V region, combined 
with junctional diversity) (see section 2.2.21). The PCR products are then separated on 
polyacrylamide gels (Figures 3.2.7). To facilitate analysis, size of product and intensity of 
fluorescence are represented as histograms (Figure 3.2.8). Spectratyping analysis of a mixed T 
cell culture will result in a gaussian distribution of PCR products of various lengths. In contrast, 
if a clonal expansion of T cells occurs, this gaussian distribution of the corresponding Vβ family 
is disrupted. In a monoclonal expansion this results in a single band, allowing the product to be 
sequenced by RT-PCR. This technique provides detailed information on the clonality and 
complexity of an antigen-specific T cell response.  
In order to clearly identify the clonal expansions associated with the cross-reactive 
response, TCR usage was compared in TCLs derived from MOG-immunised rats and selected 
by repeated restimulation with either M74-90 or the cross-reactive BTN peptide B74-90. As 
controls, cells were selected with MOG-Igd or M93-109, the immunodominant MOG-peptide 
which does not cross-react with either M74-90 or B74-90 and which should therefore expand a 
different sub-population of the MOG-Igd-specific T cell repertoire. In addition, thymus from 
naïve DA rats was used as a source for a polyclonal T cell population. 
Proliferation assays confirmed the antigen specificity of the TCLs (Table 3.2.1). Within 
two cycles of restimulation, TCLs selected with M93-109 lost all responsiveness to M74-90 and  
B74-90. Conversely, selection with M74-90 or B74-90 resulted in a loss of responsiveness to M93-109, 
while the responsiveness to MOG was retained. Interestingly, the B74-90–selected cell lines 
always proliferated better in response to M74-90 than to their selective peptide B74-90 (Figure 
3.2.5), a phenomenon, which has been described for altered peptide ligands previously 
(Nicholson et al., 1995; Nicholson et al., 2000). After six restimulation cycles T cell blasts were 
isolated and analysed by spectratyping. 
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Proliferation (c.p.m.) Antigen                                     
T cell line No antigen MOG M93-109 M74-90 B74-90 
MOG - selected 48 +/- 14 3268 +/-  263 1387 +/-135 724 +/-  82 318 +/-  54 
M93-109-selected 4  +/-  4 3206 +/-  486 2936 +/- 343 2   +/-  2 2   +/-  2 
M74-90 - selected 19 +/-  2 501  +/-  293 28 +/- 3 1665 +/-  177 901 +/- 65 
B74-90  - selected 24 +/-  7 1801 +/-  154 17 +/- 8 3805 +/- 176 3554 +/- 192 
 
Table 3.2.1 Representative proliferative response of the four different T cell lines to MOG and peptides.  
TCLs were restimulated in the presence of irradiated thymocytes and antigens. Shown are the mean c.p.m. and 
standard deviation of quadruplicate measurements  
 
Analysis of mRNA derived from DA thymus confirmed that all of the primer pairs used in 
this study generated a typical gaussian distribution of PCR products for each Vβ family (Figure 
3.2.7 A). In contrast, spectratyping of the MOG-Igd-specific TCL and its three peptide-selected 
derivatives demonstrated the presence of multiple clonal expansions. This indicates that unlike 
the response of Lewis rats to MBP, which is dominated by a monoclonal expansion of Vβ8.2 
expressing T cells (Chluba et al., 1989), the MOG-Igd-specific response in the DA rat is 
oligoclonal, even when specificity is restricted to the single peptide epitopes (Figure 3.2.7 B-D). 
Nevertheless, despite this complexity some of the TCLs shared TCR β-chains with CDR3 
expansions of the same size, suggesting the presence of identical T cell clones (Table 3.2.2). 
However, this can only be confirmed by sequence analysis.  
In detail, analysis of the MOG-Igd-selected TCL revealed multiple expansions in 21 of 22 
Vβ families. In nine of these Vβ families, dominant expansions could be identified as single or 
clearly prominent products (judged by fluorescence intensity), suggesting that they can be 
sequenced. One of these (Vβ4) was also dominant in the TCL selected with the immuno-
dominant peptide epitope M93-109 (Figure 3.2.8 A), which had expansions in 18/22 Vβ families 
(Table 3.2.2). Sequence analysis confirmed the presence of an identical TCR β-chain in the two 
TCLs (MOG and M93-109-selected, Figure 3.2.8 B).  
As expected, selection with M93-109 failed to generate any overlap with the M74-90- or  
B74-90-selected T cell lines and vice versa. The M93-109-selected TCL was therefore used as a 
control for the sequencing reactions to demonstrate that expansions identified in more than one 
of the other TCLs are specific and not due to contamination.  
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Figure 3.2.7 Spectratypes of rat thymus and T cell lines 
A) Thymus control; B-E) T cell lines selected with B) MOG; C) M93-109; D) M74-90 and E) B74-90. Each lane 
represents a single Vβ-family, analysed sequentially from Vβ1 to Vβ20 (s. Table 3.2.2). The horiyontal double/or 
quadruple bands are molecular size markers. Note that there are multiple expansions in most of the Vβ families, but 
these differ from the gaussion distribution observed in the thymus 
A) B)
C) D)
E)
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 MOG M93-109 M74-90 B74-90 
Vβ1   _   +   + 365 
Vβ2   +   +   +   + 
Vβ3   +   +   -   - 
Vβ4 415 415   + 417 
Vβ5   + 395   + 390 
Vβ6 (280) (272) (285) (285) 
Vβ7 287 (278) 287 292 
Vβ8.1/2   +   +   - 340 
Vβ8.5   +   +   +   + 
Vβ8.6   +   + (338) 335 
Vβ9 398   + 398 393 
Vβ10 287   +   +   + 
Vβ11   +   + (398) 398 
Vβ12   +   +   +   + 
Vβ13   + 375   +   + 
Vβ14   +   +   +   + 
Vβ15 (410)   - (405) 415 
Vβ16   +   - (339) 335 
Vβ17   +   -   - (405) 
Vβ18 (405) 418 (420) 420 
Vβ19 360   + 360 365 
Vβ20 360   - 363 and 370 363 
 
Table 3.2.2 TCR β-chain spectratyping revealed expansions in 21/22 Vβ families in MOG, 18/22 families in 
M93-109, 18/22 families in M74-90 and 21/22 in B74-90.  
Oligoclonal expansions are presented as + or, if clearly prominent expansions were present, by the size of the PCR 
products. Monoclonal expansions are without brackets, dominant bands with brackets. Similarly sized CDR3s are 
printed in red. 
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Selection with the subdominant MOG-epitope M74-90 (which had expansions in 19/22 Vβ 
families) generated dominant expansions of a similar size to dominant expansions in the MOG-
Igd-selected cell line in Vβ7, Vβ9 and Vβ19 (Examples in Figure 3.2.8). The presence of 
identical CDR3 regions was subsequently confirmed for Vβ19 and Vβ7 by sequencing (Figure 
3.2.7 B). In contrast, there was no sequence identity in Vβ9.  
Strikingly, the spectratypes of the M74-90- and B74-90- selected TCLs were more closely 
related than any other two pairings. The B74-90-selected TCL contained dominant expansions 
with five different Vβ chains, which had the same size as expansions – but not necessarily 
dominant expansions - in the M74-90-selected T cells (Examples in Figure 3.2.9). Sequencing 
confirmed that the two lines used identical TCR β-chain rearrangements in at least three of 
these expansions (Vβ6, Vβ18 and Vβ20). However, in Vβ20 this involved only a sub-
population of the M74-90 selected T cells (Figure 3.2.9) and therefore required an additional PCR 
amplification step using primers in Vβ20 and Jβ2.3, the Jβ element which was identified in the 
corresponding B74-90 sequence. Intriguingly, sequencing of the MOG and M93-109-selected TCLs 
using primers in Vβ20 and Jβ2.3 revealed a second identical TCR β-chain in those two cell 
lines. This TCR β-chain was different to the one used by the M74-90 and B74-90 selected cell lines.  
It should also be noted that spectratyping/sequencing of the TCL selected with MOG-Igd 
failed to identify any of the expansions shared by the M74-90 and B74-90 –selected TCLs (Vβ6, 
Vβ18 and Vβ20). This confirms the concept that the M74-90/B74-90-cross-reactive T cells are only 
a minor component of the total MOG-specific T cell repertoire in the DA rat.  
To test whether the Vβ-chains, which were shared between the M74-90- and B74-90-selected 
cell lines and therefore presumably cross-reactive, might be pathogenic, we then analysed 
whether cells expressing TCRs would be able to invade the CNS. M74-90- and B74-90-selected T 
cell blasts were transferred into naïve syngeneic recipients and 5 d.p.t. the spinal cords were 
analysed for the expression (transcription) of Vβ6, Vβ18 and Vβ20. At this time point, the 
animals that had received the M74-90-selected T cell showed the first symptoms of EAE, while 
the other animals were completely healthy. Using Jβ-specific primers, the shared Vβ6 and 
Vβ20 could be detected in animals injected with either cell line. 
This study demonstrates that the BTN/MOG cross-reactive T cell response is complex 
and involves at least three different T cell clones. This is in part disappointing, as this will 
complicate further molecular analysis and suggests that specific TCR-directed therapies are 
unlikely to be effective in inhibiting MOG-induced EAE (Acha-Orbea, 1988; Vandenbark et al., 
1993; Wraith et al., 1989; Anderton et al., 1998). 
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Vβ4 MOG   CASS – QDRD - TGQLYFGEGS-Jβ2.2 
  M93-109   CASS – QDRD - TGQLYFGEGS-Jβ2.2 
Vβ7 MOG    CASS – DDRGDTE - VFFGKGT-Jβ1.1 
  M74-90    CASS – DDRGDTE - VFFGKGT-Jβ1.1 
Vβ19 MOG    CASS – HTGGSYE - QYFGPGT-Jβ2.6 
  M74-90    CASS – HTGGSYE - QYFGPGT-Jβ2.6 
Figure 3.2.8 Identification of TCR β-chain CDR3 regions, which are identical in MOG- or MOG-peptide 
selected TCLs.  
Upper panel: Comparison of spectratypes of Vβ4 and Vβ19 in MOG- and MOG-peptide selected TCLs. Histograms 
showing the relative amount of PCR product (intensity of fluorescence, y-axis) with respect to the product size (x-axis). 
Thymocytes show a gaussian distribution of peaks, which is disrupted in all TCLs. In some Vβ families dominant expansions 
were observed as single peaks (e.g. Vβ19 in the MOG- and M74-90  - selected TCLs). Identical location of the peaks in MOG and 
M93-109-selected lines (Vβ4, left) or MOG and M74-90-selected lines (Vβ19, right) suggests identical expansions in the two TCLs, 
while the selection with the other peptide induced multiple expansions in these Vβ families. Lower panel: Amino acid 
sequence comparison of Vβ4, Vβ7 and Vβ19. Amino acid sequences were deduced from the sequences obtained from RT-
PCR products and are represented in the one-letter-code. This revealed that cells with the same TCR β chains were expanded in 
the MOG or MOG-peptide selected TCLs. CDR3-regions are printed in red, surrounding Vβ and Jβ region in black. Jβ families 
were identified after Williams et al., 1991 after sequencing of the product.  
V 19β
Thymus
MOG
M93-109
M74-90
V 4β
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  Vβ6  M93-109  CASS –     IEKG   – ERLFFGHGT-Jβ1.4 
     M74-90 CASS – PPLGGH – SQNTLFFGAGT-Jβ2.4 
    B74-90 CASS – PPLGGH – SQNTLFFGAGT-Jβ2.4 
  Vβ18 M74-90  CSS – GDFHAF –  TTDKIYFGSGT - Jβ2.3 
    B74-90  CSS – GDFHAF – TTDKIYFGSGT - Jβ2.3 
  Vβ20 M74-94 CSS - CQGQWG – DKIYFGSGT - Jβ2.3    
   B74-90 CSS - CQGQWG – DKIYFGSGT - Jβ2.3   
 
Figure 3.2.9 Identification of  clones with identical TCR Vβ-usage in the BTN/MOG cross-reactive T cells  
Upper panel: Comparison of spectratypes of Vβ6, Vβ18 and Vβ20 of M74-90- and B74-90-selected TCLs. Histograms 
showing relative amount of PCR products (intensity of fluorescence, y-axis) with respect to the product size (x-axis). 
Thymocytes show a gaussian distribution of peaks. In contrast, monoclonal expansions were observed in the B74-90-selected 
TCLs. Note that the product size (location of the peak) is identical in M74-90- and B74-90-selected TCLs, but different in the MOG-
selected line. Lower panel: Amino acid sequence comparison of Vβ6, Vβ18 and Vβ20. Amino acid sequences were deduced 
from the sequences obtained from RT-PCR products and are represented in the one-letter code. Note that for Vβ6, the clone 
expanded in the M93-109-selected TCL uses a different CDR3 as well as a different Jβ fragment. CDR3-regions are printed in red, 
surrounding Vβ and Jβ region in black. Jβ families were identified after Williams et al., 1991 after sequencing of the product. 
Sequencing of Vβ20 in the M74-90 selected TCL required a second round of PCR using Jβ-specific primer.  
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3.2.4 Four conserved amino acid residues are essential for the BTN/MOG cross-
reactive T cell response  
Clearly the identification of cross-reactive TCRs is vital for subsequent analysis of the 
MOG/BTN cross-reactive T cell response. At the same time it is important to identify those 
amino acid residues, which are necessary for this cross-reactivity. In order to define the amino 
acid residues contributing to the cross-reactive T cell response, M74-90- or B74-90-selected TCLs 
were restimulated with M74-90, B74-90, or a panel of 15 alanine substituted versions of B74-90, in 
which single amino acids were replaced by alanine residues (alanine in position 9 was replaced 
by glycine). Substitution of residues E78 and R84 dramatically reduced the proliferative 
response (>80%) of M74-90-selected TCLs (Figure 3.2.10 A), and a similarly pronounced loss of 
proliferation was observed when residues G79 and V81 were substituted (approximately 60%). 
In addition, substitutions at a further five sites (I85, Q86, I76, V88 and V83) had a consistent 
but low effect on the proliferation of M74-90-selected T cells. (Figure 3.2.10 A). None of the 
substitutions resulted in significantly enhanced proliferation. An identical pattern emerged when 
the study was performed using B74-90-selected TCLs. The same four residues were essential for 
significant proliferation (E78, R84, G79 and V81) (Figure 3.2.10 B). Additionally, some of the 
less important residues (I76, V83 and Q 86) also had an effect on the proliferation of these cell 
lines, while no additional residues were involved. 
This analysis demonstrates that the substitution of any of four amino acids (E78, R84, 
G79 and V81) by alanine dramatically suppressed the proliferative response, implying that these 
residues are crucial to maintain the cross-reactive response between MOG and BTN. In 
addition, modifications at five other sites also induced a significant reduction of the cross-
reactive T cell response. It should be noted that one of these a.a. residues (V83) is not conserved 
between MOG and BTN (Figure 3.2.10 C). However, at this position the difference between 
MOG and BTN is conservative, involving a switch between two bulky aliphatic amino acids 
(valine and leucine). In contrast, although alanine is also hydrophobic, it is much smaller. Two 
of the four residues which are very important for the cross-reactivity between rat MOG and 
bovine BTN (E78 and V81) were not conserved in rat BTN, supporting the hypothesis that the 
lack sequence identity in this peptide is responsible for the failure of rat BTN to modulate the 
M74-90-specific immune response in the DA rat.  
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 Figure 3.2.10 Proliferative response of M74-90 or B74-90-selected T cell lines to alanine substituted versions of 
B74-90 
A) Representative proliferative response of M74-90 selected TCLs to the alanine substituted B74-90 peptides. B) 
Representative proliferative response of B74-90 selected TCLs to the alanine substituted B74-90 peptides. C) Graphic 
presentation of  the residues which are important for the cross-reactive response in the  rat MOG and the bovine and 
comparison with the homologous rat BTN peptide. Amino acids are represented in the one-letter-code, amino acids 
identical to rat MOG are represented as bars. Amino acid residues, which are vital for the cross-reactive response 
are printed in red, less important residues in blue. Irrelevant residues are printed in black. For E78, G79, V81 and 
R84, significance was very high (p<0.001, using two-tailed student´s T-test for samples with equal variance). 
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3.2.5 High dose soluble antigen treatment with butyrophilin - peptide suppresses EAE 
mediated by M74-90 specific T cells 
This study has demonstrated that a peptide derived from bovine BTN is a naturally 
occurring APL for MOG-Igd-specific T cells in the DA rat, but cross-reactivity only involves a 
minor subset of the MOG-Igd-specific T cell repertoire. In order to test the physiological 
importance of these effects in an in vivo system, we decided to investigate the extent by which 
B74-90 could replace the MOG-peptide in inducing antigen-specific tolerance. This was tested for 
two paradigms, one of which investigated the effect on an established, M74-90-specific T cell 
response and the other the effect on the developing MOG-Igd-specific immune response.  
A well-established method to induce antigen specific tolerance of T cells is treatment with 
high dose soluble antigen (HDSA) (reviewed in Liblau et al., 1997). This induces activation 
induced T cell death and/or anergy and results in a transient suppression and/or deletion of 
antigen-specific T cells (Bercovici et al., 1999). Since cross-reactivity between MOG and 
butyrophilin in DA rats is restricted to only one of the two encephalitogenic T cell epitopes 
(Stefferl et al., 2000), we investigated whether treatment with the homologous butyrophilin 
peptide (B74-90) could suppress EAE induced by the transfer of M74-90-specific T cells.  
The transfer of 5 x 106 M74-90-specific T cells induced severe clinical disease with a 
maximal score of 2.5 +/- 0.3 in naïve syngeneic recipients (Figure 3.2.11). Clinical symptoms 
were completely suppressed when the animals were treated intravenously with 1 mg M74-90 two 
and four d.p.t.. A protective effect was also observed after treatment with the homologous BTN 
peptide B74-90. However, in this case suppression of disease was less efficient and all animals 
developed mild symptoms of EAE. This indicates that B74-90 cannot fully replace the tolerogenic 
effect of M74-90. This reflects that the cross-reactive T cell response involves only a subset of the 
M74-90-specific T cells and suggests that the non-cross-reactive T cells escape “tolerisation” and 
persist to induce an attenuated form of disease. 
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Figure 3.2.11 Treatment with HDSA suppresses T cell mediated EAE 
Shown is the mean clinical course and standard deviation after adoptive transfer of 7 x 106 M74-90-specific T cells 
into naïve DA rats. Animals were treated i.v. with 1 mg Ova (triangles, n=6), B74-90 (squares, n=6) or M74-90 
(diamonds, n=5) at 2 and 4 d.p.t.. Disease suppression was significant (p<0.05, Duncan´s post hoc test) 
 
3.2.6 Intra-nasal application of BTN-peptide can fully replace the homologous MOG-
peptide in suppressing MOG-Igd-induced EAE 
The effect of B74-90 on the developing immune response was investigated by intra-nasal 
induction of tolerance. Nasal tolerance duplicates many of the immunological features of oral 
tolerance (Strobel and Mowat, 1998), but avoids digestion in the gastro-intestinal tract and 
requires minimal amounts of peptide (Metzler and Wraith, 1993). For the induction of nasal 
tolerance, a protocol was employed that had previously been shown to inhibit MBP-induced 
EAE in the DA rat (Bai et al., 1997).  
As described in section 3.1.3.1.2, immunisation of DA rats with MOG-Igd induces 
pathogenic T cell responses against two distinct epitopes, M74-90 and M93-109. Since only one of 
these responses cross-reacts with BTN, we examined the influence of the individual peptides as 
well as combinations of peptides on MOG-Igd-induced EAE. Female DA rats were treated 
intra-nasally with either M74-90, B74-90 or M93-109 alone, or alternatively with a combination of the 
immunodominant peptide M93-109 with either M74-90 or B74-90 for 10 consecutive days prior to 
immunisation with MOG-Igd. Ovalbumin-treated control rats developed biphasic disease 
comparable to that seen in untreated animals (Figure 3.1.1) and this was only slightly 
suppressed by pre-treatment with the any of the individual peptides (Figure 3.2.12 A-D). 
Strikingly, treatment with combinations of peptides was far more efficient (Figure 3.2.12 E, F). 
The combination of B74-90 and M93-109 resulted in complete suppression of the first phase of 
disease and a strongly reduced severity of relapse, similar to the effect of treatment with the 
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combination of the two MOG-peptides. These results indicate that bystander suppression does 
not play a major role in this disease model, since both T cell epitopes need to be targeted for full 
suppression of disease. Intriguingly, B74-90 can fully replace M74-90 in the induction of intra-nasal 
tolerance in this model, although we have demonstrated previously that not all of the M74-90-
specific T cells cross-react.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.12  Intranasal treatment with MOG- or BTN-peptides can suppress MOG-Igd-induced EAE  
Female DA rats were treated intranasally for 10 consecutive days with A) 50 µg Ova (n=6); B) M74-90 (n=6);  C) 
B74-90  (n=6); D) M93-109 (n=6); E) M74-90 + M93-109 (n=6) or F) B74-90 + M93-109 (n=5) prior to induction of MOG-
Igd/IFA-EAE. Shown are the mean clinical course of groups of 5 - 6 rats and SEM.   
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3.2.7 Cross-reactivity of antibodies 
3.2.7.1 The antibody response to MOG-Igd does not cross-react with BTN 
The unique feature of MOG as a target for EAE is that the MOG-specific antibodies are 
capable of mediating demyelination in rats and primates (Linington et al., 1988; Lassmann et 
al., 1988; Genain et al., 1995, 1999; t´Hart et al., 2000). Since rat MOG and bovine BTN share 
approximately 50% sequence identity as well as a conserved IgV-like structure, it was thought 
to be probable that molecular mimicry would extend to the B cell response. In consequence, 
BTN/MOG cross-reactive antibodies may be pathogenic and contribute to disease pathogenesis. 
However, analysis of the antibody response in DA rats 19 d.p.i. with 100 µg MOG-Igd in 
IFA by ELISA identified only a minimal level of cross-reactivity to BTNexo that was restricted 
to peptide B89-113. No cross-reactivity was detected with the peptides B1-26 and B50-74, which are 
homologous to the immunodominant MOG peptides (Figure 3.2.13 A). 
 
3.2.7.2 No cross-reactivity of antibodies after DNA vaccination with BTN or MOG 
One possible explanation for the low cross-reactivity to BTNexo is that the animals were 
immunised with denatured, non-glycosylated MOG-Igd, while their serum was tested for a 
cross-reactive antibody response using recombinant insect-derived BTNexo, which is 
glycosylated and also believed to be in its native conformation. We therefore used a DNA 
vaccination approach to generate antibody responses to the “native” IgV-like domains of both 
proteins and then retested their cross-reactivity by ELISA.  
In order to minimise the influence of the intracellular domains of butyrophilin on protein 
expression, the cDNA encoding the extracellular domain of bovine BTN was fused to the 
cDNA encoding the trans-membrane and intra-cellular domains of mouse MOG and cloned into 
pcDNA3.1(-), the same vector which had been used for the MOG construct (See section 
2.2.18). Vaccination with pcDNA-BTN/MOG induced a BTN specific antibody response in DA 
rats, which – in contrast to the MOG-response - was not purely conformation dependent, but 
also recognised peptide B1-26 (Figure 3.2.13 B). However, no binding could be detected to either 
MOG-Igd or any MOG peptide (Figure 3.2.13 C). Conversely, the serum of MOG-vaccinated 
DA rats did not bind to either BTNexo or any BTN peptide (Figure 3.2.13 D).  
As anticipated from this lack of cross-reactivity, DNA vaccination with pcDNA-
BTN/MOG did not enhance the disease induced 4 weeks later by adoptive transfer of 2 x 106 
M93-109-selected TCLs (data not presented). Moreover, as described in 3.1.3.4, there was no 
significant absorption of BTN-specific antibodies in the inflamed CNS of rats with EAE. These 
observations demonstrate that despite the extensive sequence homology between MOG and 
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BTN, there is little or no cross-reactivity between the B cell responses to these two proteins in 
the rat.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.13 Specificity of MOG and BTN-specific antibodies in the DA rat  
A) Analysis of serum derived 19 d.p.i. with MOG-Igd/IFA. Shown is the mean O.D.405 and standard deviation of 
quadruplicate analysis of sera pooled from 3 animals. Black columns: binding to MOG peptides, white columns: 
binding to BTN peptides. Minimal binding was observed to the BTN peptide 89-113 and BTNexo; B) and C) 
antibody response after vaccination with pcDNA-BTN/MOG. B) Response to BTN peptides. Note that a linear 
epitope is recognised in addition to the dominating response to BTNexo; C) response to MOG peptides. Shown are 
mean O.D.405 and standard deviation of sera derived from 4 rats analysed individually in quadruplicates. No binding 
was detected to MOG-Igd nor to any linear MOG peptide. D) Serum derived from MOG-vaccinated rats also failed 
to bind to BTNexo or any of the linear BTN peptides (black columns: binding to MOG peptides, white columns: 
binding to BTN peptides).  
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3.2.8 Discussion 
This study demonstrates that functional modulation of a sub-population of the MOG-
specific T cell repertoire is sufficient to modify the clinical course of MOG- induced EAE. The 
BTN-derived peptide appears to act as an APL for a population of MOG/BTN cross-reactive T 
cells, skewing their cytokine production towards a less inflammatory phenotype. The 
demonstration that the environment, in this case the diet, can provide APLs that modify the 
function of the autoimmune repertoire adds a further level of complexity to the aetiology of 
complex disorders such as MS and diabetes.   
The only other myelin autoantigen for which TCR usage was investigated extensively is 
MBP (Chluba et al., 1989; Burns et al., 1989; Wucherpfennig et al., 1990). In the Lewis rat, the 
immunodominant epitope of MBP is MBP68-86, and the T cell response to this peptide is 
dominated by clones using the TCR Vβ8.2 gene (Chluba et al., 1989; Burns et al., 1989; 
Matsumoto, 2000). In contrast, the MOG-specific T cell response in the DA rat is far more 
heterogeneous. Not only are two distinct epitopes recognised, but in each case the T cell 
response is oligoclonal, as demonstrated by spectratyping. Comparison with the results obtained 
on epitope specificity and TCR gene usage by human myelin antigen specific TCLs and clones 
suggests that the MOG-specific T cell response in DA rats more closely resembles the human 
situation. Despite initial reports that the auto-reactive repertoire was restricted in complexity 
(Wucherpfennig et al., 1990), detailed studies revealed that for any given myelin antigen, 
epitope specificity and TCR gene usage are complex in both MS patients and healthy controls. 
(Ausubel et al., 1997; Pette et al., 1990). Unfortunately, this complexity almost certainly means 
that immuno-therapies based on the concept that disease can be suppressed by specific 
elimination of a limited number of autoantigen specific clonal expansions in the T cell 
repertoire (Vanderbark et al., 1993; Appel et al., 2001) are unlikely to succeed in clinical 
practise.   
The complexity of the T cell response to MOG extends to the cross-reactive response to 
the BTN peptide 74-90. Although in this case only a single MOG peptide is involved, 
spectratyping suggest the presence of at least three distinct TCRs that will support the cross-
reactive T cell response. However, this must still be confirmed by identifying the TCR α chains 
associated with these particular TCR β-chains and demonstrating that these TCRs really do 
support a cross-reactive T cell response. Such studies are the first step towards generating TCR 
transgenic rats, in which the immune repertoire is skewed in favour of recognition of the cross-
reactive peptide epitope. These animals would enable a detailed in vivo analysis of the 
physiological consequences of molecular mimicry between a dietary antigen and self, and the 
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molecular and cellular mechanisms that regulate the impact of oral tolerance on the autoimmune 
repertoire. 
In DA rats, those T cells recognising both M74-90 and BTN74-90 appear to be only a minor 
component of the MOG-reactive repertoire, possibly accounting for less than half of the total 
response to M74-90 induced by immunis ation with MOG-Igd. This estimate is based on two 
observations. First, the proliferative response of M74-90-selected TCLs to B74-90 is approximately 
50-80% of the response obtained using M74-90 (Figure 3.2.5 A). Second, spectratyping revealed 
that only a small proportion of the M74-90-and B74-90-selected T cells use the same TCR Vβ 
elements. Indeed, only three CDR3 sequences were identified that were expanded in both TCLs 
and none of them were significantly expanded in MOG-Igd-selected TCLs, suggesting that 
these clones represent a small subpopulation of the MOG-specific T cell repertoire. However, 
neither of these methods provide a true estimate of the frequency of cross-reactive T cells in the 
immune repertoire. It is anticipated that the generation of RT1.Bav1 class II MHC tetramers 
(Olsson, personal communication) will soon allow this question to be answered directly, as well 
as providing the means to isolate the cross-reactive T cell population by FACS sorting. This 
will also facilitate the identification of the TCR α chains.  
In this study, HDSA treatment with the BTN peptide reduces, but does not eliminate the 
pathogenic potential of the cross-reactive T cell response. This observation is in agreement with 
the spectratyping data, which demonstrate that not all M74-90-selected T cells express the same 
TCR Vβ rearrangements as the M74-90-selected cells. However, in spite of this heterogeneity, 
treatment with B74-90, in vitro stimulation of M74-90-selected TCLs with this peptide dramatically 
reduces their ability to induce EAE. Loss of the encephalitogenic/inflammatory potential of the 
TCLs was associated with a relative increase in the secretion of IL-10, a marker for a Th2 like 
response in the rat, and conversely with decreased secretion of IFN-γ, a marker of Th1 activity. 
Stimulation with the BTN peptide therefore induces immune deviation in the M74-90-selected 
TCLs away from a pro-inflammatory Th1 towards a counter-inflammatory Th0/Th2-like 
response, suggesting that B74-90 acts as an altered peptide ligand (APL).  
The concept of APL mediated immune deviation in EAE was first investigated by 
Nicholson et al., 1995, who demonstrated that single amino acid substitutions in an 
encephalitogenic PLP peptide inhibits EAE in SJL/J mice by inducing immune deviation. Prior 
to this, different peptide analogues were shown to induce suppression of autoimmune diseases 
by variable mechanisms, sometimes by blocking TCR-antigen binding without triggering a 
response, acting as TCR antagonists (De Magistris et al., 1992; Kuchroo et al., 1994; Franco et 
al., 1994), in other cases by inducting anergy (Sloan-Lancaster et al, 1993) or by partial 
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activation of T cells (Evavold and Allen, 1991). In other cases, modifications of 
encephalitogenic peptides induced enhanced responsiveness, and they were therefore termed 
“superagonist ligands”. (Vergelli et al., 1997) 
In the current study, stimulation of M74-90-selected TCLs with B74-90 increased the 
synthesis of IL-10 (a marker for enhanced Th2 activity in the rat)(Xiao et al., 1998; Vandebriel 
et al., 2000) relative to the classical Th1 associated “pro-inflammatory” cytokine IFN-γ in vitro. 
This was paralleled by marked reduction in the pathogenicity of the TCLs in vivo. As no 
increase in TGF-β production was observed in this system, these effects may be attributable to 
the counter-inflammatory effects of IL-10, which have previously been exploited to suppress 
EAE. Systemic application of IL-10 was shown to suppress induced EAE (Rott et al., 1994), 
and mRNA transcripts for IL-10 are reported to be up-regulated in both the CNS and peripheral 
immune organs during remission (Kennedy et al., 1992; Rott et al., 1994; Diab et al., 1997). IL-
10 is also up-regulated after the induction of nasal tolerance (Burkhart et al., 1999), and 
combined application of IL-10 and MBP-peptide enhances both oral and nasal tolerance in 
Lewis rats (Slavin et al., 2001). Its importance for disease suppression was further demonstrated 
by nasal application of IL-10 alone, which prevents EAE in rats in both acute and relapsing 
remitting disease models (Xiao et al., 1998). In addition, IL-10 seems to be involved in 
protection mediated by antigen-pulsed DCs (Yang et al., 2000). Last but not least, transgenic 
mice over-expressing IL-10 were resistant to the induction of EAE (Bettelli et al., 1998;  Cua et 
al., 1999), while IL-10-deficient mice show enhanced clinical EAE (Bettelli et al., 1998). The 
mode of action of IL-10 in these systems is unclear and its effects are probably pleiotropic.  
The confirmation that environmental antigens such as BTN can provide APLs that 
modulate the functional activity of the self-reactive immune repertoire is important with respect 
to both our understanding of the aetiology of complex autoimmune disorders such as MS, as 
well as for the development of APL based immunotherapies. Currently, the degeneracy of the T 
cell repertoire makes it virtually impossible to design an APL which will have a predictable 
therapeutic outcome on an established immune response. This was recently demonstrated in 
MBP-induced EAE in the B10.PL mouse. In this well defined mouse model with a highly 
restricted TCR usage (8/9 T cell clones had virtually identical TCRs, Acha-Orbea et al.,1988), 
antagonistic APLs for the dominant T cell receptor were found to induce EAE rather than 
protect from disease induction (Anderton et al., 1998). Similarly, the first clinical trials of APLs 
in MS using peptides identified by in vitro assays had to be terminated due to various 
unexpected side effects. In one trial (142 patients, double blind, placebo controlled, three doses 
tested; Kappos et al., 2000), treatment with the lowest concentration of APL induced immune 
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deviation associated with decreased MRI activity, but the study had to be stopped after 
induction of hypersensitivity reactions in 9% of the patients. In contrast, treatment with the 
same APL in another trial (8 patients, not blinded, no controls, using only the highest dose 
applied in the Kappos trial; Bielekova et al., 2000) was associated with enhanced Th1-responses 
together with enhanced MRI and relapse activity. Not surprisingly this trial was also terminated 
prematurely. However, a different “modified peptide”, Copaxone 1 or glatiramer acetate, is an 
approved treatment for MS. Copaxone 1 is a synthetic random polymer (4.7-11 kDa) consisting 
of only 4 amino acids (A, K, E and Y) in a defined ratio, which was initially designed as a 
MBP-analogue to induce EAE (Teitelbaum, 1971). In contrast, however, it reduces disease 
activity in a significant proportion of MS patients, although its mode of action is still poorly 
understood. It is possible that this random mix of amino acids results in a variety of agonistic 
and antagonistic peptides, limited only by the restraints of the amino acid composition, which 
favour anti-inflammatory Th2-responses (Neuhaus et al., 2001, Farina et al., 2001). 
In the current study, the amino acid sequence identity between the encephalitogenic MOG 
peptide and its BTN peptide analogue was only 53% (9/17 residues). Four of the residues which 
are conserved between the two peptides (E78, G79, V81 and R84) are vital for the cross-
reactive response, while another five residues seem to play a minor role (Figure 3.2.10 A) and 
none of the modifications enhanced proliferation. In collaboration with Drs K. de Graaf and R. 
Weissert in Tübingen, we are currently identifying the residues involved in the binding to MHC 
and those that are critical interaction points with the TCR. This information will allow the 
design of further M74-90/B74-90 homologues substituted only at the TCR interaction site, which 
can then be used to investigate the molecular determinants involved in the APL mediated 
modulation of cytokine production by the MOG-reactive T cell repertoire.  
This study has investigated the influence of xenogenic BTN on the rat MOG-reactive T 
cell repertoire. However, it should not be forgotten that this repertoire develops in the neonatal 
animal during the same period that it is exposed to autologous BTN in the mothers milk. It was 
recognised several years ago that sensitisation with MOG-Igd in the Lewis rat fails to induce a 
strong proliferative response to the encephalitogenic MOG peptides M1-20 and M35-55, although 
these are present in the repertoire and can be selected in vitro. Could this reflect the presence of 
a suppressor cell population induced by rat BTN that cross-reacts with MOG? The sequencing 
of rat BTN provides the basic information necessary for further investigations of this 
speculation. The availability of synthetic rat BTN peptides will not only permit the analysis of 
the development of oral tolerance to BTN/MOG in neonates, but also of the mechanisms 
responsible for the maintenance of tolerance to BTN in the lactating mother.  
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A surprising outcome of the study was the virtual absence of cross-reactivity between 
MOG and BTN within the B cell response, as demonstrated by both active immunisation and 
DNA vaccination. This may be due to the high level of homology in terms of both structure and 
amino acid sequence that exists between the N-terminal domains of MOG and BTN and an 
expanding family of BTN-like proteins. This family of proteins contains at least 5 closely 
related subfamilies (MOG, BTN, BT2, BT3 and BTL II), with up to three members per group 
(Henry et al., 1997; Stammers et al., 2000), as well as closely related homologues in other 
species e.g the B-G antigens in birds (Henry et al., 1997). These proteins are also related to the 
co-stimulatory proteins B7-1 and B7-2 (Linsley et al., 1994) and have been termed the 
“extended B7 family”. All these proteins are encoded in the MHC and the amino acid sequence 
identity between sub-families ranges from 30-50%, while for any individual subfamily the 
sequence identity of the N-terminal domain is approximately 95%. The pattern of tissue 
expression of these proteins is broad, and some are expressed in immune organs. It is 
conceivable that each member provides a partially overlapping set of tolerogenic signals, which 
in DA rats combine to effectively eliminate any B cell clones that may recognise epitopes 
shared by MOG and BTN.  
Although the relevance of these findings for MS is still uncertain, molecular mimicry 
involving BTN may have a significant impact on the composition and function of the MOG-
specific T cell repertoire. Whether this leads to tolerance or the induction or a potentially 
pathogenic, auto-aggressive T cell response will be determined by multiple genetic and 
environment factors, which are poorly understood.  
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4 Conclusion and Perspectives 
This study investigated the immunobiology of MOG-induced EAE in the DA rat, an 
animal model, which reproduces the immunopathology of the type II MS lesion (Lucchinetti et 
al., 2000). A newly established immunisation protocol results in a highly synchronised biphasic 
form of EAE, which mimics the disease course of secondary progressive MS, albeit in a 
strongly abbreviated time course (Figure 3.1.1). This study demonstrates that MOG-specific 
autoantibodies are responsible for initiating clinical relapse and driving disease progression. On 
the background of mild, sub-clinical inflammatory activity in the CNS, pathogenic antibodies 
enter the CNS and mediate demyelination, a process that in turn amplifies the local 
inflammatory response (Figure 3.1.14 A). It should however be noted that lethal clinical 
relapses may also occur in the absence of a pathogenic antibody response if an inflammatory 
lesion develops in a region of the CNS that is particularly sensitive to damage, or where it may 
perturb vital functions, such as the brain stem. Although antibodies have been shown to amplify 
the severity of ongoing clinical EAE (Schluesener et al., 1987; Linington et al., 1988; Lassmann 
et al., 1988), firm evidence for a role in driving relapse and disease progression was missing. 
This study has now established this principal, which in all probability is relevant to our 
understanding of the pathogenesis of severe, steroid non-responsive relapses in MS patients. 
However, this model of EAE is an artificial system, in which the role of antibody is only 
apparent because of the different kinetics of MOG-specific T and B cell responses. In MS we 
still have to answer two crucial questions, namely the identity of the autoantigens targeted by 
the demyelinating antibody response, and the factors that may trigger this response.  
MOG is the only myelin protein known to initiate a demyelinating antibody response in 
EAE, and MOG-induced EAE has provided a valuable tool to identify the role of pathogenic 
autoantibodies in immune mediated demyelination. However, there is a major discrepancy 
between the proportion of MS patients with pathogenic MOG-specific antibodies in their 
circulation (5%; Haase et al., 2000) and the frequency of patients with pathological changes 
suggestive of antibody-mediated pathomechanisms (>50%; Lucchinetti et al., 2000). This 
discrepancy may in part be accounted for by the absorption of the pathogenic antibodies into the 
CNS, which will lead to a dramatic reduction of the antibody titre in the periphery, as 
demonstrated in section 3.1.3.4 of this study. On the other hand, it is unlikely that MOG is the 
only target autoantigen, which is exposed on the myelin surface and can therefore initiate a 
demyelinating autoantibody response. The identification of potential targets is a prerequisite to 
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develop diagnostic kits to identify those patients with pathogenic autoantibody responses and 
then provide an appropriate therapy such as plasma exchange, or immuno-absorption.  
As demonstrated in this study, DNA vaccination using a plasmid encoding a myelin 
antigen is one approach to generate high titre autoantibody responses directed against the native 
protein. The pathogenicity of this antibody response can then be assayed in the same animal by 
inducing EAE. This method circumvents problems such as purity, yield and denaturation, all of 
which complicate any study using antigens isolated from the CNS or generated using 
recombinant technologies. Coupling this approach to a proteomics based analysis of the myelin 
membrane and reverse genomics to identify candidate gene products provides the means to map 
out those protein antigens that can be targeted by a demyelinating autoantibody response. The 
feasibility of this concept is currently being tested in the rat using PLP and MAG as myelin 
components that may in certain circumstances provoke a pathogenic autoantibody response. 
Such an analysis will, however, not detect pathogenic antibody responses to glycolipid 
antigens, which are major target autoantigens in a number of diseases affecting the peripheral 
nervous system such as Guillain Barré syndrome (GBS). In GBS a pathogenic antibody 
response to gangliosides appears to be triggered by infections with particular serotypes of 
Campylobacter jejuni (Fredman, 1998; Willison and O´Hanlon, 1999). In the majority of 
patients these antibody responses are an acute phenomenon and disappear as the patients 
recover (Hahn, 1998). It is conceivable that a similar mechanism is responsible for the initiation 
of severe relapses in some MS patients, if an infection triggers a cross-reactive antibody 
response to a surface glycolipid epitope. This would induce an episode of acute CNS 
demyelination that would not be immediately responsive to immunosuppressive therapy, as 
tissue damage and amplification of the local inflammatory response would be driven by the pre-
existing antibody response. Analysis of the autoantibody responses in MS should therefore be 
extended to examine lipid as well as protein autoantigens. Such studies should also not be 
restricted to myelin, but also address the question of responses to other structures such as the 
axon and oligodendrocyte progenitor cells.  
Such autoantibody responses are however only conditionally pathogenic, in other words 
their pathogenic potential is only expressed if they can enter the CNS across the blood brain 
barrier (BBB)(Litzenburger et al., 1998; Bourquin et al., 2000). In EAE the inflammatory insult 
to the CNS is responsible for the disruption of BBB function and the entry of antibody into the 
nervous system. MS is characterised by repeated episodes of CNS inflammation but what 
initiates and maintains this response is unclear. The observation, that DA rats develop a similar, 
although eventually self-limiting response in the CNS after immunisation with MOG-peptide in 
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CFA provides a model to investigate the immuno-regulatory deficit(s) responsible for chronic 
CNS inflammation. The disease model is very reproducible with >90% of animals relapsing 
after peptide immunisation as opposed to <40% after immunisation with MBP in IFA 
(Lorentzen et al., 1995). This will make it feasible to use genetic methods, such as disease 
induction in congenic and intra-MHC congenic rat strains and whole genome screens in F2 
backcrosses, to identify genetic loci responsible for this defect. The understanding of the 
mechanisms involved may help to identify new targets for therapeutic strategies concerning 
chronic inflammatory diseases like MS and rheumatoid arthritis (RA). 
The second part of this thesis investigated a very different aspect of the autoimmune 
response to MOG, the consequences of immunological cross-reactivity with BTN, a major 
component of the milk fat globule membrane. The demonstration of cross-reactive T cell 
responses between MOG and a dietary antigen opens a new perspective for the aetiology of MS, 
since former investigations of environmental influences were concentrated on molecular 
mimicry with microbial peptides (Bray et al., 1983; Wucherpfennig et al., 1995; Challoner et 
al., 1995; Gautam et al., 1998; Ufret-Vicency et al., 1998; Burgoon et al., 1999). 
Epidemiological studies identified a link between milk consumption and other dietary factors 
and MS (Butcher, 1986; Malosse et al., 1992; Lauer, 1997), but the identity of the mechanistic 
basis in the immune system was unknown. It would be naïve to imagine that milk in the diet 
would per se induce an auto-aggressive response to MOG and thereby trigger MS. Indeed, 
disease induction is now thought to involve the chance interactions of several environmental 
factors on a susceptible genotype. In the case of the cross-reactive pair of antigens BTN/MOG, 
BTN in the diet would normally induce oral tolerance to the cross-reactive epitope, but this may 
be broken either by early post-natal exposure to bovine milk products (Miller et al., 1994), 
gastro-intestinal infections (Hornquist and Lycke, 1993; Weiner 1997) or a combination of both 
(as discussed in Introduction 3.2). However, would this combination of effects be sufficient to 
induce an inflammatory autoimmune mediated response in the CNS? 
Any prediction would at this time be premature. Analysis in the DA rat revealed that the 
cross-reactive repertoire in this model is complex and involves multiple clonal expansions. 
Moreover, the sequence of the BTN peptide is not identical to the corresponding MOG 
sequence and the cross-reactive BTN peptide acts as an APL. In view of the degeneracy of TCR  
- peptide/MHC recognition, the BTN peptide may initiate a range of responses ranging from 
superagonistic (Vergelli et al., 1997) to antagonistic (DeMagistris et al., 1992) in the different T 
cell clones. The identification of TCR β-chains used by the cross-reactive T cells is a first step 
towards generating a transgenic animal model. This may allow us to examine the 
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immunopathological consequences of cross-reactivity involving a dietary antigen and the 
impact of manipulating the gastro-intestinal flora on the immune response.  
Whether or not this is relevant for the aetiology of MS is uncertain. Certainly T cell cross-
reactivity between the two proteins is very limited and as yet was only demonstrated in the 
context of the RT1av1 rat MHC haplotype (Stefferl et al., 2000). No cross-reactive T cell 
response was detected in LEW and BN rats (Stefferl et al., 2000), as well as in SJL/J, C57/BL6, 
DBA.1 and CBA.1 mice (Schubart and Wissing, unpublished results). In addition, despite the 
presence of regions with a high level of sequence identity between the two proteins it was not 
possible to induce a significant cross-reactive antibody response in the DA rat (section 3.2.7). 
Why is this? 
In the course of this study it became apparent that BTN is a member of a family of 
structurally related gene products that are termed the BTN-, or extended B7- gene family. The 
N-terminal IgV-like domain of all these proteins exhibits a high degree of amino acid sequence 
identity with both MOG and BTN (Henry et al., 1999; Stammers et al., 2000; Rhodes et al., 
2001; see discussion of chapter 3.2), and members of this family are expressed in a variety of 
organs. It is possible that during B and T cell maturation in the bone marrow and thymus, cross-
reactive peptides derived from these proteins will eliminate many clones that would otherwise 
cross-react with MOG reactive T and B cells, and only those cells which escape this network of 
tolerogenic stimuli enter the periphery.  
As the sequences of the BTN-gene family members in the rat are currently unknown 
(with the exception of MOG), the identification of the extracellular domains of rat BTN 
provides the first opportunity to test this hypothesis. The oral consumption of milk during 
suckling should induce rat-BTN-specific suppressor T cells, characterised by low proliferative 
responsiveness and the secretion of IL-10 and TGF-β (Weiner et al., 1994). The identification 
and characterisation (epitope specificity) of these suppressor T cell responses in the different rat 
strains (LEW, BN and DA) may provide an explanation why MOG-specific T cell responses are 
only poorly encephalitogenic in Lewis rats and might help to elucidate the mechanisms of the 
development of tolerance in the newborn animals. 
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6 Appendices  
6.1 MOG-Igd-induced EAE as a model system to investigate novel treatment 
strategies for MS 
MOG-Igd/IFA-induced EAE in the DA rat is a disease model, which closely mimics 
multiple sclerosis (Storch et al., 1998), reproducing the complex histopathological changes seen 
in a large subset of MS patients (Lucchinetti et al., 2000; Lassmann et al., 2001). The pathology 
of this subset of patients is characterised by sharply demarcated demyelinating lesions, the 
deposition of antibody and C9 at the edge of active lesions as well as CD4+ and CD8+ T cell 
infiltrates, suggesting an important role of both antibodies and T cells in the pathogenesis of 
these diseases (Lucchineti et al., 1996, 2000; Lassmann et al., 2001). Other features, which are 
similar in both diseases, are myelin vesiculation as well as the presence of macrophages 
containing myelin debris, Ig and complement and ultimately partial remyelination resulting in 
shadow plaques (Storch et al., 1998; Genain et al., 1999; Raine et al., 1999; Prineas and 
Graham, 1981). In addition, lesions are also characterised by the activation of microglia, the 
formation of gliotic scars and irreversible axonal loss leading to persistent neurological deficits 
(Ferguson et al., 1997; Trapp et al., 1998; Kornek et al., 2000).  
Currently, therapeutic strategies for MS target the immunological component of the 
disease and while beneficial, fail to prevent disease progression in many patients (Noseworthy, 
1999 and 2000). There is therefore a vital need to further explore the immunological, as well as 
the neurological basis of MS and develop strategies that target other pathogenic pathways. One 
potential target are microglia, which upon activation can not only act as APCs to potentiate the 
local inflammatory response (Aloisi et al., 2001 A and B), but may also mediate neuro-toxic 
responses via secretion of pro-inflammatory cytokines (Boje and Arora, 1992; Streit, 1996, 
Hohlfeld, 1996).   
Literature searches identified the second-generation tetracycline minocycline as a 
substance, which not only has anti-inflammatory properties, but also inhibits microglial 
activation in models of focal and global ischemia (Yränheikki et al., 1998; Yränheikki et al., 
1999) and in a mixed spinal cord culture system exposed to excitotoxins (Tikka et al., 2001). Its 
anti-inflammatory properties include the reduced production of matrix metalloproteinases 
(MMPs), TNF-α and inducible nitric oxide synthase (iNOS), factors intimately involved in the 
pathophysiology of MS and EAE. Minocycline treatment of a transgenic mouse model for 
Huntington’s disease delayed disease progression, an effect associated with inhibition of 
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caspases 1 and 3 and iNOS by microglia (Chen et al., 2000).  In addition to these pleiotropic 
effects on both immune and central nervous system, another advantage of minocycline is that it 
is an established therapy against rheumatoid arthritis and acne, with minor side effects. These 
pleiotrophic actions make minocycline an interesting candidate to inhibit disease progression in 
multiple sclerosis. 
In a collaborative study with Drs. I. Duncan and N. Popovic, University of Madison, 
Wisconsin, U.S.A., we therefore investigated the effects of minocycline on both actively 
induced MOG-Igd-EAE and EAE induced by adoptive transfer of committed MOG-specific 
Th1-effector cell lines.  
 
6.1.1 Minocycline delays and reduces the severity of MOG-Igd-induced EAE 
Daily treatment of DA rats with 45 mg/kg minocycline, beginning 1 d.p.i. significantly 
reduced disease activity after active immunisation with 100 µg MOG-Igd in IFA (Figure 6.1 A). 
Minocycline not only delayed disease onset by 48-72 hours, but also reduced disease severity. 
All animals then recovered from the first phase of EAE and were completely healthy at 20 
d.p.i., at which time the PBS treated controls had developed a severe relapse and had to be 
sacrificed in accordance with the local animal care regulations. However, the therapeutic effect 
of minocycline was unable to influence the ultimate outcome of this clinically severe model of 
EAE, as the treated animals also relapsed 2 to 4 days later.  
In view of these encouraging observations, the effect of minocycline treatment was then 
investigated in a clinically less aggressive, relapsing remitting disease model induced by 
immunisation with 10 µg MOG-Igd in CFA (performed at the University of Wisconsin, 
Madison, U.S.A by Dr. N. Popovic).  The clinical course of this disease model more closely 
resembles that seen in most cases of MS than the relatively acute disease induced by 100 µg 
MOG-Igd and is characterised by focal demyelinating lesions and varying degrees of axonal 
loss. Daily treatment with minocycline delayed disease onset and dramatically reduced disease 
severity for at least 30 d.p.i. (Figure 6.1 B). This protective effect could be observed even if 
treatment was delayed until the animals developed the first clinical symptoms of EAE, in 
particular when the dose of minocycline given on the first two days of disease was doubled 
(Figure 6.1 B, Popovic, 2001). 
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Figure 6.1 Daily treatment with minocycline reduces disease activity after immunisation with MOG-Igd 
A) Mean clinical score and standard deviations after immunisation with 100 µg MOG-Igd/IFA. Animals were 
treated daily beginning 1 d.p.i.. Black squares: PBS treated controls (n=5); white diamonds: minocycline treated, 
(n=6; n=4 after 20 d.p.i.). B) Mean clinical score and SEM after immunisation with 10 µg MOG-Igd/CFA. Blue 
squares: PBS-treated controls; green squares: minocycline treated from 1 d.p.i.; orange triangles: minocycline 
treated from disease onset; red diamonds: double dose from disease onset. Figure B) provided by Dr. N Popovic, 
U.S.A. 
. 
6.1.2 Immunomodulatory effects of minocycline 
Previous studies have attributed the beneficial effects of minocycline in the treatment of 
rheumatoid arthritis to immuno-suppression (Alarcon, 1998; Greenwald, 1994). In our study, 
prophylactic treatment with minocycline strongly influenced the induction phase of MOG-Igd-
induced EAE. In addition, the rapidity of its effects was revealed, when treatment was started 
after disease onset in the low dose paradigm. However, its mode of action was unclear. In order 
to determine, whether the protective effects of minocycline were due to the direct modulation of 
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the MOG-Igd-specific immune response, we analysed its in vitro effect on MOG-specific T cell 
lines as well as the in vivo effect on the developing immune response to MOG-Igd.  
 
6.1.2.1  In spite of several in vitro effects, minocycline has no effect on the pathogenicity 
of committed MOG-specific T cells 
6.1.2.1.1 Minocycline enhances T cell proliferation 
Serial dilutions of minocycline were added to antigen specific T cell restimulation assays 
of MOG-or MOG-peptide-specific T cells in the presence of irradiated thymus cells and 
antigen. In contrast to published observations (Kloppenburg et al., 1995; Sewell et al., 1996), 
proliferation was not reduced, but enhanced in a dose dependent fashion. At concentrations of 
50-250 µM, minocycline resulted in a 50 to 70% increase in proliferation, but at higher doses 
was toxic (Figure 6.2). Interestingly, although the absolute proliferation remained very low, 
minocycline also strongly enhanced proliferation in the absence of antigen, but did not 
significantly enhance proliferation in response to the T cell mitogen Concanavalin A (Con A).  
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Minocycline enhances the proliferative response in vitro 
MOG-specific T cells were restimulated for 72 hours in the presence of irradiated thymocytes and 20 µg/ml antigen 
(black columns) or in the absence of antigen (white columns) and increasing doses of minocycline. Note that 
minocycline induces increased proliferation both in the presence and absence of antigen. High doses are toxic 
 
6.1.2.1.2 Minocycline modifies the expression of activation markers on T cell blasts 
FACS analysis of T cell blasts restimulated in the presence or absence of 250 µM 
minocycline and antigen demonstrated that these changes in proliferation were accompanied by 
alterations in the surface expression of several cell surface markers. While the expression of 
CD4 and MHC class I was unaltered (Figure 6.3 E; C), the presence of minocycline led to a 
reduced expression of the activation markers OX40 and IL2-R (Figure 6.3 D; F). In a subset of 
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the cells, there was also a reduction of CD3 and the αβ−TCR on the cell surface (Figure 6.3 B; 
G).   
 
 
Figure 6.3 Influence of minocycline on the expression of T cell surface markers  
MOG-specific T cells were stimulated for three days in the presence of MOG, irradiated thymocytes and with or 
without 250 µM minocycline. After this, T cell blasts were stained for the expression of the following cell surface 
markers: A) Negative control; B) CD3; C) MHC class I; D) OX40; E) CD4; F) IL-2 receptor and G) α/β T cell 
receptor. Blue: Cells restimulated in the absence of minocycline; green overlay: Cells restimulated in the presence 
of minocycline; red overlay: Negative control  
 
A) B) C)
D) E) F)
G)
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6.1.2.1.3 Minocycline does not influence the pathogenicity of MOG-specific T cells  
The influence of minocycline on the pathogenic potential of MOG-specific T cells was 
first studied by adoptive transfer of T cell blasts, which had been restimulated in the presence or 
absence of 250 µM minocycline, into naïve syngeneic recipients. We could not observe any 
significant effect of in vitro treatment with minocycline on the pathogenicity of the T cells. This                                 
indicates that in spite of its effects on the expression of various activation markers, minocycline 
was incapable of modulating the pathogenic potential of a pre-existing encephalitogenic Th1- T 
cell response in vitro (Figure 6.4, red and orange). 
However, since minocycline may act directly in the CNS by suppressing microglial 
activation and MMP synthesis in the target organ, we also investigated the influence of in vivo 
treatment with minocycline on EAE induced by adoptive transfer of encephalitogenic Th1 T 
cells. Naïve syngeneic recipients were treated daily with 45 mg/kg minocycline or PBS 
beginning either 1 d.p.t. or 6 days prior to the transfer of MOG specific T cell blasts (Figure 6.4; 
blue and green). Once again we could demonstrate no effect on the ability of the transferred T 
cells to induce disease, suggesting that minocycline was inefficient to suppress a committed 
encephalitogenic Th1- response in vivo. 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 Minocyline does not significantly influence the clinical course of EAE induced by T cell transfer 
Shown is the mean clinical course and standard deviation after the transfer of 1.7 x106 freshly restimulated MOG-
specific T cell blasts. White squares: Control rats treated daily with PBS from 7 days before transfer, cells 
untreated (n=4); black diamonds: Rats treated daily with minocycline from 7 days before transfer, cells untreated 
(n=4). Note: this increase in disease activity was not observed consistently in different experiments; black 
triangles: T cells restimulated in the presence of 250 µM minocycline, animals not treated (n=3); white circles: 
Cells untreated, rats untreated (n=3) 
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6.1.2.2 Minocycline induces immune deviation in the periphery  
The above observations demonstrated that minocycline does not influence EAE induced 
by a committed Th1 effector T cell population. This suggests that its suppressive effect on EAE 
induced by active immunization with MOG-Igd may be due to a modulation of the developing 
immune responses. DA rats were therefore immunised with 100 µg MOG-Igd in IFA and 
treated daily as described above. The peripheral immune response to MOG was investigated 10 
d.p.i., at the peak of clinical disease in the PBS treated controls. 
Analysis of the draining lymph nodes and spleen revealed that minocycline treatment 
resulted in a slight enhancement of MOG-Igd-specific proliferation in both tissues (Figure 6.5 A 
for lymph node cells), which was paralleled by marked changes in cytokine production. 
Strikingly, the synthesis of the Th2-associated cytokine IL-10 was increased, whilst synthesis of 
the proinflammatory cytokines TNF-α and IFN-γ were either unaffected or slightly reduced 
(Figure 6.5 B). Analysis of MOG-specific antibody isotypes as a surrogate marker for Th1- and 
Th2- like T cell responses confirmed that these changes in the cytokine milieu resulted in 
immune deviation away from a disease-associated Th1-like response in favour of a counter-
inflammatory Th2-like response. The production of the Th1-associated isotypes IgG2A, IgG2B 
and IgG2C was significantly decreased, while the titre of the Th2-associated isotype IgG1 was 
enhanced, resulting in a reduction of the IgG2b/IgG1 ratio from 0.80 to 0.17 when assayed at a 
serum dilution of 1/300 (Figure A-5C). In other EAE paradigms, similar shifts from a Th1 to 
Th2-like responses are associated with decreased disease activity (Karin et al., 1994; Kuchroo et 
al., 1995), suggesting that this effect on the antigen-specific immune response will contribute to 
the protection afforded by minocycline.   
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Figure 6.5 In vivo treatment with minocycline modulates the peripheral immune response 10 d.p.i. with 100 
µg MOG/IFA 
A) Shown are mean c.p.m. and standard deviations of a primary stimulation assay of lymph node cells, analysed in 
quadruplicate; B) cytokines secreted by these primary lymph node cultures stimulated with 20 µg MOG (in the 
absence of minocycline in vitro); C) isotypes of MOG-Igd-specific antibodies. Sera were diluted 1/900 (IgG) or 
1/300 (others). Shown is the mean O.D.405 and standard deviation of quadruplicate analyses. DA rats were treated 
daily beginning 1 d.p.i. with PBS (black) or minocycline (white). Tissues/Sera were pooled from 3 animals. 
 
6.1.2.3 Does minocycline affect the microglial response? 
In order to determine, whether the treatment with minocycline induced any direct effects 
on microglia, CNS tissue sections were examined for inflammation, microglial activation and 
MMP-2 expression (performed by B. Goetz in Madison, Wisconsin, U.S.A.).   
In both MOG-Igd EAE paradigms, the therapeutic effect of minocycline was paralleled 
by a strong reduction of inflammation and demyelination (Figure 6.6). Since microglial 
activation is a response to CNS inflammation, the reduction in inflammation will be associated 
with a concomitant loss of microglial activation. It was therefore extremely difficult to judge 
whether the lack of microglial activation was due to a direct effect of minocycline on the 
microglia, or simply to the lower level of inflammatory activity in the CNS. However, the 
analysis of CNS tissue in the areas of focal, low grade inflammation suggests that minocycline 
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induces a reduction of microglial activation (as indicated by microglial morphology and MHC 
class II-expression) as well as reduced MMP-2 expression (Dr. I. Duncan, personal 
communication). Analysis for these markers in the CNS derived from minocycline treated rats 
with T cell mediated disease may be more informative and is currently in progress.    
 
Figure 6.6 Treatment with minocycline reduces inflammation and demyelination in the CNS 
DA rats were immunised with with 10 µg MOG/CFA and treated daily with 45 mg/kg minocycline. a) and d) PBS-
treated control rats; b) and e) minocycline treated rats; a) and b) stained for inflammatory infiltrates (hematoxylin 
eosin), d) and e) stained for myelin (toluidine blue).   
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6.1.3 Discussion 
In this collaborative study, we employed relapsing remitting EAE induced by MOG-Igd 
to investigate the therapeutic effects of minocycline, a second-generation tetracycline. This drug 
was chosen, because it not only has anti-inflammatory properties (Alarcon, 1998; Greenwald, 
1994), but also suppresses microglial activation (Yränheikki et al., 1998; Yränheikki et al., 
1999; Tikka et al., 2001). We demonstrate that minocycline suppresses the developing 
inflammatory response in the CNS and will even inhibit further activation of the inflammatory 
cascade in the CNS in established disease. However, at present its mode of action is uncertain.  
Previous studies attributed the beneficial effects of minocycline in the treatment of 
rheumatoid arthritis to global immuno-suppression (Alarcon, 1998; Greenwald, 1994), but the 
current study indicates that the action of minocycline on the developing immune response is 
more complex. Continuous treatment with minocycline directly affects the cytokine milieu in 
the draining lymph nodes, enhancing IL-10 synthesis, reducing TNF-α production, but with a 
minimal effect on the synthesis of IFN-γ. This functional shift towards a “counter-
inflammatory” Th2 response was confirmed by analysis of immunoglobulin isotype usage. In 
the context of Th1 T cell mediated autoimmune diseases, Th1 and Th2 T cell responses are seen 
as being mutually antagonistic by virtue of the reciprocal-regulatory effects of Th1 (IFN-γ, IL-
12) and Th-2 (IL-4, IL-5, IL-10) associated cytokines (Liblau et al., 1995). Shifting the balance 
of the immune response in favour of Th2 like responses is associated with suppression of 
disease activity in EAE in immuno-competent animals (Khoruts et al., 1995) and will contribute 
significantly to the overall efficacy of minocycline in the current study. In addition, IL-10 might 
also have a direct effect (see discussion of chapter 3.2). The induction of immune deviation by 
minocycline is a novel observation that helps to clarify its mode of action in both rheumatoid 
arthritis and EAE. One the other hand, this study clearly demonstrates that minocycline is 
incapable of inhibiting EAE mediated by committed encephalitogenic Th1 TCLs.  
However, the rapidity of the response, when the therapy was started at disease onset 
suggests, that minocycline might not simply act by inducing immune deviation. Previous 
studies indicate that minocycline also suppresses microglial activation. It is, unfortunately, very 
difficult to test this by histological analysis, as in EAE inflammation and microglial activation 
are tightly inter-related. Invading encephalitogenic Th1 T cells, which recognise their target 
antigen in the CNS, secrete IFN-γ and other inflammatory and chemotactic mediators. These 
factors activate microglia (Shrikant and Beneviste, 1996), which then in turn act as local antigen 
presenting cells to augment the T-cell mediated inflammatory response (Aloisi et al., 2001), and 
are thought to play a crucial role in tissue destruction through the production of 
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proinflammatory cytokines. In the absence of a strong inflammatory response, it is therefore 
difficult to decide whether the suppression of microglia is responsible for the lack of 
inflammation, or whether the lack of inflammation, possibly caused by immune deviation, is 
responsible for the lack of microglial activation. However, we are currently examining tissues 
of minocycline-treated animals with clinical EAE induced by adoptive transfer of MOG-
specific T cells to address this question.   
Our data demonstrates that in MOG-Igd-induced EAE, T cell recruitment into the CNS is 
markedly reduced by treatment with minocycline. This may be in part mediated directly by the 
counter-inflammatory effects of the enhanced Th-2 like response induced by minocycline or by 
direct actions on microglia, but is also likely to involve other factors. These may include the 
down-regulation of metalloproteinase (MMP) activity by minocycline (Greenwald et al., 1992), 
as MMPs are crucially involved at many stages of the immuno-pathogenesis of EAE (Liedtke et 
al., 1998; Kieseier et al., 1999). We observed that MMP-2 expression is increased in areas of 
inflammation in sham-treated rats with EAE. In contrast, this was not seen in animals treated 
with minocycline, even in areas with evidence of a local T cell infiltrate (I. Duncan, personal 
communication). Intriguingly, alpha-4 integrin-mediated induction of MMP-2 expression plays 
a crucial role in the pathogenesis of EAE (Graesser et al, 2000), degrading the sub-endothelial 
basement membrane and facilitating T cell/macrophage entry into the CNS.  Disruption of the 
coordinate activation of MMP-2 may also influence the subsequent expression of other MMPs, 
such as MMP-9, which also plays a vital role in EAE and MS (Yong et al., 1998) 
Experimental data from models of rheumatoid arthritis support the view that inhibition of 
MMP expression is at least in part responsible for the clinical efficacy of minocycline 
(Greenwald et al., 1992).  However, once again, it remains to be determined whether the lack of 
MMP-2-expression after treatment with minocycline might not simply be due to the absence of 
an inflammatory response in the CNS.  
Although not investigated directly in the current study, we speculate that in addition to 
blocking or reducing inflammation and immune mediated damage per se, minocycline 
treatment may also be neuroprotective and reduce axonal damage directly or through inhibition 
of microglia. Minocycline prevents the death of cultured neurons exposed to glutamate or kainic 
acid (Tikka et al., 2001 A/B). Recently, glutamate antagonists have been shown to reduce 
disease in EAE models and to be neuroprotective (Pitt et al., 2000; Smith et al., 2000). 
Stimulation of glutamate receptors is thought to cause microglial proliferation with subsequent 
glutamate release which may not only result in neuronal loss, but also in oligodendrocyte death 
in both EAE and MS (Matute et al., 2001).  
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As a safe drug commonly used for extended periods in clinical practice to treat infections 
and in patients with rheumatoid arthritis, minocycline would thus seem to be an excellent 
candidate for a clinical trial in MS. While its efficacy might be greatest if given prior to the 
onset of clinical signs, for example at a time when a triggering episode such as a viral infection 
occurs, our data suggest that it could be given at relapse onset.  Its intermittent use may have 
advantages over the β-interferon drugs, which need to be given for life; but long-term treatment 
with minocycline is also possible (as is currently the case in the treatment of rheumatoid 
arthritis and acne (Goulden et al., 1996) and could extend its use into patients with other forms 
of MS.  It is not yet proven that long-term therapy with β-interferon will result in axonal 
protection and the possibility that minocycline may also be a useful neuroprotective drug 
suggests that minocycline could become a therapy of choice in MS.  Importantly, minocycline 
would be a much less expensive therapy than those currently approved for the treatment of MS. 
In addition, minocycline could be used in other demyelinating disorders such as 
adrenoleucodystrophy (Powers and Moser, 1998) and the Guillain-Barré syndrome (Griffin et 
al., 1990), where T cell recruitment and inflammation also play a key role in their pathogenesis. 
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6.2 Chemicals and Biochemicals 
Acetic acid     Merck, Darmstadt 
Acrylamid/Bis, Rotiphorese 30  Roth, Karlsruhe 
Agar  Fluka, Seelze 
Agarose   Biozym, Hess. Oldendorf 
L-Aspargine  GibcoBRL, Paisley, Scotland 
Ammonium chloride  Merck, Darmstadt 
Ammoniumperoxodisulfate   Sigma, Deisenhofen 
Ampicillin  Sigma, Deisenhofen 
β−Mercaptoethanol  Merck-Schuchardt, Hohenbrunn 
Boric acid  Merck, Darmstadt 
Brome phenol blue  Sigma, Deisenhofen  
BSA  Roth, Karlsruhe 
Butanol Riedl-deHaën, Seelze 
Calciumchloride  Merck, Darmstadt 
Citric acid-Monohydrate  Merck, Darmstadt 
Concanavalin A  Sigma, Deisenhofen 
Coomassie Brilliant Blue  Sigma, Deisenhofen  
Chloroform  Merck, Darmstadt 
Diethanolamine Sigma, Deisenhofen 
Diethylpyrocarbonat (DEPC) Sigma, Deisenhofen  
Dimethylsulfoxide (DMSO) Sigma, Deisenhofen  
DTT (Dithiothreitol) Gibco BRL, Paisley, Schottland 
dNTPs Boehringer, Mannheim 
Dulbecco´s Modification of Eagles Medium (DMEM) Gibco BRL, Paisley, Schottland  
EDTA Merck, Darmstadt 
Ethanol Riedl-deHaën, Seelze 
Ether Hoechst, Frankfurt 
Ethidiumbromide Sigma, Deisenhofen 
Fetal calf serum Gibco, Paisley/Schottland 
Glucose Merck, Darmstadt 
L-Glutamine Gibco, Paisley/Schottland  
Glycerol Merck, Darmstadt 
Glycin Riedl-deHaën, Seelze 
HEPES Sigma,Steinheim 
Horse serum Gibco BRL, Paisley, Schottland Hydrochloric 
acid (37%) Riedl-deHaën, Seelze 
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Hydrogen peroxide Aldrich-Chemie, Steinheim  
Imidazole Merck, Darmstadt 
Isopropanol Riedl-deHaën, Seelze 
Isopropyl-b-D-Thiogalaktosid (IPTG) bts, Leon-Rot 
Kanamycine Sigma, Deisenhofen 
Lowry Protein Assay Kit Sigma Diagnostics, USA 
Lysozyme Sigma, Steinheim 
Magnesiumchloride x 6H2O Merck, Darmstadt 
Magnesiumsulfate Merck, Darmstadt 
Manganese chloride Merck, Darmstadt 
MEM Non-essentiel amino acids Gibco, Paisley/Schottland 
Methanol Riedl-deHaën, Seelze 
Milk powder Frema Reform 
Nickel chloride Sigma, Deisenhofen 
p-nitrophenyl phosphate Sigma, Deisenhofen 
Oligo-dT-Primer Gibco BRL, Paisley, Schottland 
Orthophenyldiamin (OPD) Sigma, Deisenhofen 
Ovalbumine Roth, Karlsruhe 
Paraformaldehyde Merck, Darmstadt 
Peptone from casein Merck, Darmstadt 
Penicillin/Streptomycin Gibco BRL, Paisley, Schottland 
Phenol Appligene, Heidelberg 
Phenol red Sigma, Deisenhofen 
Pfu-DNA polymerase Stratagene  
Polyoxyethylensorbitan Monolaurat (Tween 20)Sigma, Deisenhofen 
Potassium acetate Merck, Darmstadt 
Potassium bicarbonate  Merck, Darmstadt 
Potassium chloride Merck, Darmstadt 
Mono-Potassiumphosphat Merck, Darmstadt  
Rubidium chloride Sigma, Deisenhofen 
Sodium acetate Merck, Darmstadt 
Sodium azide Merck, Darmstadt 
Sodium bicarbonate Merck, Darmstadt 
Sodium chloride Merck, Darmstadt 
Sodium hydrogencarbonate Merck, Darmstadt 
Sodiumhydroxide Merck, Darmstadt 
Disodium phosphate Merck, Darmstadt 
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Sodiumlaurylsulfate (SDS) Roth, Karlsruhe 
Sodiumphosphate Merck, Darmstadt 
Sodium pyruvate Gibco, Paisley/Schottland 
SuperscriptTM RT with buffer Gibco BRL, Paisley, Schottland 
Taq-Polymerase with buffer  Boehringer Mannheim 
Tetramethylethylenediamine (TEMED) Sigma, Deisenhofen 
Tris-(hydroxymethyl)-aminomethan Riedl-deHaën, Seelze 
Triton-X-100 Sigma, Deisenhofen 
Trizol Gibco BRL, Paisley, Schottland 
Trypanblue Sigma Cell Culture, UK 
Tryptone Sigma, Deisenhofen 
Tuberculin syringes Poulten & Graf GmbH, Wertheim  
Tween 20 Sigma 
Urea Merck, Darmstadt  
Xylene cyanol Sigma, Deisenhofen 
Yeast extract Merck, Darmstadt 
 
Plastics and films 
Plastics were obtained from Assistent (Sondheim), Falcon (Becton Dickinson, 
Plymouth/England), Amersham (Braunschweig), Greiner (Flacht), Schleicher & Schuell 
(Dassel) and Agfa (München). 
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6.3 Common abbreviations 
a.a. Amino acids 
ADCC Antibody-dependent cellular cytotoxicity 
AP Alkaline phosphatase 
APC Antigen presenting Cell 
APL Altered peptide liganc 
APS Ammoniumperoxisulfate 
BBB Blood brain barrier 
BN Brown Norway (inbred rat strain) 
Bov Bovine 
BTN butyrophilin 
BTNexo  Extracellular domains of bov. Butyrophilin, 
derived from insect cells 
bp Base pairs 
BSA Bovine serum albumin 
°C Degrees Celsius (centigrades) 
cDNA DNA which is complementary to mRNA  
CDR Complementarity determining region 
CFA Complete freunds adjuvans 
CNS Central nervous system 
ConA Concanavalin A 
c.p.m. counts per minute 
dATP 2´-Desoxyadenosin-5´-triphosphat 
DA Dark Agouti (inbred rat strain) 
DEPC Diethylpyrocarbonat 
DMEM Dulbecco´s Modified Eagles Medium 
DMSO Dimethylsulfoxide 
DNA Desoxyribonucleic acid 
dNTP 2´-Desoxynukleosid-5´-triphosphate 
d.p.i. days post immunisation 
d.p.t. days post transfer 
d.p.v. days post vaccination 
EAE Experimental autoimmune encephalomyelitis 
E. coli Escherichia coli 
e.g. For example  
EH Eagles HEPES 
ELISA Enzyme linked immunosorbant assay 
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et al. And others 
EtBr Ethidiumbromide 
FACS Fluorescence activated cell sorting 
FCS Fetale calf serum   
h hours 
HS Horse serum 
HP Horseradish peroxidase 
IFA Incomplete freunds adjuvant 
IFN Interferon 
Ig Immunoglobulin  
IgV Variable domain of Ig 
IL-4 /10 Interleukin 4/10  
IPTG Isopropyl-β-Thiogalactoside  
kb Kilobases 
kDa Kilodalton 
LEW Lewis (inbred rat strain) 
LNCs Lymph node cells 
M  Molar 
mM Millimolar  
mAB monoclonale antibodies 
MAG Myelin-associated glycoprotein 
MBP Myelin basic protein 
MHC Major histocompatibility complex  
min Minutes 
ml Milliliter  
MOBP Myelin oligodendrocyte basic protein 
MOG-Igd  Extracellular immunoglobulin domain of rat 
MOG 
MOG Myelin oligodendrocyte-glycoprotein 
MS Multiple Sclerosis 
µg Microgramm 
µl Microliter 
mRNA Messenger-RNA 
ng Nanogramm 
nm nanometer 
ODx Optical density at  wave length x 
PAGE Polyacrylamidgelelektrophorese 
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PBS Phosphate buffered saline  
PCR Polymerase chain reaction   
pers. comm Personal communication 
PFA Paraformaldehyde 
pg Picogramm 
PLP Proteolipidprotein 
PMN Polymorphonuclear cells 
PNS Peripheral nervous system 
RNA Ribonucleic acid 
rpm Rounds per minute 
RT Room temperature 
RT-PCR  Reverse transcription-Polymerase chain 
reaction 
s.  See 
s Second 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
TBS Tris buffered saline 
TBE Tris-Borat/EDTA 
TCGF T-cell growth factor 
TEMED Tetramethylendiamin 
TGF Tumor growth factor 
Th T-helper cell 
TNF Tumor Necrosis Faktor 
Tris/Cl  Tris-(hydroxymethyl)-aminomethan titred 
with HCl 
U Unit, (for enzyme activities) 
UV Ultraviolet 
V Volt  
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6.4 Curriculum Vitae 
Anna Schubart, born 25.09.1971 in Frankfurt/Main, Germany 
June 1990 Abitur at the Lessing-Gymnasium, Frankfurt/Main (1.7) 
1990-1991  Au-pair in Paris, France  
University Career 
1991-1993   Biology student at the J.W.Goethe-Universität, Frankfurt, Germany 
July 1993  Vordiplom (1.0) 
1993-1994   Biology student at the University of Edinburgh, Scotland 
1994-1997   Biology student at the Ludwig-Maximilian-Universität, Munich 
Feb1995      Four weeks Neuroimmunology research training, Dr. M. Bradl, MPI for 
Psychiatry, Department of Neuroimmunology (Prof. Wekerle) 
Sep/Oct 1995  Eight weeks research training in Autoimmunity (rheumatoid arthritis), Dr. 
A. Davidson, Albert Einstein College of Medicine, New York  
1997  Diploma project with Dr C. Linington, MPI for Psychiatry, Department of 
Neuroimmunology (Prof. Wekerle). Title: “Induction of tolerance to MOG 
in experimental autoimmune encephalomyelitis (EAE).”  
Nov 1997 Awarded Diploma in Biology, grade 1.0 (outstanding) 
Since Jan 1998  PhD studies with Dr. C. Linington, MPI for Neurobiology, Department of 
Neuroimmunology (Prof. Wekerle) 
 
Teaching experience 
June 1999 Course tutor, Farmades Neuroimmunology course, Martinsried 
1998-2001 Supervision of biochemistry and medical student projects:  
                        Hannah Pellkofer   :  “T cell mediated autoaggresion to neuronal paraneoplastic  
                                                            autoantigens.” 
                        Simone Dill            :  “RNA expression analysis of MOG-reactive T cell lines.” 
                        Silke Wissing         :  “Baculovirus expression of butyrophilin and analysis of the  
                                 butyrophilin immune response in different mouse strains.” 
                        Jessica Mittelstädt  :  ”Induction of pathogenic autoantibody responses by DNA   
                                                            vaccination,“ 
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6.5 List of Publications 
1. Original Articles 
Schwaeble WJ, Stover CM, Schall TJ, Dairaghi DJ, Trinder PKE, Linington C, Iglesias I, Schubart A, 
Lynch NJ, Weihe E and Schäfer MKH (1998) 
Neuronal expression of fractalkine in the presence and absence of inflammation 
FEBS Letters 439: 203-207  
 Stefferl A*, Schubart A*, Storch M*, Amini A, Mather I, Lassmann H and Linington C (2000) 
Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte 
glycoprotein in experimental autoimmune encephalomyelitis  
J Immunol 154: 2859-2865 
* These authors contributed equally to this publication 
Popovic N, Schubart A, Goetz B, Zhang S-C, Linington C and Duncan ID (2001) 
Inhibition of autoimmune encephalomylitis by a tetracycline 
Ann Neurol in press 
Pham-Dinh D, Daubas P, Vizler C, Delarasse C, Dimitri D, Goude K, Della Gaspera B, Bauer J, 
Litzenburger T, Iglesias A, Schubart A, Dierich A, LeMeur M, Roussel G, Nussbaum JL, Dautigny A 
and Liblau RS (2001) 
Myelin/oligodendrocyte glycoprotein (MOG)-deficient mice reveal a critical role for MOG in 
autoimmue encephalomyelitis 
submitted 
Schubart A, Höftberger R, Stefferl A, Lassmann H and Linington C 
Spontaneous relapse and disease progression in myelin oligodendrocyte glycoprotein experimental 
autoimmune encephalomyelitis is driven by the autoantibody response 
in preparation 
Schubart A, Eiglmeier I, Kosin S, Höftberger R, De Graaf K, Weissert R, Lassmann H , Goebels N and 
Linington C 
Butyrophilin provides a naturally occurring source of altered peptide ligand that modulates the 
encephalitogenic potential of the MOG-specific T cell repertoire 
in preparation 
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2. Review Articles 
Iglesias A, Bauer J, Litzenburger T, Schubart A and Linington C (2001) 
T and B cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune 
encephalomyelitis and multiple sclerosis 
Glia 36: 220 – 234 
 
3. Book Chapters 
Schubart A and Linington C (2001) 
Aktuelle tierexperimentelle Aspekte der Multiple-Sklerose-Therapie: Antigen-spezifische 
Immuntherapien bei Myelin-Oligodendrozyten-Glykoprotein (MOG)-induzierter experimenteller 
autoimmuner Enzephalomyelitis 
In: Zettl UK and Mix E (Hrsg): Multiple Sklerose: Kausalorientierte, symptomatische und rehabilitative 
Therapie, Springer –Verlag Berlin Heidelberg 
 
4. Oral presentations: 
Departmental Seminar in the Institute of Veterinary Medicine, Madison, Wisconsin, U.S.A., group of Dr. 
Ian Duncan, August 1998 
MOG-induced EAE as a model system for multiple sclerosis 
 
Annual meeting of the Deutsche Gesellschaft für Immunologie, Düsseldorf, Dec. 2000 
Schubart AS, Guggenmos J, Haase C, Mather I and Linington C (2000) 
Molecular mimicry between the myelin oligodendrocyte glycoprotein and the milk protein butyrophilin 
in EAE and multiple sclerosis 
Immunobiology 203:503 
 
VIth International Congress of Neuroimmunology, Sept. 2001 
 Schubart A, Höftberger R, Lassmann H and Linington C 
Antibody dependent mechanisms mediate relapse in MOG-induced EAE  
J Neuroimmunol 118: 46 (No 130) 
 
Schubart A, Eiglmeier I, Goebels N and Linington C 
The molecular basis of T cell cross-reactivity between the myelin oligodendrocyte glycoprotein and the 
milk protein butyrophilin 
J Neuroimmunol 118: 55 (No 157) 
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5. Poster Presentations 
5th annual congress of the British Society for Immunology 1997 
Schubart A, Storch M, Lassmann H and Linington C 
Treatment with soluble antigen modulates the clinical course of myelin oligodendrocyte glycoprotein 
(MOG)-induced EAE 
Immunology 92 (Suppl 1): 9 (2.16) 
 
Vth International Congress of Neuroimmunology, Aug. 1998 
Schubart A, Storch M, Lassmann H and Linington C (1998) 
Treatment with soluble antigen modulates the clinical course of myelin oligodendrocyte glycoprotein 
(MOG)-induced EAE 
J Neuroimmunol 90: 83 
 
Joint annnual meeting 2000 of the german and dutch societies of Immunology, Nov 2000 
Schubart AS, Guggenmos J, Haase C, Mather I and Linington C (2000) 
Molecular mimicry between the myelin oligodendrocyte glycoprotein and the milk protein butyrophilin 
in EAE and multiple sclerosis 
Immunobiology 203:503 
 
